AU2006287481A1 - Pharmaceutical compositions for delivery of ribonucleic acid to a cell - Google Patents
Pharmaceutical compositions for delivery of ribonucleic acid to a cell Download PDFInfo
- Publication number
- AU2006287481A1 AU2006287481A1 AU2006287481A AU2006287481A AU2006287481A1 AU 2006287481 A1 AU2006287481 A1 AU 2006287481A1 AU 2006287481 A AU2006287481 A AU 2006287481A AU 2006287481 A AU2006287481 A AU 2006287481A AU 2006287481 A1 AU2006287481 A1 AU 2006287481A1
- Authority
- AU
- Australia
- Prior art keywords
- sirna
- polynucleotide delivery
- peptide
- enhancing polypeptide
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012384 transportation and delivery Methods 0.000 title claims description 98
- 229920002477 rna polymer Polymers 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 518
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 489
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 280
- 210000004027 cell Anatomy 0.000 claims description 272
- 102000040430 polynucleotide Human genes 0.000 claims description 251
- 108091033319 polynucleotide Proteins 0.000 claims description 251
- 239000002157 polynucleotide Substances 0.000 claims description 250
- 229920001184 polypeptide Polymers 0.000 claims description 248
- 150000007523 nucleic acids Chemical class 0.000 claims description 159
- 239000000203 mixture Substances 0.000 claims description 147
- 102000039446 nucleic acids Human genes 0.000 claims description 142
- 108020004707 nucleic acids Proteins 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 230000014509 gene expression Effects 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 86
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 80
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 66
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 47
- -1 cationic lipid Chemical class 0.000 claims description 42
- 230000000295 complement effect Effects 0.000 claims description 38
- 108010033040 Histones Proteins 0.000 claims description 34
- 229940063675 spermine Drugs 0.000 claims description 33
- 230000027455 binding Effects 0.000 claims description 31
- 102000006947 Histones Human genes 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 24
- 230000002708 enhancing effect Effects 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 23
- 125000002091 cationic group Chemical group 0.000 claims description 22
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 20
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 210000004102 animal cell Anatomy 0.000 claims description 15
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 14
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 10
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 10
- 239000001294 propane Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 108010036176 Melitten Proteins 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 claims description 8
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 claims description 7
- QBJFCIRZABYLPK-UHFFFAOYSA-N CN(CCCN(CCCCN(CCC(N(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)C)C)C Chemical compound CN(CCCN(CCCCN(CCC(N(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)C)C)C QBJFCIRZABYLPK-UHFFFAOYSA-N 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 6
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims description 5
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- HKUFIYBZNQSHQS-UHFFFAOYSA-N n-octadecyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC HKUFIYBZNQSHQS-UHFFFAOYSA-N 0.000 claims description 5
- QPYUGOUSOOCGGQ-UHFFFAOYSA-N CN(CCCN(CCCCN(CCC(N(CCCCCCCCCCCC)CCCCCCCCCCCC)(CCCCCCCCCCCC)CCCCCCCCCCCC)C)C)C Chemical compound CN(CCCN(CCCCN(CCC(N(CCCCCCCCCCCC)CCCCCCCCCCCC)(CCCCCCCCCCCC)CCCCCCCCCCCC)C)C)C QPYUGOUSOOCGGQ-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 description 159
- 125000003729 nucleotide group Chemical group 0.000 description 158
- 230000000694 effects Effects 0.000 description 150
- 238000003197 gene knockdown Methods 0.000 description 87
- 108020004999 messenger RNA Proteins 0.000 description 71
- 238000001890 transfection Methods 0.000 description 69
- 230000000692 anti-sense effect Effects 0.000 description 60
- 239000000562 conjugate Substances 0.000 description 55
- 241000282414 Homo sapiens Species 0.000 description 49
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 49
- 101710107065 Myosin regulatory light polypeptide 9 Proteins 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 45
- 210000001616 monocyte Anatomy 0.000 description 42
- 230000001404 mediated effect Effects 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 39
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 33
- 230000009368 gene silencing by RNA Effects 0.000 description 33
- 206010039073 rheumatoid arthritis Diseases 0.000 description 31
- 108091093037 Peptide nucleic acid Proteins 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 28
- 230000004048 modification Effects 0.000 description 28
- 238000012986 modification Methods 0.000 description 28
- 238000003556 assay Methods 0.000 description 27
- 238000012217 deletion Methods 0.000 description 26
- 230000037430 deletion Effects 0.000 description 26
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 26
- 239000013642 negative control Substances 0.000 description 25
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 24
- 239000012124 Opti-MEM Substances 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000003833 cell viability Effects 0.000 description 21
- 229940107161 cholesterol Drugs 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 210000002950 fibroblast Anatomy 0.000 description 20
- 125000005647 linker group Chemical group 0.000 description 20
- 108091081021 Sense strand Proteins 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 230000002452 interceptive effect Effects 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- 239000002924 silencing RNA Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 108010005774 beta-Galactosidase Proteins 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000000799 fusogenic effect Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 108091028664 Ribonucleotide Proteins 0.000 description 13
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 13
- 230000030279 gene silencing Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 239000010452 phosphate Substances 0.000 description 13
- 239000002336 ribonucleotide Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000581650 Ivesia Species 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 12
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 11
- 230000004700 cellular uptake Effects 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 125000002652 ribonucleotide group Chemical group 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 208000035657 Abasia Diseases 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 102100031829 Myosin light polypeptide 6 Human genes 0.000 description 10
- 101710101143 Myosin light polypeptide 6 Proteins 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 102000005936 beta-Galactosidase Human genes 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 9
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 9
- 108091027967 Small hairpin RNA Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000012226 gene silencing method Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000012096 transfection reagent Substances 0.000 description 8
- 102100039869 Histone H2B type F-S Human genes 0.000 description 7
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 108010001267 Protein Subunits Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 206010054094 Tumour necrosis Diseases 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000005547 deoxyribonucleotide Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000010468 interferon response Effects 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 108010048032 cyclophilin B Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002015 acyclic group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 239000000863 peptide conjugate Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000008300 phosphoramidites Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 101710103773 Histone H2B Proteins 0.000 description 4
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 4
- 102000002067 Protein Subunits Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000037440 gene silencing effect Effects 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- RVKIPWVMZANZLI-ZFWWWQNUSA-N Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-ZFWWWQNUSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 150000001484 arginines Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- 108010011767 m-calpain Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000013580 millipore water Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 108091008104 nucleic acid aptamers Proteins 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000008196 pharmacological composition Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 239000005451 thionucleotide Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
- FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical compound NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 description 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical class NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1h-pyrrole Chemical class [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 101150092328 22 gene Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 description 1
- VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- LAVZKLJDKGRZJG-UHFFFAOYSA-N 4-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C=CN2 LAVZKLJDKGRZJG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 description 1
- PSWCIARYGITEOY-UHFFFAOYSA-N 6-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2C=CNC2=C1 PSWCIARYGITEOY-UHFFFAOYSA-N 0.000 description 1
- JBCNZZKORZNYML-UHFFFAOYSA-N 7h-purine;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.C1=NC=C2NC=NC2=N1 JBCNZZKORZNYML-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 101710185380 Androctonin Proteins 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000270718 Caiman crocodilus Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000089409 Erythrina poeppigiana Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101100189057 Homo sapiens SLC10A3 gene Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 101100052669 Schizosaccharomyces pombe (strain 972 / ATCC 24843) N118 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100030018 Tumor protein p73 Human genes 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PHNWGDTYCJFUGZ-UHFFFAOYSA-L hexyl phosphate Chemical compound CCCCCCOP([O-])([O-])=O PHNWGDTYCJFUGZ-UHFFFAOYSA-L 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ABCVHPIKBGRCJA-UHFFFAOYSA-N nonyl 8-[(8-heptadecan-9-yloxy-8-oxooctyl)-(2-hydroxyethyl)amino]octanoate Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCCCC(=O)OCCCCCCCCC ABCVHPIKBGRCJA-UHFFFAOYSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 238000012302 perinuclear staining Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000002743 phosphorus functional group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- JUGKVSNCOWXSFE-UHFFFAOYSA-N pyrimidine;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.C1=CN=CN=C1 JUGKVSNCOWXSFE-UHFFFAOYSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
WO 2007/030619 PCT/US2006/034859 5 PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF RIBONUCLEIC ACID TO A CELL TECHNICAL FIELD 0 The invention relates to methods and compositions for delivering nucleic acids into cells. More specifically, the invention relates to procedures and preparations for delivering double-stranded polynucleotides into cells to modify expression of target genes to alter a phenotype, such as a disease state or potential, of the cells. BACKGROUND OF THE INVENTION 5 Delivering nucleic acids into animal and plant cells has long been an important object of molecular biology research and development. Recent developments in the areas of gene therapy, antisense therapy and RNA interference (RNAi) therapy have created a need to develop more efficient means for introducing nucleic acids into cells. A diverse array of plasmids and other nucleic acid "vectors" have been developed for 0 delivering large polynucleotide molecules into cells. Typically these vectors incorporate large DNA molecules comprising intact genes for the purpose of transforming target cells to express a gene of scientific or therapeutic interest. The process by which exogenous nucleic acids are delivered artificially into cells is generally referred to as transfection. Cells can be transfected to uptake a functional nucleic acid 5 from an exogenous source using a variety of techniques and materials. The most commonly used transfection methods are calcium phosphate transfection, and electroporation. A variety of other methods for tranducing cells to deliver exogenous DNA or RNA molecules have been developed, including viral-mediated transduction, cationic lipid or liposomal delivery, and numerous methods that target mechanical or biochemical membrane disruption/penetration (e.g., 0 using detergents, microinjection, or particle guns). RNA interference is a process of sequence-specific post transcriptional gene silencing in cells initiated by a double-stranded (ds) polynucleotide, usually a dsRNA, that is homologous in sequence to a portion of a targeted messenger RNA (mRNA). Introduction of a suitable dsRNA into cells leads to destruction of endogenous, cognate mRNAs (i.e., mRNAs that share 5 substantial sequence identity with the introduced dsRNA). The dsRNA molecules are cleaved by an RNase III family nuclease called dicer into short-interfering RNAs (siRNAs), which are 19-23 nucleotides (nt) in length. The siRNAs are then incorporated into a multicomponent nuclease complex known as the RNA-induced silencing complex or "RISC." The RISC identifies mRNA 1 WO 2007/030619 PCT/US2006/034859 5 substrates through their homology to the siRNA, and effectuates silencing of gene expression by binding to and destroying the targeted mRNA. RNA interference is emerging a promising technology for modifying expression of specific genes in plant and animal cells, and is therefore expected to provide useful tools to treat a wide range of diseases and disorders amenable to treatment by modification of endogenous 0 gene expression. There remains a long-standing need in the art for better tools and methods to deliver siRNAs and other small inhibitory nucleic acids (siNAs) into cells, particularly in view of the fact that existing techniques for delivering nucleic acids to cells are limited by poor efficiency and/or high toxicity of the delivery reagents. Related needs exist for improved methods and 5 formulations to deliver siNAs in an effective amount, in an active and enduring state, and using non-toxic delivery vehicles, to selected cells, tissues, or compartments to mediate regulation of gene expression in a manner that will alter a phenotype or disease state of the targeted cells. SUMMARY OF THE INVENTION One aspect of the present invention is a composition comprising a polynucleotide ,0 delivery-enhancing polypeptide and a double stranded ribonucleic acid (dsRNA), wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties. In a related embodiment, the polynucleotide delivery-enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a sequence selected from the group consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, 5 Mellitin, Histone H1, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186. In another embodiment, the composition causes uptake of the dsRNA into an animal cell. In another embodiment, the animal cell is a mammalian cell. In another embodiment, the composition is administered to an animal. In a related embodiment, the animal is a mammal. In 0 another embodiment, the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated. In a related embodiment, the N-terminus of the polynucleotide delivery-enhancing polypeptide is pegylated. In yet another embodiment, the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tmnor Necrosis Factor-alpha (TNF-a) gene. In a related 5 embodiment, the dsRNA is a siRNA consisting of about 10 to about 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187. In another embodiment, the polynucleotide delivery-enhancing polypeptide is admixed, complexed or conjugated to the 2 WO 2007/030619 PCT/US2006/034859 5 dsRNA. In another embodiment, the polynucleotide delivery-enhancing polypeptide binds to the dsRNA. In yet another embodiment, any of the compositions above, further comprising a cationic lipid. In a related embodiment, the cationic lipid is selected from the group consisting of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, 1,2-bis(oleoyloxy)-3-3 (trimethylammonium)propane, 1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium 0 bromide, dimethyldioctadecylammonium bromide, 2,3-dioleyloxy-N [2(spennrminecarboxamido)ethyl]-N,N-dimethyl- 1-propanaminiu m trifluoracetate, 1,3 dioleoyloxy-2-(6-carboxyspermyl)-propylamid, 5-carboxyspermylglycine dioctadecylamide, tetramethyltetrapalmitoyl spermine, tetramethyltetraoleyl spermine, tetramethyltetralauryl spermine, tetramethyltetramyristyl spermine and tetramethyldioleyl spermine, DOTMA (N-[1 5 (2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAP (1,2-bis(oleoyloxy) 3,3-(trimethylammonium)propane), DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide), DDAB (dimethyl dioctadecyl ammonium bromide), polyvalent cationic lipids, lipospermines, DOSPA (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl 1-propanamini um trifluoro-acetate), DOSPER (1,3-dioleoyloxy-2-(6carboxy spermyl)-propyl 0 amid, di- and tetra-alkyl-tetra-methyl spermines, TMTPS (tetramethyltetrapalmitoyl spermine), TMTOS (tetramethyltetraoleyl spermine), TMTLS (tetramethlytetralauryl spermine), TMTMS (tetramethyltetramyristyl spermine), TMDOS (tetramethyldioleyl spermine) DOGS (dioctadecyl amidoglycylspermnnine (TRANSFECTAM®), cationic lipids combined with non-cationic lipids, DOPE (dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine) or 5 cholesterol, a cationic lipid composition composed of a 3:1 (w/w) mixture of DOSPA and DOPE, and a 1:1 (w/w) mixture of DOTMA and DOPE. In another aspect of the present invention is a method for causing uptake of a double stranded ribonucleic acid (dsRNA) into an animal cell, which comprises incubating the animal cells with a mixture comprising a polynucleotide delivery-enhancing polypeptide and the 0 dsRNA, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties. In another aspect of the present invention is a method for modifying expression of a target gene in an animal cell, which comprises incubating the animal cell with a mixture comprising a polynucleotide delivery-enhancing polypeptide, wherein the polynucleotide 5 delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA), wherein the dsRNA is complementary to a region of the target gene. 3 WO 2007/030619 PCT/US2006/034859 5 In a related embodiment, is any of the methods above, the animal cell is a mammalian cell. In another aspect of the present invention is a method for changing a phenotype of an animal subject, which comprises administering to the animal subject a mixture of a polynucleotide delivery-enhancing polypeptide, wherein the polynucleotide delivery-enhancing 0 polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA), wherein the dsRNA is complementary to a region of a target gene in the subject. In a related embodiment, the animal may be a mammal. In another embodiment, is any of the methods above, the polynucleotide delivery enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a 5 sequence selected from the group consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, Mellitin, Histone H1, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186. In a related embodiment, is any of the methods above, the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated. In another related embodiment, 0 is any of the methods above, the N-terminus of the polynucleotide delivery-enhancing polypeptide is pegylated. In another embodiment, is any of the methods above, the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tumor Necrosis Factor-alpha (TNF-ol) gene. In a related embodiment, is any of the methods above, the dsRNA is a siRNA consisting of about 10 to about 5 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187. In another embodiment, is any of the methods above, the polynucleotide delivery-enhancing polypeptide is admixed, complexed or conjugated to the dsRNA. In yet another embodiment, is any of the methods above, the polynucleotide delivery-enhancing polypeptide binds to the dsRNA. In another embodiment, is any of the methods above, further comprising a cationic 0 lipid. In a related embodiment, is any of the methods above the cationic lipid is selected from the group consisting of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, 1,2 bis(oleoyloxy)-3-3-(trimethylammonium)propane, 1,2-dimyristyloxypropyl-3 dimethylhydroxyethylammonium bromide, dimethyldioctadecylammonium bromide, 2,3 dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl- 1 -propanaminiu m trifluoracetate, 5 1,3-dioleoyloxy-2-(6-carboxyspennyl)-propylamnid, 5-carboxyspermylglycine dioctadecylamide, tetramethyltetrapalmitoyl spenrmine, tetramethyltetraoleyl spermine, tetramethyltetralauryl spermine, tetramethyltetramyristyl spermnnine and tetramethyldioleyl spermine, DOTMA (N-[1 (2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAP (1,2-bis(oleoyloxy) 4 WO 2007/030619 PCT/US2006/034859 5 3,3-(trimethylammonium)propane), DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide), DDAB (dimethyl dioctadecyl ammonium bromide), polyvalent cationic lipids, lipospermines, DOSPA (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl 1-propanamini um trifluoro-acetate), DOSPER (1,3-dioleoyloxy-2-(6carboxy spermyl)-propyl amid, di- and tetra-alkyl-tetra-methyl spermines, TMTPS (tetramethyltetrapalmitoyl spermine), 10 TMTOS (tetramethyltetraoleyl spermine), TMTLS (tetramethlytetralauryl spermine), TMTMS (tetramethyltetramyristyl spermine), TMDOS (tetramethyldioleyl spermine) DOGS (dioctadecyl amidoglycylspermine (TRANSFECTAM®), cationic lipids combined with non-cationic lipids, DOPE (dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine) or cholesterol, a cationic lipid composition composed of a 3:1 (w/w) mixture of DOSPA and 15 DOPE, and a 1:1 (w/w) mixture of DOTMA and DOPE. In another aspect of the invention is a use of a mixture comprising a polynucleotide delivery-enhancing polypeptide, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA) for the production of a medicament for the treatment of a Tumor Necrosis Factor 20 alpha (TNF-a) associated inflammatory condition(s) in an animal subject, wherein the medicament is capable of reducing TNF-x RNA levels thereby preventing or reducing the occurrence or severity of one or more symptom(s) of the TNF-oa associated inflammatory condition(s). In an embodiment, the polynucleotide delivery-enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a sequence selected from the group 25 consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, Mellitin, Histone H1, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186. In a related embodiment, the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated. In another related embodiment, the N-terminus of the polynucleotide delivery 30 enhancing polypeptide is pegylated. In another embodiment, the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tumor Necrosis Factor-alpha (TNF-a) gene. In a related embodiment, the dsRNA is a siRNA consisting of about 10 to about 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187. In another embodiment, 35 the polynucleotide delivery-enhancing polypeptide is admixed, complexed or conjugated to the dsRNA. In another embodiment, the polynucleotide delivery-enhancing polypeptide binds to the dsRNA. In another embodiment, the animal subject is a mammal. 5 WO 2007/030619 PCT/US2006/034859 5 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates peptide-mediated uptake and the effect on cell viability of siRNAs complexed or conjugated to a polynucleotide delivery-enhancing polypeptide of the invention (SEQ ID NO: 35). Cell uptake and cell viability are expressed in percent. Figure 2 further illustrates peptide-mediated uptake of siRNAs complexed or conjugated 0 to a polynucleotide delivery-enhancing polypeptide of the invention (SEQ ID NO: 35). Cell uptake is expressed as mean fluorescent intensity (MFI). Figure 3 shows peptide-mediated uptake of siRNAs in human monocytes with several different polynucleotide delivery-enhancing polypeptides. Figure 4 illustrates the effect on human monocyte viability after exposure to siRNAs .5 complexed with several different polynucleotide delivery-enhancing polypeptides. Figure 5 shows that siRNA/peptide injected mice have a delayed RA progression comparable to that exhibited by Ramicade-treated subjects. RA progression was measured by a paw scoring index. Figure 6 provides results of uptake efficacy and viability studies in mouse tail fibroblast 20 cells for PN73 rationally-designed derivative polynucleotide delivery-enhancing polypeptides of the invention. Figure 7 illustrates that peptide-mediated uptake of siRNAs complexed to a polynucleotide delivery-enhancing polypeptide of the invention does not elicit an interferon response compared to lipofectamine mediated delivery of siRNAs. (A): siRNA complexed with 25 Lipofectamine (B): siRNA complexed with PN73(1:5) Figure 8 shows that siNAs conjugated to a polynucleotide delivery-enhancing polypeptide have greater knockdown activity in vitro than siRNAs complexed with a polynucleotide delivery-enhancing polypeptide. Figure 9 shows a comparison of cell uptake between cholesterol conjugated siRNAs and 30 unconjugated siNAs with a polynucleotide delivery-enhancing polypeptide. Figure 10 shows that serum inhibition of cell uptake of cholesterol conjugated siRNAs can be rescued with a polynucleotide delivery-enhancing polypeptide. DESCRIPTION OF EXEMPLARY EMBODIMENTS OF THE INVENTION The present invention satisfies these needs and fulfills additional objects and advantages 35 by providing novel compositions and methods that employ a short interfering nucleic acid (siNA), or a precursor thereof, in combination with a polynucleotide delivery-enhancing polypeptide. The polynucleotide delivery-enhancing polypeptide is a natural or artificial 6 WO 2007/030619 PCT/US2006/034859 5 polypeptide selected for its ability to enhance intracellular delivery or uptake of polynucleotides, including siNAs and their precursors. Within the novel compositions of the invention, the siNA may be admixed or cominplexed with, or conjugated to, the polynucleotide delivery-enhancing polypeptide to form a composition that enhances intracellular delivery of the siNA as compared to delivery resulting from 10 contacting the target cells with a naked siNA (i.e., siNA without the delivery-enhancing polypeptide present). In certain embodiments of the invention, the polynucleotide delivery-enhancing polypeptide is a histone protein, or a polypeptide or peptide fragment, derivative, analog, or conjugate thereof. Within these embodiments, the siNA is admixed, complexed or conjugated 15 with one or more full length histone proteins or polypeptides corresponding at least in part to a partial sequence of a histone protein, for example of one or more of the following histones: histone H1, histone H2A, histone H2B, histone H3 or histone H4, or one or more polypeptide fragments or derivatives thereof comprising at least a partial sequence of a histone protein, typically at least 5-10 or 10-20 contiguous residues of a native histone protein. In more detailed 20 embodiments, the siRNA/histone mixture, complex or conjugate is substantially free of amphipathic compounds. In other detailed embodiments, the siNA that is admixed, complexed, or conjugated with the histone protein or polypeptide will comprise a double-stranded double stranded RNA, for example a double-stranded RNA that has 30 or fewer nucleotides, and is a short interfering RNA (siRNA). In exemplary embodiments, the histone polynucleotide 25 delivery-enhancing polypeptide comprises a fragment of histone H2B, as exemplified by the polynucleotide delivery-enhancing polypeptide designated PN73 described herein below. In yet additional detailed embodiments, the polynucleotide delivery-enhancing polypeptide may be pegylated to improve stability and/or efficacy, particularly in the context of in vivo administration. 30 Within additional embodiments of the invention, the polynucleotide delivery-enhancing polypeptide is selected or rationally designed to comprise an amphipathic amino acid sequence. For example, useful polynucleotide delivery-enhancing polypeptides may be selected which comprise a plurality of non-polar or hydrophobic amino acid residues that form a hydrophobic sequence domain or motif, linked to a plurality of charged amino acid residues that form a 35 charged sequence domain or motif, yielding an amphipathic peptide. In other embodiments, the polynucleotide delivery-enhancing polypeptide is selected to comprise a protein transduction domain or motif, and a fusogenic peptide domain or motif. A protein transduction domain is a peptide sequence that is able to insert into and preferably transit 7 WO 2007/030619 PCT/US2006/034859 5 through the membrane of cells. A fusogenic peptide is a peptide that destabilizes a lipid membrane, for example a plasma membrane or membrane surrounding an endosome, which may be enhanced at low pH. Exemplary fusogenic domains or motifs are found in a broad diversity of viral fusion proteins and in other proteins, for example fibroblast growth factor 4 (FGF4). To rationally design polynucleotide delivery-enhancing polypeptides of the invention, a 10 protein transduction domain is employed as a motif that will facilitate entry of the nucleic acid into a cell through the plasma membrane. In certain embodiments, the transported nucleic acid will be encapsulated in an endosome. The interior of endosomes has a low pH resulting in the fusogenic peptide motif destabilizing the membrane of the endosome. The destabilization and breakdown of the endosome membrane allows for the release of the siNA into the cytoplasm 15 where the siNA can associate with a RISC complex and be directed to its target mRNA. Examples of protein transduction domains for optional incorporation into polynucleotide delivery-enhancing polypeptides of the invention include: 1. TAT protein transduction domain (PTD) (SEQ ID NO: 1) KRRQRRR; 2. Penetratin PTD (SEQ ID NO: 2) RQIKIWFQNRRMKWKK; 20 3. VP22 PTD (SEQ ID NO: 3) DAATATRGRSAASRPTERPRAPARSASRPRRPVD; 4. Kaposi FGF signal sequences (SEQ ID NO: 4) AAVALLPAVLLALLAP, and SEQ ID NO: 5) AAVLLPVLLPVLLAAP; 5. Human P3 integrin signal sequence (SEQ ID NO: 6) VTVLALGALAGVGVG; 6. gp41 fusion sequence (SEQ ID NO: 7) GALFLGWLGAAGSTMGA; 25 7. Caiman crocodylus Ig(v) light chain (SEQ ID NO: 8) MGLGLHLLVLAAALQGA; 8. hCT-derived peptide (SEQ ID NO: 9) LGTYTQDFNKFHTFPQTAIGVGAP; 9. Transportan (SEQ ID NO: 10) GWTLNSAGYLLKINLKALAALAKKIL; 10. Loligomer (SEQ ID NO: 11) TPPKKKRKVEDPKKKK; 11. Arginine peptide (SEQ ID NO: 12) RRRRRRR; and 30 12. Amphiphilic model peptide (SEQ ID NO: 13) KLALKLALKICALKAALKLA. Examples of viral fusion peptides fusogenic domains for optional incorporation into polynucleotide delivery-enhancing polypeptides of the invention include: 1. Influenza HA2 (SEQ ID NO: 14) GLFGAIAGFIENGWEG; 2. Sendai F1 (SEQ ID NO: 15) FFGAVIGTIALGVATA; 35 3. Respiratory Syncytial virus F1 (SEQ ID NO: 16) FLGFLLGVGSAIASGV; 4. HIV gp41 (SEQ ID NO: 17) GVFVLGFLGFLATAGS; and 5. Ebola GP2 (SEQ ID NO: 18) GAAIGLAWIPYFGPAA. 8 WO 2007/030619 PCT/US2006/034859 5 Within yet additional embodiments of the invention, polynucleotide delivery-enhancing polypeptides are provided that incorporate a DNA-binding domain or motif which facilitates polypeptide-siNA complex formation and/or enhances delivery of siNAs within the methods and compositions of the invention. Exemplary DNA binding domains in this context include various "zinc finger" domains as described for DNA-binding regulatory proteins and other proteins 10 identified in Table 1, below (see, e.g., Simpson, et al., J Biol. Chem. 278:28011-28018, 2003). 9 WO 2007/030619 PCT/US2006/034859 5 Table 1: Exemplary Zinc Finger Motifs of Different DNA-Binding Proteins
C
2
H
z Zinc finger motif 665 675 685 695 705 715 Spl ACTCPYCDS EGRGSG---- DPGI BIC HIQORYG TSIhtPABR W ~GWPC Sp2 ACTCPNCDG BKRS------ GEQIGEVC BIPDGIER SILAfl~R BITGERkP7C Sp3 ACTaCscKEG GMr---- -aGIuaeIC aGeGKYG R9BALanmL WSsRPFrC Sp4 ACSCPNCREG EGNs---- EGmoQIeC IsEGeXOYG sILRAnLR WHGerIC DrosBtd RCTCPNCTNE MSGLPPIVGP DEREGRKHIC HIIPGCERLYG ISE.RTBIR HTGE RFM DrosSp ~TCDC~ECA EBPRLGPAGV-- BRaISC RHIPGC G KTSIRAIRlL HTGWERPFVC CeT22CB .5 RCTCPNKAI EIs ------- DRnSQteC SVcPG MW HSBIIBR RBTGDRPMVC Y40BIA. PUSLKEIF FFINFSR-- GDGERHIIC E--CNRYG ETSHLPARER GH~1PFAC Prosite pattern C-x(2 ,4) -C-x(12) -H-x(3) -H *The table demonstrates a conservative zinc fingerer motif for double strand DNA binding 0 which is characterized by the C-x(2,4)-C-x(12)-H-x(3)-H motif pattern (SEQ ID NO: 188), which itself can be used to select and design additional polynucleotide delivery-enhancing polypeptides according to the invention. **The sequences shown in Table 1, for Spl, Sp2, Sp3, Sp4, DrosBtd, DrosSp, CeT22C8.5, and Y4pB1A.4, are herein assigned SEQ ID NO:s 19, 20, 21, 22, 23, 24, 25, and 26, respectively. 5 Alternative DNA binding domains useful for constructing polynucleotide delivery enhancing polypeptides of the invention include, for example, portions of the HIV Tat protein sequence (see, Examples, below). Within exemplary embodiments of the invention described herein below, polynucleotide delivery-enhancing polypeptides may be rationally designed and constructed by combining any 0 of the foregoing structural elements, domains or motifs into a single polypeptide effective to mediate enhanced delivery of siNAs into target cells. For example, a protein transduction domain of the TAT polypeptide was fused to the N-terminal 20 amino acids of the influenza 10 WO 2007/030619 PCT/US2006/034859 5 virus hemagglutinin protein, termed HA2, to yield one exemplary polynucleotide delivery-enhancing polypeptide herein. Various other polynucleotide delivery-enhancing polypeptide constructs are provided in the instant disclosure, evincing that the concepts of the invention are broadly applicable to create and use a diverse assemblage of effective polynucleotide delivery-enhancing polypeptides for enhancing siNA delivery. 0 Yet additional exemplary polynucleotide delivery-enhancing polypeptides within the invention may be selected from the following peptides: WWETWKPFQCRICMRNFSTRQARRNHRRRHR (SEQ ID NO: 27); GKINLKALAALAKKIL (SEQ ID NO: 28), RVIRVWFQNKRCKDKK (SEQ ID NO: 29), GRKKRRQRRRPPQGRKKRRQRRRPPQGRKKRRQRRRPPQ (SEQ ID NO: 30), 5 GEQIAQLIAGYIDIILKKKKSK (SEQ ID NO: 31), Poly Lys-Trp, 4:1, MW 20,000-50,000; and Poly Omrn-Trp, 4:1, MW 20,000-50,000. Additional polynucleotide delivery-enhancing polypeptides that are useful within the compositions and methods herein comprise all or part of the mellitin protein sequence. Still other exemplary polynucleotide delivery-enhancing polypeptides are identified in 0 the examples below. Any one or combination of these peptides may be selected or combined to yield effective polynucleotide delivery-enhancing polypeptide reagents to induce or facilitate intracellular delivery of siNAs within the methods and compositions of the invention. In more detailed aspects of the invention, the mixture, complex or conjugate comprising a siRNA and a polynucleotide delivery-enhancing polypeptide can be optionally combined with 5 (e.g., admixed or complexed with) a cationic lipid, such as LIPOFECTIN@. In this context it is unexpectedly disclosed herein that polynucleotide delivery-enhancing polypeptides complexed or conjugated to a siRNA alone will effectuate delivery of the siNA sufficient to mediate gene silencing by RNAi. However, it is further unexpectedly disclosed herein that a siRNA/polynucleotide delivery-enhancing polypeptide complex or conjugate will exhibit even 0 greater activity for mediating siNA delivery and gene silencing when admixed or complexed with a cationic lipid, such as lipofectin. To produce these compositions comprised of a polynucleotide delivery-enhancing polypeptide, siRNA and a cationic lipid, the siRNA and peptide may be mixed together first in a suitable medium such as a cell culture medium, after which the cationic lipid is added to the mixture to form a siRNA/delivery peptide/cationic lipid 5 composition. Optionally, the peptide and cationic lipid can be mixed together first in a suitable medium such as a cell culture medium, whereafter the siRNA can be added to fonnrm the siRNA/delivery peptide/cationic lipid composition. 11 WO 2007/030619 PCT/US2006/034859 5 Examples of useful cationic lipids within these aspects of the invention include N-[1 (2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, 1,2-bis(oleoyloxy)-3-3 (trimethylammonium)propane, 1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium bromide, and dimethyldioctadecylammonium bromide, 2,3-dioleyloxy-N [2(sperminecarboxamido)ethyl]-N,N-dimethyl-1 -propanaminiu m trifluoracetate, 1,3 0 dioleoyloxy-2-(6-carboxyspennrmyl)-propylamid, 5-carboxyspennylglycine dioctadecylamide, tetramethyltetrapalmitoyl spermine, tetramethyltetraoleyl spermine, tetramethyltetralauryl spermine, tetramethyltetramyristyl spermine and tetramethyldioleyl spermine. DOTMA (N-[1 (2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAP (1,2-bis(oleoyloxy) 3,3-(trimethylammonium)propane), DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl 5 ammonium bromide) or DDAB (dimethyl dioctadecyl ammonium bromide). Polyvalent cationic lipids include lipospermines, specifically DOSPA (2,3-dioleyloxy-N [2(spenninecarboxamido)ethyl]-N,N-dimethyl-l1-propanamini urn trifluoro-acetate) and DOSPER (1,3-dioleoyloxy-2-(6carboxy spennrmyl)-propyl-amid, and the di- and tetra-alkyl-tetra methyl spermines, including but not limited to TMTPS (tetramethyltetrapalmitoyl spermine), '0 TMTOS (tetramethyltetraoleyl spermine), TMTLS (tetramethlytetralauryl spermine), TMTMS (tetramethyltetramyristyl spernnine) and TMDOS (tetramethyldioleyl spermine) DOGS (dioctadecyl-amidoglycylspermine (TRANSFECTAM®). Other useful cationic lipids are described, for example, in U.S. Patent No. 6,733,777; U.S. Patent No. 6,376,248; U.S. Patent No. 5,736,392; U.S. Patent No. 5,686,958; U.S. Patent No. 5,334,761 and U.S. Patent 15 No. 5,459,127. Cationic lipids are optionally combined with non-cationic lipids, particularly neutral lipids, for example lipids such as DOPE (dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine) or cholesterol. A cationic lipid composition composed of a 3:1 (w/w) mixture of DOSPA and DOPE or a 1:1 (w/w) mixture of DOTMA and DOPE 30 (LIPOFECTIN®, Invitrogen) are generally useful in transfecting compositions of this invention. Preferred transfection compositions are those which induce substantial transfection of a higher eukaryotic cell line. In exemplary embodiments, the instant invention features compositions comprising a small nucleic acid molecule, such as short interfering nucleic acid (siNA), a short interfering 35 RNA (siRNA), a double-stranded RNA (dsRNA), micro-RNA (mRNA), or a short hairpin RNA (shRNA), admixed or complexed with, or conjugated to, a polynucleotide delivery-enhancing polypeptide. 12 WO 2007/030619 PCT/US2006/034859 5 As used herein, the term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically-modified short interfering nucleic acid molecule", refers to any nucleic acid molecule capable of inhibiting or down regulating gene expression or viral replication, for example by mediating RNA interference "RNAi" or gene silencing in a 0 sequence-specific manner. Within exemplary embodiments, the siNA is a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule for down regulating expression, or a portion thereof, and the sense region comprises a nucleotide sequence corresponding to (i.e., which is 5 substantially identical in sequence to) the target nucleic acid sequence or portion thereof. "siNA" means a small interfering nucleic acid, for example a siRNA, that is a short-length double-stranded nucleic acid (or optionally a longer precursor thereof), and which is not unacceptably toxic in target cells. The length of useful siNAs within the invention will in certain embodiments be optimized at a length of approximately 21 to 23 bp long. However, 0 there is no particular limitation in the length of useful siNAs, including siRNAs. For example, siNAs can initially be presented to cells in a precursor form that is substantially different than a final or processed form of the siNA that will exist and exert gene silencing activity upon delivery, or after delivery, to the target cell. Precursor forms of siNAs may, for example, include precursor sequence elements that are processed, degraded, altered, or cleaved at or following the 5 time of delivery to yield a siNA that is active within the cell to mediate gene silencing. Thus, in certain embodiments, useful siNAs within the invention will have a precursor length, for example, of approximately 100-200 base pairs, 50-100 base pairs, or less than about 50 base pairs, which will yield an active, processed siNA within the target cell. In other embodiments, a useful siNA or siNA precursor will be approximatelyl 0 to 49 bp, 15 to 35 bp, or about 21 to 0 30 bp in length. In certain embodiments of the invention, as noted above, polynucleotide delivery-enhancing polypeptides are used to facilitate delivery of larger nucleic acid molecules than conventional siNAs, including large nucleic acid precursors of siNAs. For example, the methods and compositions herein may be employed for enhancing delivery of larger nucleic 5 acids that represent "precursors" to desired siNAs, wherein the precursor amino acids may be cleaved or otherwise processed before, during or after delivery to a target cell to form an active siNA for modulating gene expression within the target cell. For example, a siNA precursor polynucleotide may be selected as a circular, single-stranded polynucleotide, having two or more 13 WO 2007/030619 PCT/US2006/034859 5 loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof, and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an 0 active siNA molecule capable of mediating RNAi. In mammalian cells, dsRNAs longer than 30 base pairs can activate the dsRNA-dependent kinase PKR and 2'-5'-oligoadenylate synthetase, normally induced by interferon. The activated PKR inhibits general translation by phosphorylation of the translation factor eukaryotic initiation factor 2a (eIF2a), while 2'-5'-oligoadenylate synthetase causes 5 nonspecific mRNA degradation via activation of RNase L. By virtue of their small size (referring particularly to non-precursor forms), usually less than 30 base pairs, and most commonly between about 17-19, 19-21, or 21-23 base pairs, the siNAs of the present invention avoid activation of the interferon response. In contrast to the nonspecific effect of long dsRNA, siRNA can mediate selective gene 10 silencing in the mammalian system. Hairpin RNAs, with a short loop and 19 to 27 base pairs in the stem, also selectively silence expression of genes that are homologous to the sequence in the double-stranded stem. Mammalian cells can convert short hairpin RNA into siRNA to mediate selective gene silencing. RISC mediates cleavage of single stranded RNA having sequence complementary to the 15 antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex. Studies have shown that 21 nucleotide siRNA duplexes are most active when containing two nucleotide 3'-overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA 30 overhang nucleotides with deoxy nucleotides (2'-H) has been reported to be tolerated. Studies have shown that replacing the 3'-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3' overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with 35 deoxyribonucleotides results in no RNAi activity. Alternatively, the siNAs can be delivered as single or multiple transcription products expressed by a polynucleotide vector encoding the single or multiple siNAs and directing their expression within target cells. In these embodiments the double-stranded portion of a final 14 WO 2007/030619 PCT/US2006/034859 5 transcription product of the siRNAs to be expressed within the target cell can be, for example, 15 to 49 bp, 15 to 35 bp, or about 21 to 30 bp long. Within exemplary embodiments, double-stranded portions of siNAs, in which two strands pair up, are not limited to completely paired nucleotide segments, and may contain nonpairing portions due to mismatch (the corresponding nucleotides are not complementary), bulge (lacking in the corresponding 0 complementary nucleotide on one strand), overhang, and the like. Nonpairing portions can be contained to the extent that they do not interfere with siNA formation. In more detailed embodiments, a "bulge" may comprise 1 to 2 non-pairing nucleotides, and the double-stranded region of siNAs in which two strands pair up may contain from about 1 to 7, or about 1 to 5 bulges. In addition, "mismatch" portions contained in the double-stranded region of siNAs may 5 be present in numbers from about 1 to 7, or about 1 to 5. Most often in the case of mismatches, one of the nucleotides is guanine, and the other is uracil. Such mismatching may be attributable, for example, to a mutation from C to T, G to A, or mixtures thereof, in a corresponding DNA coding for sense RNA, but other cause are also contemplated. Furthermore, in the present invention the double-stranded region of siNAs in which two strands pair up may contain both 0 bulge and mismatched portions in the approximate numerical ranges specified. The terminal structure of siNAs of the invention may be either blunt or cohesive (overhanging) as long as the siNA retains its activity to silence expression of target genes. The cohesive (overhanging) end structure is not limited only to the 3' overhang as reported by others. On the contrary, the 5' overhanging structure may be included as long as it is capable of inducing 5 a gene silencing effect such as by RNAi. In addition, the number of overhanging nucleotides is not limited to reported limits of 2 or 3 nucleotides, but can be any number as long as the overhang does not impair gene silencing activity of the siNA. For example, overhangs may comprise from about 1 to 8 nucleotides, more often from about 2 to 4 nucleotides. The total length of siNAs having cohesive end structure is expressed as the sum of the length of the paired 0 double-stranded portion and that of a pair comprising overhanging single-strands at both ends. For example, in the exemplary case of a 19 bp double-stranded RNA with 4 nucleotide overhangs at both ends, the total length is expressed as 23 bp. Furthennore, since the overhanging sequence may have low specificity to a target gene, it is not necessarily complementary (antisense) or identical (sense) to the target gene sequence. Furthennore, as long 5 as the siNA is able to maintain its gene silencing effect on the target gene, it may contain low molecular weight structure (for example a natural RNA molecule such as tRNA, rRNA or viral RNA, or an artificial RNA molecule), for example, in the overhanging portion at one end. 15 WO 2007/030619 PCT/US2006/034859 5 In addition, the terminal structure of the siNAs may have a stem-loop structure in which ends of one side of the double-stranded nucleic acid are connected by a linker nucleic acid, e.g., a linker RNA. The length of the double-stranded region (stem-loop portion) can be, for example, 15 to 49 bp, often 15 to 35 bp, and more commonly about 21 to 30 bp long. Alternatively, the length of the double-stranded region that is a final transcription product of siNAs to be expressed 10 in a target cell may be, for example, approximately 15 to 49 bp, 15 to 35 bp, or about 21 to 30 bp long. When linker segments are employed, there is no particular limitation in the length of the linker as long as it does not hinder pairing of the stem portion. For example, for stable pairing of the stemin portion and suppression of recombination between DNAs coding for this portion, the linker portion may have a clover-leaf tRNA structure. Even if the linker has a length that would 15 hinder pairing of the stem portion, it is possible, for example, to construct the linker portion to include introns so that the introns are excised during processing of a precursor RNA into mature RNA, thereby allowing pairing of the stem portion. In the case of a stem-loop siRNA, either end (head or tail) of RNA with no loop structure may have a low molecular weight RNA. As described above, these low molecular weight RNAs may include a natural RNA molecule, such 20 as tRNA, rRNA or viral RNA, or an artificial RNA molecule. The siNA can also comprise a single stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (for example, where such siNA molecule does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), 25 wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5'-phosphate (see for example, Martinez, et al., Cell. 110:563-574, 2002, and Schwarz, et al., Molecular Cell 10:537-568, 2002, or 5',3'-diphosphate. As used herein, the term siNA molecule is not limited to molecules containing only naturally-occurring RNA or DNA, but also encompasses chemically-modified nucleotides and 30 non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'-OH) containing nucleotides. In certain embodiments short interfering nucleic acids do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH group). Such siNA 35 molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. Optionally, 16 WO 2007/030619 PCT/US2006/034859 5 siNA molecules can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), short hairpin 10 RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In other embodiments, siNA molecules for use within the invention may comprise separate sense and antisense sequences or regions, wherein the sense and antisense regions are .5 covalently linked by nucleotide or non-nucleotide linker molecules, or are alternately non-covalently linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking interactions. "Antisense RNA" is an RNA strand having a sequence complementary to a target gene mRNA, and thought to induce RNAi by binding to the target gene mRNA. "Sense RNA" has a 0 sequence complementary to the antisense RNA, and annealed to its complementary antisense RNA to form siRNA. These antisense and sense RNAs have been conventionally synthesized with an RNA synthesizer. As used herein, the term "RNAi construct" is a generic term used throughout the specification to include small interfering RNAs (siRNAs), hairpin RNAs, and other RNA species 5 which can be cleaved in vivo to form siRNAs. RNAi constructs herein also include expression vectors (also referred to as RNAi expression vectors) capable of giving rise to transcripts which fornn dsRNAs or hairpin RNAs in cells, and/or transcripts which can produce siRNAs in vivo. Optionally, the siRNA include single strands or double strands of siRNA. An siHybrid molecule is a double-stranded nucleic acid that has a similar fimunction to 0 siRNA. Instead of a double-stranded RNA molecule, an siHybrid is comprised of an RNA strand and a DNA strand. Preferably, the RNA strand is the antisense strand as that is the strand that binds to the target mnRNA. The siHybrid created by the hybridization of the DNA and RNA strands have a hybridized complementary portion and preferably at least one 3'overhanging end. siNAs for use within the invention can be assembled from two separate oligonucleotides, 5 where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e., each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure, for example wherein the double 17 WO 2007/030619 PCT/US2006/034859 5 stranded region is about 19 base pairs). The antisense strand may comprise a nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof, and the sense strand may comprise a nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, the siNA can be assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA 0 are linked by means of a nucleic acid-based or non-nucleic acid-based linker(s). Within additional embodiments, siNAs for intracellular delivery according to the methods and compositions of the invention can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence that is 5 complementary to a nucleotide sequence in a separate target nucleic acid molecule or a portion thereof, and the sense region comprises a nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Non-limiting examples of chemical modifications that can be made in an siNA include without limitation phosphorothioate internucleotide linkages, 2'-deoxyribonucleotides, 2'-O 0 methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides, and terminal glyceryl and/or inverted deoxy abasic residue incorporation. These chemical modifications, when used in various siNA constructs, are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. 5 In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid molecules'can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic 0 acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the .5 overall activity of the modified nucleic acid molecule can be greater than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native umnodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans. 18 WO 2007/030619 PCT/US2006/034859 5 The siNA molecules described herein, the antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the antisense region can comprise about one to about five phosphorothioate internucleotide linkages at the 5'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the 3'-terminal 0 nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or 5 more acyclic nucleotides. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 0 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand, the antisense 5 strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate 0 internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate intemrnucleotide linkages in the sense strand, the antisense strand, or both strands. An siNA molecule may be comprised of a circular nucleic acid molecule, wherein the 5 siNA is about 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops. 19 WO 2007/030619 PCT/US2006/034859 5 A circular siNA molecule contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides. 10 Modified nucleotides present in siNA molecules, preferably in the antisense strand of the siNA molecules, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for 5 example, Saenger, Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, are resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a '0 northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2'-O, 4'-C methylene-(D-ribofuranosyl) nucleotides); 2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio ethyl, 2'-deoxy-2'-fluoro nucleotides. 2'-deoxy-2'-chloro nucleotides, 2'-azido nucleotides, and 2' O-methyl nucleotides. The sense strand of a double stranded siNA molecule may have a terminal cap moiety 5 such as an inverted deoxybasic moiety, at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand. Non-limiting examples of conjugates include conjugates and ligands described in Vargeese, et al., U.S. Application Serial No. 10/427,160, filed April 30, 2003, incorporated by reference herein in its entirety, including the drawings. In another embodiment, the conjugate is 0 covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In yet another 5 embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological 20 WO 2007/030619 PCT/US2006/034859 5 system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a poly ethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified siNA molecules are described in Vargeese et al., U.S. Patent Application Publication 10 No. 20030130186, published July 10, 2003, and U.S. Patent Application Publication No. 20040110296, published June 10, 2004. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi activity. As such, one skilled in the art can screen siNA 15 constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art. A siNA further may be further comprised of a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of 20 the siNA. In one embodiment, a nucleotide linker can be a linker of >2 nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In another embodiment, the nucleotide linker can be a nucleic acid aptamer. By "aptamer" or "nucleic acid aptamer" as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule 5 in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that 0 other embodiments can be readily generated using techniques generally known in the art. See, for example, Gold, et al., Annu. Rev. Biochem. 64:763, 1995; Brody and Gold, J. Biotechnol. 74:5, 2000; Sun, Curr. Opin. Mol. Ther. 2:100, 2000; Kusser, J Biotechnol. 74:27, 2000; Hermann and Patel, Science 287:820, 2000; and Jayasena, Clinical Chemistiy 45:1628, 1999. A non-nucleotide linker may be comprised of an abasic nucleotide, polyether, polyamine, 5 polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g., polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 18:6353, 1990, and Nucleic Acids Res. 15:3113, 1987; Cload and Schepartz, J. Am. Chem. Soc. 113:6324, 1991; 21 WO 2007/030619 PCT/US2006/034859 5 Richardson and Schepartz, J. Am. Chem. Soc. 113:5109, 1991; Ma, et al., Nucleic Acids Res. 21:2585, 1993, and Biochemistry 32:1751, 1993; Durand, et al., Nucleic Acids Res. 18:6353, 1990; McCurdy, et al., Nucleosides & Nucleotides 10:287, 1991; Jschke, et al., Tetrahedron Lett. 34:301, 1993; Ono, et al., Biochemistry 30:9914, 1991; Arnold, et al., International Publication No. WO 89/02439; Usman, et al., International Publication No. WO 95/06731; Dudycz, et al., 10 International Publication No. WO 95/11910 and Ferentz and Verdine, J. Am. Chem. Soc. 113:4000, 1991. A "non-nucleotide" further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly 15 recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymidine, for example at the C1 position of the sugar. The synthesis of a siNA molecule of the invention, which can be chemically-modified, comprises: (a) synthesis of two complementary strands of the siNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double-stranded siNA 20 molecule. In another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase tandem oligonucleotide synthesis. Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides 25 lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers, et al., Methods in Enzymology 211:3-19, 1992; Thompson, et al., International PCT Publication No. WO 99/54459; Wincott, et al., Nucleic Acids Res. 23:2677-2684, 1995; Wincott, et al., Methods Mol. Bio. 74:59, 1997; Brennan, et al., Biotechnol Bioeng. 61:33-45, 1998; and Brennan, U.S. Patent No. 6,001,311. Synthesis of RNA, including 30 certain siNA molecules of the invention, follows general procedures as described, for example, in Usman, et al., J Am. Chem. Soc. 109:7845, 1987; Scaringe, et al., Nucleic Acids Res. 18:5433, 1990; and Wincott, et al., Nucleic Acids Res. 23:2677-2684, 1995; Wincott, et al., Methods Mol. Bio. 74:59, 1997. Supplemental or complementary methods for delivery of nucleic acid molecules for use 5 within then invention are described, for example, in Akhtar, et al., Trends Cell Bio. 2:139, 1992; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995; Maurer, et al., Mol. Membr. Biol. 16:129-140, 1999; Hofland and Huang, Handb. Exp. Pharmacol. 137:165-192, 1999; and Lee, et al.,ACS Symp. Ser. 752:184-192, 2000. Sullivan, et al., 22 WO 2007/030619 PCT/US2006/034859 5 International PCT Publication No WO 94/02595, further describes general methods for delivery of enzymatic nucleic acid molecules. These protocols can be utilized to supplement or complement delivery of virtually any nucleic acid molecule contemplated within the invention. Nucleic acid molecules and polynucleotide delivery-enhancing polypeptides can be administered to cells by a variety of methods known to those of skill in the art, including, but not 10 restricted to, administration within formulations that comprise the siNA and polynucleotide delivery-enhancing polypeptide alone, or that further comprise one or more additional components, such as a pharmaceutically acceptable carrier, diluent, excipient, adjuvant, emulsifier, buffer, stabilizer, preservative, and the like. In certain embodiments, the siNA and/or the polynucleotide delivery-enhancing polypeptide can be encapsulated in liposomes, 15 administered by iontophoresis, or incorporated into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, bioadhesive microspheres, or proteinaceous vectors (see e.g., O'Hare and Normand, International PCT Publication No. WO 00/53722). Alternatively, a nucleic acid/peptide/vehicle combination can be locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid molecules of the 0 invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry, et al., Clin. Cancer Res. 5:2330-2337, 1999, and Barry, et al., International PCT Publication No. WO 99/31262. The compositions of the instant invention can be effectively employed as pharmaceutical 5 agents. Pharmaceutical agents prevent, modulate the occurrence or severity of, or treat (alleviate one or more symptom(s) to a detectable or measurable extent) of a disease state or other adverse condition in a patient. Thus within additional embodiments the invention provides pharmaceutical compositions and methods featuring the presence or administration of one or more polynucleic acid(s), 0 typically one or more siNAs, combined, complexed, or conjugated with a polynucleotide delivery-enhancing polypeptide, optionally formulated with a pharmaceutically-acceptable carrier, such as a diluent, stabilizer, buffer, and the like. The present invention satisfies additional objects and advantages by providing short interfering nucleic acid (siNA) molecules that modulate expression of genes associated with a 5 particular disease state or other adverse condition in a subject. Typically, the siNA will target a gene that is expressed at an elevated level as a causal or contributing factor associated with the subject disease state or adverse condition. In this context, the siNA will effectively downregulate expression of the gene to levels that prevent, alleviate, or reduce the severity or 23 WO 2007/030619 PCT/US2006/034859 5 recurrence of one or more associated disease symptoms. Alternatively, for various distinct disease models where expression of the target gene is not necessarily elevated as a consequence or sequel of disease or other adverse condition, down regulation of the target gene will nonetheless result in a therapeutic result by lowering gene expression (i.e., to reduce levels of a selected mRNA and/or protein product of the target gene). Alternatively, siNAs of the invention 10 may be targeted to lower expression of one gene, which can result in upregulation of a "downstream" gene whose expression is negatively regulated by a product or activity of the target gene. Within exemplary embodiments, the compositions and methods of the invention are useful as therapeutic tools to regulate expression of tumor necrosis factor-a (TNF-a) to treat or 15 prevent symptoms of rheumatoid arthritis (RA). In this context the invention further provides compounds, compositions, and methods useful for modulating expression and activity of TNF- a by RNA interference (RNAi) using small nucleic acid molecules. In more detailed embodiments, the invention provides small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), 20 micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules, and related methods, that are effective for modulating expression of TNF-a and/or TNF-a genes to prevent or alleviate symptoms of RA in mammalian subjects. Within these and related therapeutic compositions and methods, the use of chemically-modified siNAs will often improve properties of the modified siNAs in comparison to properties of native siNA molecules, for example by providing increased 25 resistance to nuclease degradation in vivo, and/or through improved cellular uptake. As can be readily determined according to the disclosure herein, useful siNAs having multiple chemical modifications will retain their RNAi activity. The siNA molecules of the instant invention thus provide useful reagents and methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications. 30 This siNAs of the present invention may be administered in any form, for example transdermally or by local injection (e.g., local injection at sites of psoriatic plaques to treat psoriasis, or into the joints of patients afflicted with psoriatic arthritis or RA). In more detailed embodiments, the invention provides formulations and methods to administer therapeutically effective amounts of siNAs directed against of a mRNA of TNF-a, which effectively 35 down-regulate the TNF- a RNA and thereby reduce or prevent one or more TNF-a-associated inflammatory condition(s). Comparable methods and compositions are provided that target expression of one or more different genes associated with a selected disease condition in animal 24 WO 2007/030619 PCT/US2006/034859 5 subjects, including any of a large number of genes whose expression is known to be aberrantly increased as a causal or contributing factor associated with the selected disease condition. The siNA/polynucleotide delivery-enhancing polypeptide mixtures of the invention can be administered in conjunction with other standard treatments for a targeted disease condition; for example in conjunction with therapeutic agents effective against inflammatory diseases, such 10 as RA or psoriasis. Examples of combinatorially useful and effective agents in this context include non-steroidal antiinflammatory drugs (NSAIDs), methotrexate, gold compounds, D-penicillamine, the antimalarials, sulfasalazine, glucocorticoids, and other TNF-a neutralizing agents such as infliximab and entracept. Negatively charged polynucleotides of the invention (e.g., RNA or DNA) can be 15 administered to a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention may also be formnnulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for 20 injectable administration, and the other compositions known in the art. The present invention also includes pharmaceutically acceptable formulations of the compositions described herein. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid. 25 A pharmacological composition or formulation refers to a composition or formulation in a fonn suitable for administration, e.g., systemic administration, into a cell or patient, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged nucleic acid is 30 desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity. By "systemic administration" is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration 5 routes which lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function 25 WO 2007/030619 PCT/US2006/034859 5 of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of 10 the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells. By "pharmaceutically acceptable formulation" is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents 15 suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, Fundam. Clin. Pharmacol. 13:16-26, 1999); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, D.F., et al., Cell Transplant 8:47-58, 1999) (Alkermes, 0 Inc. Cambridge, Mass.); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry 23:941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado, et al., J. Pharm. Sci. 87:1308-1315, 1998; Tyler, 15 et al., FEBSLett. 421:280-284, 1999; Pardridge, et al., PNAS USA. 92:5592-5596, 1995; Boado, Adv. Drug Delivery Rev. 15:73-107, 1995; Aldrian-Herrada, et al., Nucleic Acids Res. 26:4910-4916, 1998; and Tyler, et al., PNAS USA. 96:7053-7058, 1999. The present invention also includes compositions prepared for storage or administration, which include a pharmaceutically effective amount of the desired compounds in a 0 pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., A.R. Gennaro ed., 1985. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and 5 suspending agents may be used. A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence of, or treat (alleviate a symptom to some extent, preferably all of the symptoms) a disease state. The phanrmaceutically effective dose depends on the type of disease, the composition used, the 26 WO 2007/030619 PCT/US2006/034859 5 route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer. 10 Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecitlhin, or condensation products of an alkylene 15 oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan 20 monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid 25 paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by 30 the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present. Phanrmaceutical compositions of the invention can also be in the form of oil-in-water 5 emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and 27 WO 2007/030619 PCT/US2006/034859 5 condensation products of the said partial esters with ethylene oxide, for example' polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using 10 those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally 15 employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The siNAs can also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a 20 suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols. The siNAs can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H. For a 25 review see Usman and Cedergren, TIBS 17:34, 1992; Usman, et al., Nucleic Acids Symp. Ser. 31:163, 1994. SiNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography and re-suspended in water. Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their 30 potency. See e.g., Eckstein, et al., International Publication No. WO 92/07065; Perrault, et al., Nature 344:565, 1990; Pieken, et al., Science 253:314, 1991; Usman and Cedergren, Trends in Biochemn. Sci. 17:334, 1992; Usman, et al., International Publication No. WO 93/15187; and Rossi, et al., International Publication No. WO 91/03162; Sproat, U.S. Patent No. 5,334,711; Gold, et al., U.S. Patent No. 6,300,074. All of the above references describe various chemical 35 modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease 28 WO 2007/030619 PCT/US2006/034859 5 stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide base modifications. For a review see Usman and Cedergren, TIBS 17:34, 1992; Usman, et al., Nucleic Acids Symp. Ser. 31:163, 1994; Burgin, et al., Biochemisty 35:14090, 1996. Sugar modification of nucleic acid 10 molecules have been extensively described in the art. See Eckstein, et al., International Publication PCT No. WO 92/07065; Perrault, et al. Nature 344:565-568, 1990; Pieken, et al., Science 253:314-317, 1991; Usman and Cedergren, Trends in Biochem. Sci. 17:334-339, 1992; Usman, et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Patent No. 5,334,711 and Beigelman, et al., J Biol. Chem. 270:25702, 1995; Beigelman, et al., 15 International PCT Publication No. WO 97/26270; Beigelman, et al., U.S. Patent No. 5,716,824; Usman, et al., U.S. Patent No. 5,627,053; Woolf, et al., International PCT Publication No. WO 98/13526; Thompson, et al., Karpeisky, et al., Tetrahedron Lett. 39:1131, 1998; Eamrnshaw and Gait, Biopolymers (Nucleic Acid Sciences) 48:39-55, 1998; Verma and Eckstein, Annu. Rev. Biochem. 67:99-134, 1998; and Burlina, et al., Bioorg. Med. Chem. 5:1999-2010, 1997. Such Z0 publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis. In view of such teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi in cells is not significantly inhibited. .5 While chemical modification of oligonucleotide intemucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5'-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting 0 in increased efficacy and higher specificity of these molecules. In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, fonnacetal, thioformacetal, and/or 5 alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, "Nucleic Acid Analogues: Synthesis and Properties, in Modem Synthetic Methods," VCH, 1995, pp. 331-417, and Mesmaeker, et al., "Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research," ACS, 1994, pp. 24-39. 29 WO 2007/030619 PCT/US2006/034859 5 Methods for the delivery of nucleic acid molecules are described in Akhtar, et al., Trends Cell Bio. 2:139, 1992; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995; Maurer, et al., MoL. Membr. BioL 16:129-140, 1999; Hofland and Huang, Handb. Exp. Pharmacol. 137:165-192, 1999; and Lee, et al., ACS Symp. Ser. 752:184-192, 2000. Beigelman, et al., U.S. Patent No. 6,395,713 and Sullivan, et al., PCT WO 94/02595 further 0 describe the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins (see for example, Gonzalez, 15 et al., Bioconjugate Chem. 10:1068-1074, 1999; Wang, et al., International PCT Publication Nos. WO 03/47518 and WO 03/46185), poly(lactic-co-glycolic)ac- id (PLGA) and PLCA microspheres (see for example, U.S. Patent No. 6,447,796 and U.S. Patent Application Publication No. US 2002130430), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication 20 No. WO 00/53722). Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid molecules of the invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry, et al., Clin. Cancer Res. 5:2330-2337, 1999, and Barry, et al., International 25 PCT Publication No. WO 99/31262. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, modulate the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a subject. The term "ligand" refers to any compound or molecule, such as a drug, peptide, hormone, 30 or neurotransmitter, that is capable of interacting with another compound, such as a receptor, either directly or indirectly. The receptor that interacts with a ligand can be present on the surface of a cell or can alternately be an intracellular receptor. Interaction of the ligand with the receptor can result in a biochemical reaction, or can simply be a physical interaction or association. 35 By "asymmetric hairpin" as used herein is meant a linear siNA molecule comprising an antisense region, a loop portion that can comprise nucleotides or non-nucleotides, and a sense region that comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and form a 30 WO 2007/030619 PCT/US2006/034859 5 duplex with loop. For example, an asymmetric hairpin siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a T-cell (e.g., about 19 to about 22 (e.g., about 19, 20, 21, or 22) nucleotides and a loop region comprising about 4 to about 8 (e.g., about 4, 5, 6, 7, or 8) nucleotides, and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are 10 complementary to the antisense region. The asymmetric hairpin siNA molecule can also comprise a 5'-terminal phosphate group that can be chemically modified. The loop portion of the asymmetric hairpin siNA molecule can comprise nucleotides, non-nucleotides, linker molecules, or conjugate molecules as described herein. By "asymmetric duplex" as used herein is meant a siNA molecule having two separate 5 strands comprising a sense region and an antisense region, wherein the sense region comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and form a duplex. For example, an asymmetric duplex siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a T-cell (e.g., about 19 to about 22 (e.g., 0 about 19, 20, 21, or 22) nucleotides and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region. By "modulate gene expression" is meant that the expression of a target gene is upregulated or downregulated, which can include upregulation or downregulation of mRNA 5 levels present in a cell, or of mRNA translation, or of synthesis of protein or protein subunits, encoded by the target gene. Modulation of gene expression can be determined also be the presence, quantity, or activity of one or more proteins or protein subunits encoded by the target gene that is up regulated or down regulated, such that expression, level, or activity of the subject protein or subunit is greater than or less than that which is observed in the absence of the 0 modulator (e.g., a siRNA). For example, the term "modulate" can mean "inhibit," but the use of the word "modulate" is not limited to this definition. By "inhibit", "down-regulate", or "reduce" expression, it is meant that the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or level or activity of one or more proteins or protein subunits 5 encoded by a target gene, is reduced below that observed in the absence of the nucleic acid molecules (e.g., siNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with an siNA molecule is below that level observed in the presence of an inactive or attenuated molecule. In another embodiment, inhibition, down-regulation, or reduction with 31 WO 2007/030619 PCT/US2006/034859 5 siNA molecules is below that level observed in the presence of, for example, an siNA molecule with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule of the instant invention is greater in the presence of the nucleic acid molecule than in its absence. Gene "silencing" refers to partial or complete loss-of-function through targeted inhibition 10 of gene expression in a cell and may also be referred to as "knock down." Depending on the circumstances and the biological problem to be addressed, it may be preferable to partially reduce gene expression. Alternatively, it might be desirable to reduce gene expression as much as possible. The extent of silencing may be determined by methods known in the art, some of which are summarized in International Publication No. WO 99/32619. Depending on the assay, 15 quantification of gene expression permits detection of various amounts of inhibition that may be desired in certain embodiments of the invention, including prophylactic and therapeutic methods, which will be capable of knocking down target gene expression, in terms of mRNA levels or protein levels or activity, for example, by equal to or greater than 10%, 30%, 50%, 75% 90%, 95% or 99% of baseline (i.e., normal) or other control levels, including elevated expression 0 levels as may be associated with particular disease states or other conditions targeted for therapy. The phrase "inhibiting expression of a target gene" refers to the ability of a siNA of the invention to initiate gene silencing of the target gene. To examine the extent of gene silencing, samples or assays of the organism of interest or cells in culture expressing a particular construct are compared to control samples lacking expression of the construct. Control samples (lacking 5 construct expression) are assigned a relative value of 100%. Inhibition of expression of a target gene is achieved when the test value relative to the control is about 90%, often 50%, and in certain embodiments 25-0%. Suitable assays include, e.g., examination of protein or mRNA levels using techniques known to those of skill in the art such as dot blots, northern blots, in situ hybridization, ELISA, inununoprecipitation, enzyme function, as well as phenotypic assays 0 known to those of skill in the art. By "subject" is meant an organism, tissue, or cell, which may include an organism as the subject or as a donor or recipient of explanted cells or the cells that are themselves subjects for siNA delivery. "Subject" therefore may refers to an organism, organ, tissue, or cell, including in vitro or ex vivo organ, tissue or cellular subjects, to which the nucleic acid molecules of the 5 invention can be administered and enhanced by polynucleotide delivery-enhancing polypeptides described herein. Exemplary subjects include mammalian individuals or cells, for example human patients or cells. 32 WO 2007/030619 PCT/US2006/034859 5 As used herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing 10 or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell. By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid. By "comprising" is meant including, but not limited to, whatever follows the word 15 "comprising." Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of' is meant including, and limited to, whatever follows the phrase "consisting of." Thus, the phrase "consisting of' indicates that the listed elements are required or mandatory, and that no other elements may be present. By "consisting essentially of' is meant including any 20 elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of' indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements. 25 By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a .beta.-D-ribo furanose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, 30 deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can 35 be referred to as analogs or analogs of naturally-occurring RNA. By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other. 33 WO 2007/030619 PCT/US2006/034859 5 By "sense region" is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence. By "antisense region" is meant a nucleotide sequence of a siNA molecule having 10 complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity to a sense region of the siNA molecule. By "target nucleic acid" is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA. 15 By "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free 20 energies for nucleic acid molecules is well known in the art (see, e.g., Turner, et al., CSHSymp. Quant. Biol., LII, 1987, pp. 123-133; Frier, et al., Proc. Nat. Acad. Sci. USA 83:9373-9377, 1986; Turner, et al., J Amn. Chemn. Soc. 109:3783-3785, 1987. A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 25 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. 30 The term "universal base" as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example, Loakes, 35 Nucleic Acids Research 29:2437-2447, 2001). The term "acyclic nucleotide" as used herein refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide. 34 WO 2007/030619 PCT/US2006/034859 5 The term "biodegradable" as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation. The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siNA molecules either alone or in combination with other 10 molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention 15 also include molecules capable of modulating the pharmacokinetics and/or phannacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers. The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus-containing 20 group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups. By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic, et al., U.S. Patent No. 5,998,203, incorporated by reference herein). These terminal modifications protect the 25 nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminal (3'-cap) or may be present on both termini. In non-limiting examples, the 5'-cap includes, but is not limited to, glyceryl, inverted deoxy abasic residue (moiety); 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide; carbocyclic nucleotide; 1,5 30 anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl 35 phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety. Non-limiting examples of the 3'-cap include, but are not limited to, glyceryl, inverted deoxy abasic residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) 35 WO 2007/030619 PCT/US2006/034859 5 nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2 propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aininododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5' 10 5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5' phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5' phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Lyer, Tetrahedron 49:1925, 1993; incorporated by reference herein). 15 By the tenn "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore 20 lacks a base at the 1'-position. By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or Z5 base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, supra; Eckstein, et al., International PCT Publication No. WO 92/07065; Usman, et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra, all are hereby incorporated by reference herein. There are several examples of modified nucleic acid 30 bases known in the art as summarized by Limbach, et al., Nucleic Acids Res. 22:2183, 1994. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5 '5 bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin, et al., Biochemistry 35:14090, 1996; Uhlman & Peyman, supra). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents. 36 WO 2007/030619 PCT/US2006/034859 5 By "target site" is meant a sequence within a target RNA that is "targeted" for cleavage mediated by a siNA construct which contains sequences within its antisense region that are complementary to the target sequence. By "detectable level of cleavage" is meant cleavage of target RNA (and formation of cleaved product RNAs) to an extent sufficient to discern cleavage products above the 10 background of RNAs produced by random degradation of the target RNA. Production of cleavage products from 1-5% of the target RNA is sufficient to detect above the background for most methods of detection. By "biological system" is meant, material, in a purified or unpurified form, from biological sources, including but not limited to human, animal, plant, insect, bacterial, viral or 15 other sources, wherein the system comprises the components required for RNAi activity. The term "biological system" includes, for example, a cell, tissue, or organism, or extract thereof. The term biological system also includes reconstituted RNAi systems that can be used in an in vitro setting. The term "biodegradable linker" as used herein, refers to a nucleic acid or non-nucleic 20 acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability of a nucleic acid-based 25 biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and chemically-modified nucleotides, such as 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 30 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications. By "abasic" is meant sugar moieties lacking a base or having other chemical groups in 35 place of a base at the 1' position, see for example Adamic, et al., U.S. Patent No. 5,998,203. By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1' carbon of beta.-D-ribo-furanose. 37 WO 2007/030619 PCT/US2006/034859 5 By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein. In connection with 2'-modified nucleotides as described for the present invention, by 0 "amino" is meant 2'-NH 2 or 2'-O--NH 2 , which can be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Patent No. 5,672,695 and Matulic-Adamic, et al., U.S. Patent. No. 6,248,878. The siNA molecules can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can 5 be locally administered to through injection, infusion pump or stent, with or without their incorporation in biopolymers. In another embodiment, polyethylene glycol (PEG) can be covalently attached to siNA compounds of the present invention, to the polynucleotide delivery enhancing polypeptide, or both. The attached PEG can be any molecular weight, preferably from about 2,000 to about 50,000 daltons (Da). 0 The sense region can be connected to the antisense region via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker. "Inverted repeat" refers to a nucleic acid sequence comprising a sense and an antisense element positioned so that they are able to form a double stranded siRNA when the repeat is transcribed. The inverted repeat may optionally include a linker or a heterologous sequence such 5 as a self-cleaving ribozyme between the two elements of the repeat. The elements of the inverted repeat have a length sufficient to form a double stranded RNA. Typically, each element of the inverted repeat is about 15 to about 100 nucleotides in length, preferably about 20-30 base nucleotides, preferably about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. 0 "Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. 5 Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). 38 WO 2007/030619 PCT/US2006/034859 5 "Large double-stranded RNA" refers to any double-stranded RNA having a size greater than about 40 base pairs (bp) for example, larger than 100 bp or more particularly larger than 300 bp. The sequence of a large dsRNA may represent a segment of an mRNA or the entire mRNA. The maximum size of the large dsRNA is not limited herein. The double-stranded RNA may include modified bases where the modification may be to the phosphate sugar backbone or 0 to the nucleoside. Such modifications may include a nitrogen or sulfur heteroatom or any other modification known in the art. The double-stranded structure may be formed by self-complementary RNA strand such as occurs for a hairpin or a micro RNA or by annealing of two distinct complementary RNA strands. 5 "Overlapping" refers to when two RNA fragments have sequences which overlap by a plurality of nucleotides on one strand, for example, where the plurality of nucleotides (nt) numbers as few as 2-5 nucleotides or by 5-10 nucleotides or more. "One or more dsRNAs" refers to dsRNAs that differ from each other on the basis of sequence. 0 "Target gene or mRNA" refers to any gene or mRNA of interest. Indeed any of the genes previously identified by genetics or by sequencing may represent a target. Target genes or mRNA may include developmental genes and regulatory genes as well as metabolic or structural genes or genes encoding enzymes. The target gene may be expressed in those cells in which a phenotype is being investigated or in an organism in a manner that directly or indirectly impacts Z5 a phenotypic characteristic. The target gene may be endogenous or exogenous. Such cells include any cell in the body of an adult or embryonic animal or plant including gamete or any isolated cell such as occurs in an immortal cell line or primary cell culture. In this specification and the appended claims, the singular forms of "a", "an" and "the" include plural reference unless the context clearly dictates otherwise. 30 EXAMPLES The above disclosure generally describes the present invention, which is further exemplified by the following examples. These examples are described solely for purposes of illustration, and are not intended to limit the scope of the invention. Although specific terms and values have been employed herein, such terms and values will likewise be understood as 35 exemplary and non-limiting to the scope of the invention. 39 WO 2007/030619 PCT/US2006/034859 5 Example 1 Production and Characterization of Compositions Comprising a siRNA Complexed With a Polynucleotide Delivery-Enhancing Polypeptide To form complexes between candidate siRNAs and polynucleotide delivery-enhancing polypeptides of the invention, an adequate amount of siRNA is combined with a pre-determined 10 amount of polynucleotide delivery-enhancing polypeptide, for example in Opti-MEM ® cell medium (Invitrogen), in defined ratios and incubated at room temperature for about 10-30 min. Subsequently a selected volume, e.g., about 50 pl, of this mixture is brought into contact with target cells and the cells are incubated for a predetermined incubation period, which in the present example was about 2 hr. The siRNA/peptide mixture can optionally include cell culture 15 medium or other additives such as fetal bovine serum. For H3, H4 and H2b, a series of experiments was performed to complex these polynucleotide delivery-enhancing polypeptides with siRNA in different ratios. Generally this was initiated with a 1:0.01 to 1:50 of siRNA/histone ratio. To each well in a 96-well microtiter plate, 40 pm siRNA was added. Each well contained beta-gal cells at 50% confluency. Exemplary optimized ratios for transfection 20 efficiency are shown in Table 2 below. Transfections were performed with either regular siRNA or siRNA complexed with one of the above-identified histone proteins on 9L/beta-gal cells. The siRNA was designed to specifically knock down beta-galactosidase mRNA, and activities are expressed as percentage of beta-gal activities from control (control cells were transfected using lipofectamine without the 25 polynucleotide delivery-enhancing polypeptide). Assays for detecting and/or quantifying the efficiency of siRNA delivery are carried out using conventional methods, for example beta-galactosidase assay or flow cytometry methods. For beta-galactosidase assays, 9L/LacZ cells, a cell line constitutively expressing beta galactosidase, were used. 9L/LacZ cells are rat gliosarcoma fibroblast cells that constitutively 30 express LacZ and were obtained from ATCC (#CRL-2200). 9L/LacZ cells were grown in Dulbecco's Modified Essential Medium (DMEM) media with a supplement of 1 mM sodium pyruvate, nonessential amino acids, and 20% fetal bovine serum. Cells were cultured at 37 0 C and 5% CO 2 supplemented with an antibiotic mixture containing 100 units/ml penicillin, 100 gg/ml streptomycin and 0.25 mg/ml Fungizone (Invitrogen). The siRNA duplex designed 35 against beta-gal mRNA was chemically synthesized and used with delivery reagents to evaluate knock-down efficiency. 40 WO 2007/030619 PCT/US2006/034859 5 Peptide Synthesis Peptides were synthesized by solid-phase Fmoc chemistry on CLEAR-amide resin using a Rainin Symphony synthesizer. Coupling steps were performed using 5 equivalents of HCTU and Fmoc amino acid with an excess of N-methylmorpholine for 40 minutes. Fmoc removal was accomplished by treating the peptide resin with 20% piperidine in DMF for two 10 minute 10 cycles. Upon completion of the entire peptide, the Fmoc group was removed with piperidine and washed extensively with DMF. Maleimido modified peptides were prepared by coupling 3.0 equivalents of 3-maleimidopropionic acid and HCTU in the presence of 6 equivalents of N-methylmorpholine to the N-terminus of the peptide resin. The extent of coupling was monitored by the Kaiser test. The peptides were cleaved from the resin by the addition of 10 mL 15 of TFA containing 2.5% water and 2.5 triisopropyl silane followed by gentle agitation at room temperature for 2 hours. The resulting crude peptide was collected by trituration with ether followed by filtration. The crude product was dissolved in Millipore water and lyophilized to dryness. The crude peptide was taken up in 15 mL of water containing 0.05% TFA and 3 mL acetic acid and loaded onto a Zorbax RX-C8 reversed-phase (22 mm ID x 250 mm, 5 pmn particle 20 size) through a 5 mL injection loop at a flow rate of 5 mL/min. The purification was accomplished by running a linear AB gradient of 0.1% B/min where solvent A is 0.05% TFA in water and solvent B is 0.05% TFA in acetonitrile. The purified peptides were analyzed by HPLC and ESMS. siRNA Synthesis and Preparation 25 Synthesis of oligonucleotides was carried out using the standard 2-cyanoethyl phosphoramidite method on long chain alkylamine controlled pore glass derivatized with 5'-O Dimethyltrityl-2'-O-t-butyldimethylsilyl-3'-O-succinyl ribonucleoside of choice or 5'-O Dimethyltrityl-2'-deoxy-3'-O-succinyl thymidine support where applicable. All oligonucleotides were synthesized at either the 0.2 or 1-gmol scale using an ABI 3400 DNA/RNA synthesizer, 30 cleaved from the solid support using concentrated NH 4 OH, and deprotected using a 3:1 mixture of NH 4 OH : EtOH at 55 oC. The deprotection of 2'-TBDMS protecting groups was achieved by incubating the base-deprotected RNA with a solution (600 gL per pmol) of N methylpyrrolidone/triethylamnine/triethylamnine tris(hydrofluoride) (6:3:4 by volume) at 65 oC for 2.5 hours. The corresponding building blocks, 5'-dimethoxytrityl-N-(tac)-2'-O-(t 35 butyldimethylsilyl)-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidites of A, U, C and G (Proligo, Boulder CO) as well the modified phosphoramidites, 5'DMTr-5-methyl-U-TOM-CE Phosphoramidite, 5'-DMTr-2'-OMe-Ac-C-CE Phosphoramidite, 5'-DMTr-2'-OMe-G-CE 41 WO 2007/030619 PCT/US2006/034859 5 Phosphoramidite, 5'-DMTr-2'-OMe-U-CE Phosphoramidite, 5'-DMTr-2'-OMe-A-CE Phosphoramidite (Glen Research) were purchased directly from suppliers. Triethylamine trihydrofluride, N-methylpyrrolidinone and concentrated ammonium hydroxide was purchased from Aldrich. All HPLC analysis and purifications were performed on a Waters 2690 with XterraTM columns. All other reagents were purchased from Glen Research Inc. Oligonucleotides 10 were purified to greater than 97% purity as determined by RP-HPLC. siRNAs for mouse injection were purchased from Qiagen, which were HIPLC purified after annealing with acceptable endotoxin level for in vivo injection. Cell Cultures Primary Human Monocvtes: 15 Fresh human blood samples from healthy donors were purchased from Golden West Biologicals. For isolation of monocytes, blood samples were diluted with PBS at a 1:1 ratio immediately after receiving. Peripheral blood mononuclear cells (PBMC) were first isolated by Ficoll (Amersham) gradient from whole blood. Monocytes were further purified from PBMCs using the Miltenyi CD14 positive selection kit and supplied protocol (MILTENYI BIOTEC). To 20 asses the purity of the monocyte preparation, cells were incubated with an anti-CD14 antibody (BD Biosciences) and then sorted by flow cytometry. The purity of the monocyte preparation was greater than 95%. Activation of human monocytes was performed by adding 0.1 -1.0 ng /ml of Liposaccharides, LPS (Sigma, St Louis, MO) to the cell culture to stimulate tumor necrosis 25 factor-- (TNF-h) production. Cells were harvested 3 hours after incubation with LPS and mRNA levels were determined by Quantigene assay (Genospectra, Fremont, CA) according to the manufacturer's instructions. Mouse Tail Fibroblast Cells: Mouse tail fibroblast (MTF) cells were derived from the tails of C57BL/6J mice. Tails 30 were removed, immersed in 70% ethanol and then cut into small sections with a razor blade. The sections were washed three times with PBS and then incubated in a shaker at 37 0 C with 0.5 mg/mL collagenase, 100 units/mL penicillin and 100 pgg/mL streptomycin to disrupt tissue. Tail sections were then cultured in complete media (Dulbecco's Modified Essential Medium with 20% FBS, knM sodium pyruvate, nonessential amino acids and 100 units/mL penicillin and 35 100 gg/mL streptomycin) until cells were established. Cells were cultured at 37 0 C, 5% CO 2 in complete media as outlined above. 42 WO 2007/030619 PCT/US2006/034859 5 Transfection Procedure On the first day of the procedure, saturated 9L/LacZ cultures are taken from T75 flasks, and the cells are detached and diluted into 10 ml of complete medium (DMEM, IxPS, lxNa Pyruvate, lx NEAA). The cells are further diluted to 1:15, and 100 p1l of this preparation are aliquoted into wells of 96 well plates, which will generally yield about 50% cell confluence by 10 the next day for the transfection. Edges of the wells are left empty and filled with 250 p.1 water, and the plates are placed un-stacked in the incubator overnight at 37 0 C (5% CO 2 incubator). On the second day, the transfection complex is prepared in Opti-MEM, 50 p.l each well. The medium is removed from the plates, and the wells are washed once with 200 gl PBS or Opti-MEM. The plates are blotted and dried completely with tissue by inversion. The 15 transfection mixture is then added (50 p.l/well) into each well, and 250 p.l water is added to the wells on the edge to prevent them from drying. The cells are then incubated for at least 3 hours at 37 0 C (5% CO 2 incubator). The transfection mixture is removed and replaced with 100 p1 of complete medium (DMEM, lxPS, lxNa Pyruvate, lx NEAA). The cells are cultured for a defined length of time, and then harvested for the enzyme assay. 20 Cell Viability (MTT Assay) Cell viability will be assessed using the MTT assay (MTT-100, MatTek kit). This kit measures the uptake and transformation of tetrazolium salt to fonnazan dye. Thawed and diluted MTT concentrate is prepared 1 hour prior to the end of the dosing period with the lipid by mixing 2 mL of MTT concentrate with 8 mL of MTT diluent. Each cell culture insert is washed twice 25 with PBS containing Ca +2 and Mg +2 and then transferred to a new 96-well transport plate containing 100 gL of the mixed MTT solution per well. This 96-well transport plate is then incubated for 3 hours at 37 0 C and 5% CO 2 . After the 3 hour incubation, the MTT solution is removed and the cultures are transferred to a second 96-well feeder tray containing 250 pL MTT extractant solution per well. An additional 150 gL of MTT extractan solution was added to the 30 surface of each culture well and the samples sat at room temperature in the dark for a minimum of 2 hours and maximum of 24 hours. The insert membrane was then pierced with a pipet tip and the solutions in the upper and lower wells were allowed to mix. Two hundred microliters of the mixed extracted solution along with extracted blanks (negative control) was transferred to a 96-well plate for measurement with a microplate reader. The optical density (OD) of the 35 samples was measured at 570 m with the background subtraction at 650 mn on a plate reader. Cell viability was expressed as a percentage and calculated by dividing the OD readings for treated inserts by the OD readings for the PBS treated inserts and multiplying by 100. For the 43 WO 2007/030619 PCT/US2006/034859 5 purposes of this assay, it was assumed that PBS had no effect on cell viability and therefore represented 100% cell viability. Enzymatic Assay Reagents for the enzymatic assay were purchased from Invitrogen (3-Gal Assay Kit,), and Fisher (Pierce Micro BCA Protein Assay Reagent Kit, Catalog). .0 A: Cell Lysis * Remove the medium, wash once with 200 Ll PBS, blot the plate dry with inversion. * Add 30 jl lysis buffer from P -Gal Kit into each well. * Freeze-Thaw the cells twice to generate lysate. B: 3 -Gal assay 15 * Prepare assay mix (50 pl lxbuffer, 17[d ONPG each well) * Take new plate, add 65 p1 assay mix into each well. * Add 10 pl of cell lysate into each well. There should be blank wells for subtraction of the background activities. * Incubate at 37 0 C for about 20 minutes, prevent long incubation which will use up ONPG 20 and bias the high expression. * Add 100 p1 of the Stop solution. * Measure the OD at 420 nm. C: BCA assay * Prepare BSA standard (150 ul per well), points should be duplicated on each plate. 25 * Put 145 [l of water into each well, add 5 il of cell lysate into each well. * Prepare final Assay Reagent according to manufacture's instruction. * Add 150 pl of Assay Reagent into each well. * Incubate at 37 0 C for about 20 minutes. * Measure the OD at 562 nm. 30 D: Calculation of specific activity The specific activity is expressed as nmol of ONPG hydrolyzed/t/mg protein, where t is the time of incubation in minutes at 37 0 C; mg protein is the protein assayed which is determined by BCA method. Flow Cvtometry Measurement of FITC/FAM Conjugated siRNA 35 Fluorescence activated cell sorting (FACS) analysis were performed using Beckman Coulter FC500 cell analyzer (Fullerton, CA). The instrument was adjusted according to the 44 WO 2007/030619 PCT/US2006/034859 5 fluorescence probes used (FAM or Cy5 for siRNA and FITC and PE for CD14). Propidium iodide (Fluka, St Lois, MO) and AnnexinV (R&D systems, Minneapolis, MN) were used as indicators for cell viability and cytotoxicity. A brief step-by-step protocol is detailed below. a) After exposure to the complex of siRNA/peptide, cells were incubated for at least 3 hours. 10 b) Wash cells with 200 gl PBS. c) Detach cells with 15 [l TE, incubate at 37 0 C. d) Resuspend cells in five wells with 3 Opl FACS solution (PBS with 0.5% BSA, and 0.1% sodium Azide). e) Combine all five wells into a tube. 15 f) Add PI (Propidium iodide) 5 p1l into each tube. g) Analyze the cells with fluorescence activated cell sorting (FCAS) according to manufacturer's instructions. The siRNA sequence used to silence the beta-galactosidase mRNA was the following: C.U.A.C.A.C.A.A.A.U.C.A.G.C.G.A.U.U.U.DT.DT (SENSE) (SEQ ID NO: 32) 20 A.A.A.U.C.G.C.U.G.A.U.U.U.G.U.G.U.A.G.dT.dT (Antisense) (SEQ ID NO: 33) The data for the present example is shown in Table 2. The transfection efficiency inversely correlates with the amount of beta-galactosidase activity measured from the cell lysate. Upon transfection, a measured decrease in beta-galactosidase activity indicates a successful 25 transfection. Thus, in the absence of transfection, the measured beta-galactosidase activity is 100% and the transfection efficiency is 0%. As beta-galactosidase activity decreases, the transfection efficiency increases. For example, in Table 2, Histone H2B plus siRNA results in a transfection efficiency of 62.03% indicating that the measured beta-galactosidase activity decreased to 37.97%. The same approach for determining transfection efficiency was used for 30 the data presented in Table 3. 45 WO 2007/030619 PCT/US2006/034859 5 Table 2: Efficiency of siRNA Delivery Mediated by Polynucleotide Delivery-Enhancing Polypeptides in 9L/LacZ Cells Transfection Mixture Transfection Efficiency Molar Ratio: Transfection Mixture (% of total cells) (siRNA:Peptide) siRNA (40 pmol/well) alone 0.09% Cationic lipids (Invitrogen) 84.32% unknown IHistone H2B 62.03% 1:10-15 Histone H3 85.08% 1:10-20 Histone H4 72.07% 1:4-8 GEQIAQLIAGYIDIILKKKKSK (SEQ ID NO: 31) 50.86% 1:5-20 WWETWKPFQCRICMRNFSTRQARRNHRRRHR 98.29% (SEQ ID NO: 27) 1:0.5-4 Poly Lys-Trp, 4:1, MW 20,000-50,000 71.92% 1:2-8 Poly Orn-Trp, 4:1, MW 20,000-50,000 74.16% 1:2-8 siRNA/Peptide/Lipids To evaluate the effects of adding a cationic lipid to a siRNA/polynucleotide 0 delivery-enhancing polypeptide mixture, complex or conjugate, the above procedures were followed except the lipofectamine (Invitrogen) was added to siRNA/polynucleotide delivery formulation in constant concentrations, following manufacturer's instructions (0.2 pl/ 100 p l Opti-MEM). To produce the composition comprised of GKINLKCALAALAKKIL (SEQ ID NO: 28),. 15 siRNA and LIPOFECTIN® (Invitrogen), the siRNA and peptide were mixed together first in Opti-MEM cell culture medium at room temperature, after which LIPOFECTIN® was added at room temperature to the mixture to form the siRNA/peptide/cationic lipid composition. To produce the composition comprised of RVIRVWFQNKRCKDKK (SEQ ID NO: 29), siRNA and LIPOFECTIN®, the peptide and the LIPOFECTIN® were mixed together first in 20 Opti-MEM cell culture medium, into this mixture was added the siRNA to form the siRNA/peptide/LIPOFECTIN® composition. To produce the siRNA/peptide/cationic lipid composition using GRKKRRQRRRPPQGRKKRRQRRRPPQGRKKRRQRRRPPQ (SEQ ID NO: 30) or GEQIAQLIAGYIDIILKKKKSK (SEQ ID NO: 31) it does not matter in which order the 25 components are added together to produce the siRNA/peptide/cationic lipid composition. To produce the siRNA/mellitinli/LIPOFECTIN®, the siRNA and mellitin were first mixed together in Opti-MEM cell culture medium and then the LIPOFECTIN® was added to the mixture. 46 WO 2007/030619 PCT/US2006/034859 5 To produce the siRNA/histone H1/LIPOFECTIN® composition, the histone H1 and LIPOFECTIN® were first added together in Opti-MEM cell culture medium thoroughly mixed and then the siRNA was added, thoroughly and mixed with the histone LIPOFECTIN® mixture to form the siRNA/histone H1/ LIPOFECTIN® composition. 0 Table 3: Efficiency of siRNA Delivery Mediated by Polynucleotide Delivery-Enhancing Polypeptides With and Without Cationic Lipid in 9L/LacZ Cells siRNA:Peptide Transfection Transfection siRNA:Peptitio added in Transfection Mixture efficiency with lipids efficiency w/o lipids transfection (% of total cells) (% of total cells) mixture mixture siRNA alone 1.72% 0.11% Lipofectamine (no peptide) 83.48% GKINLKALAALAKKIL (SEQ ID NO: 28) 89.67% 0.26% 1:5-20 RVIRVWFQNKRCKDKK (SEQ ID NO: 29) 89% 0.59% 1:1-5 GRKKRRQRRRPPQGRKKRRQ RRRPPQGRKKRRQRRRPPQ (SEQ ID NO: 30) 89.99% 54.58% 1:5 GEQIAQLIAGYIDIILKKKKSK (SEQ ID NO: 31) 90.01% 50.86% 1:5-10 Mellitin 93.1% 5.15% 1:20 Histone H1 93.39% 0.14% 1:10-20 Based on the foregoing results, it is apparent that exemplary polynucleotide delivery 5 enhancing polypeptides of the invention can substantially enhance cellular uptake of siRNAs, while the addition of an optional cationic lipid to certain siRNA! polynucleotide delivery-enhancing polypeptides mixtures of the invention may substantially improve siRNA delivery efficiency. EXAMPLE 2 z0 Production and Characterization of Compositions Comprising a siRNA Conjugated With a TAT-HA Polvnucleotide Delivery-Enhancing Polypeptide The present example describes the synthesis and uptake activity of specific peptides covalently conjugated to one strand of a siRNA duplex. These conjugates efficiently deliver siRNA into the cytoplasm. 47 WO 2007/030619 PCT/US2006/034859 5 Peptide Synthesis Peptides were synthesized by solid-phase Fmoc chemistry on CLEAR-amide resin using a Rainin Symphony synthesizer. Coupling steps were performed using 5 equivalents of HCTU and Fmoc amino acid with an excess of N-methylmorpholine for 40 minutes. Fmoc removal was accomplished by treating the peptide resin with 20% piperidine in DMF for two 10 minutes 0 cycles. Upon completion of the entire peptide, the Fmoc group was removed with piperidine and washed extensively with DMF. Maleimido modified peptides were prepared by coupling 3.0 equivalents of 3-maleimidopropionic acid and HCTU in the presence of 6 equivalents of N-methylmorpholine to the N-terminus of the peptide resin. The extent of coupling was monitored by the Kaiser test. The peptides were cleaved from the resin by the addition of 10 mL 5 of TFA containing 2.5% water and 2.5 triisopropyl silane followed by gentle agitation at room temperature for 2 h. The resulting crude peptide was collected by trituration with ether followed by filtration. The crude product was dissolved in Millipore water and lyophilized to dryness. The crude peptide was taken up in 15 mL of water containing 0.05% TFA and 3 mL acetic acid and loaded onto a Zorbax RX-C8 reversed-phase (22 mm ID x 250 mm, 5 pm particle size) ,0 through a 5 mL injection loop at a flow rate of 5 mL/min. The purification was accomplished by running a linear AB gradient of 0.1% B/min where solvent A is 0.05% TFA in water and solvent B is 0.05% TFA in acetonitrile. The purified peptides were analyzed by HPLC and ESMS. Synthesis of Conjugates Both peptides and RNAs are prepared using standard solid phase synthesis methods. The 5 peptide and RNA molecules must be functionalized with specific moieties to allow for covalent attachment to each other. For the peptide, the N-terminus is functionalized, for example, with 3-maleimidopropionic acid. However, it is recognized that other functional groups such as bromo or iodoacetyl moieties will work as well. For the RNA molecule the 5' end of the sense strand or 3' end of the antisense strand is functionalized with, for example, a 1-0 0 dimethoxytrityl-hexyl-disulfide linker according to the following synthetic method. The 5' modified C6SS-oligonucleotide (GCAAGCUGACCCUGAAGUUCAU (SEQ ID NO: 34); 3.467 mg; 0.4582 jmol) was reduced to the free thiol group with 0.393 mg (3 eq) of tris(2-carboxyethyl)phosphine (TCEP) in 0.3 ml of 0.1 M triethylamine acetate (TEAA) buffer (pH 7.0) at room temperature for 3 h. The reduced oligonucleotide was purified by RP HPLC on 35 XTerra@MS C 1 8 4.6x50mm column using a linear gradient from 0-30% of CH 3 CN in 0.1 M TEAA buffer pH 7 within 20 min (tr=5.931 min). 48 WO 2007/030619 PCT/US2006/034859 5 Purified reduced oligonucleotide (1.361 mg, 0.19085 Imol) was dissolved in 0.2 ml of 0.1 M TEAA buffer pH=7 and then the peptide with the maleimido moiety attached to the peptide N-termnninus (0.79 mg, 1.5 eq) was added to the oligonucleotide solution. After addition of peptide a precipitate immediately formed which disappeared upon the addition of 150 p1 of 75% CH 3 CN/0.1M TEAA. After stirring overnight at room temperature, the resulting conjugate 3 was purified by RP IHPLC on XTerra®MS C 1 8 4.6x50mm column using a linear gradient from 0-30% of CH 3 CN in 0.1M TEAA buffer pH 7 within 20min and 100% C within next 5 min (tr=2 1 .007 min). The amount of the conjugate was determined by spectrophotometry based on the calculated molar absorption coefficient at k=260 rm. MALDI mass spectrometric analysis showed that the peak observed for the conjugate (10 585.3 amu) matches the calculated mass. 5 Yield: 0.509 mg, 0.04815 [mnol, 25.2%. The peptide conjugate sense strand and complimentary antisense strand were annealed in 50 mM potassium acetate, 1 mM magnesium acetate and 15 mM HEPES pH 7.4 by heating at 90 0 C for 2 min followed by incubation at 37 0 C for 1 h. The formation of the double stranded RNA conjugate was confirmed by non denaturing (15%) polyacrylamide gel electrophoresis ) followed by ethidium bromide staining. Structure of the peptide-siRNA conjugate (SEQ ID NOS 34 and 35) 0 o N ' N- RRRQRRKRGGDIMGEWGNEIFGAIAGFLG-amide S O H 0 0 O- POGCAAGCUGACCCUGAAGUUCAU 0 Uptake Experiments Cells were plated the day before in 24-well plates so that they were ~50-80% confluent at time of transfection. For complexes, siRNA and peptide were diluted in Opti-MEM® media (Invitrogen), then mixed and allowed to complex 5-10 minutes before adding to cells washed with PBS. Final concentration of siRNA was 500nM at each peptide concentration (2-50 gM). The conjugate, also diluted in Opti-MEM® media, was added to cells at final concentrations ranging from 62.5 nM to 500 nM. At 500nM concentration, we also combined with 20% FBS just before adding to washed cells. Cells were transfected for 3 hours at 37 0 C, 5%CO2. Cells were washed with PBS, treated with trypsin and then analyzed by flow cytometry. siRNA 49 WO 2007/030619 PCT/US2006/034859 5 uptake was measured by intensity of Cy5 fluorescence and cellular viability assessed by addition of propidium iodide. As shown in Figure 1, the peptide/siRNA conjugates achieve a greater percent uptake in mouse tail fibroblast cells than peptide/siRNA complexes. Further, the peptide/siRNA conjugates achieved a higher mean fluorescence intensity (MFI; Figure 2) than the 10 peptide/siRNA compolex. Thus, these data indicate that in certain embodiments it will be desirable to conjugate the polynucleotide delivery-enhancing polypeptide to the siRNA molecule. EXAMPLE 3 Screening of siRNA/Delivery Peptide Complexes Demonstrates Efficient Induction of siRNA 15 Uptake in 9L/LacZ Cells by a Diverse Assemblage of Rationally-Designed Polynucleotide Delivery-Enhancing Polypeptides The present example provides additional evidence that a broad and diverse assemblage of rationally-designed polynucleotide delivery-enhancing polypeptides of the invention enhance siRNA uptake when complexed with siRNAs. 20 Approximately 10,000 9L/lacZ cells were plated per well in flat-bottom 96-well plates so that they would be ~50% confluent the next day at the time of transfection. FAM-labeled siRNA and peptides were diluted in Opti-MEM® media (Invitrogen) at 2-fold the final concentration. Equal volumes of siRNA and peptide were mixed and allowed to complex 5-10 minutes at room temperature and then 50 gL added to cells, previously washed with PBS. Cells were transfected 25 for 3 hours at 37 0 C, 5%CO 2 . Cells were washed with PBS, treated with trypsin and then analyzed by flow cytometry. siRNA uptake was measured by intensity of FAM fluorescence and cellular viability assessed by addition of propidium iodide. Table 4 below summarizes the percent cell uptake data in 9L/LacZ cells for the various rationally-designed polynucleotide delivery-enhancing polypeptides. Included in Table 4, is the concentration of the peptide and 30 siRNA used. 50 WO 2007/030619 PCT/US2006/034859 Table 4: Efficiency of siRNA Uptake Mediated by Rationally-Designed Polynucleotide Delivery-Enhancing Polypeptides 9L/LacZ Cells. Peptide Peptide siRNA Uptake ID# Amino Acid Sequence Cone. Cone. (%PI /FAM+) PN173 GRKKRRQRRRPPQC (SEQ ID NO: 36) 10 pM 400 nM 84.8% Maleimide-AAVALLPAVLLALLAPRKKRRQRRRPPQ-ami SEQ I 1 pM 400 nM 31.0% PN227 NO: 37) PN27 AAVALLPAVLLALLAPRKKRRQRRRPPQC (SEQ ID NO: 38) 1 pM 400 nM 82.6% Maleimide- AAVALLPAVLLALLAPRKKRRQRRPPQ-amnide (SEQ ID 4 JM 400 nM 95.3% PN275 NO: 37) PN28 NH2-RKKRRQRRRPPQCAAVALLPAVLLALLAP-amide (SEQ ID NO: 2 pM 400 nM 79.3% PN28 39) 39) 80 ptM 400 nM 0.0% PN69 BrAc-GRKKRRQRRRPQ-amide (SEQ ID NO: 40) 80 pM 400 nM 0.0% PN81 BrAc-RRRQRRKRGGDIMGEWGNEIFGMAIAGFLGamide (SEQ ID NO: 8 PM 800 nM 97.9% PN81 41) __I PN250 NH2-RRRQRRKRGGDIMGEWGNEIGAIAGFLG-amide (SEQ ID NO: 15 pM 800 nM 99.5% 35) PN204 C(YGRKKRRQRRRG)2 (SEQ ID NO: 42) 1.4 M 800 nM 82.5% PN280 Maleimide-GRKKRRQRRRPPQ-amide (SEQ ID NO: 43) 80 pM 400 nM 7.9% PN350 NH2-KLWKAWPKLWKKLWKP-amide (SEQ ID NO: 44) 10 pM 400 nM 0.0% PN365 AAVALLPAVLLALLAPRRRRRR-amide (SEQ ID NO: 45) 10 pM 400 nM 81.4% PN366 RLWRALPRVLRRLLRP-amide (SEQ ID NO: 46) 10 JM 400 nM 0.0% PN29 NH2-AAVALLPAVLLALLAPSGASGLDKRDYV-amide 80 pM 400 nM 86.5% PN29_ (SEQ ID NO: 47) N2 Maleimide-AAVALLPAVLLALLAPSGASGLDKRDYV-amide (SEQ ID 80 M 400 nM 0.0% PN235 NO: 48) 8M 0
NH
2 -SGASGLDKRDYVAAVAALLPAVLLALLAP-amide 80 M 400 nM 0.0% PN30 (SEQ ID NO: 49) 00. NH2.LLETLLPFQCRICM1NFSTRQARRN HRR-amide (SEQ ID 2 pM 400 nM 70.8% PN202 NO: 50) 207 NH2-AAVACRICMRNFSTRQARRNHRRRHRR-amide 2 pM 400 nM 30.9% PN225 (SEQ ID NO: 51) PN236 Maleimide-RQIKIWFQNRRMKWKK-amide (SEQ ID NO: 52) 10 pM 400 nM 37.7% PN58 RQIKIWFQNRRMKWKK amide (SEQ ID NO: 53) 40 pM 400 nM 75.8%
NH
2 -RQIKIWFQNRRMKWKKDIMGEWGNEIFGAIAGFLG-amide (SEQ 4 pM 400 nM 44.5% PN251 ID NO: 54) PN279 Maleimide-SGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKG 40 pM 400 nM 24.7% PN279 amide (SEQ ID NO: 55) SGRGKQGGKARAICAKTRSSRAGLQFPVGRVHRLLRKGC-amide (SEQ 80 pM 800 nM 86.8% PN61 ID NO: 56) PN360 KGSKKAVTKAQKKDGKKRKRSRK-amide (SEQ ID NO: 57) 80 pM 400 nM 0.0% NH2-KIKDGKKRKRSRKESYSVYVYKVLKQ-amide 10 pM 400 nM 42.0% PN361 (SEQ ID NO: 58) 142 KGSKKAVTKAQKDGIRKRSRKESYSVYVYKVLKQ 10 pM 400 nM 99.5% PN73 (SEQ ID NO: 59) BrAc-GWTLNSAGYLLGINLKALAALAKKILamide 10 pM 400 nM 14.5% PN64 (SEQ ID NO: 60) 1 40 PN159 KLALKLALKALKAALKLAamide (SEQ ID NO: 13) .08 pM 80 nM 16.4% PN68 BrAe-KLALKLALKATKAALKLAamide (SEQ ID NO: 61) 10 pM 400 nM 0.0% P1 Ac-KETWWETWWTEWSQPKKKRKV-amide 1 pM 400 nM 84.9% PN182 (SEQ ID NO: 62) 1 4. NH2-KETWWETWWTEWSQPGRKKRRQRRlRPPQ-amide (SEQ ID NO: 20 pM 400 nM 78.1% PN183 63)_ 51 WO 2007/030619 PCT/US2006/034859 % Peptide Peptide siRNA Utake ID# Amino Acid Sequence Cone. Conc. (%PI /FAM+) PN71 BrAc-RRRRRRR (SEQ ID NO: 64) 80 pM 400 nM 0.0% PN87 QqQqQqQqQq (SEQ ID NO: 65) 10 pM 400 nM 0.0% PN249 NH2-RRRQRRKRGGqQqQqQqQqQ-amide 80 pM 400 nM 0.0% (SEQ ID NO: 66) PN158 RVIRWFQNKRCKDKK-amide (SEQ ID NO: 67) 1 pM 400 nM 94.0% PN86 Ac-LGLLLRHLRHHSNLLANI-amide (SEQ ID NO: 68) 80 pM 400 nM 62.2% PN162 GQMSEIEAKVRTVKLARS-amide (SEQ ID NO: 69) 80 pM 400 nM 0.0% PN228 NH2-KLWSAWPSLWSSLWKP-amide (SEQ ID NO: 70) 80 pM 400 nM 6.8% PN357 NH2-KKKKKKKK-amide (SEQ ID NO: 71) 10 pM 400 nM 0.0% PN358 NH2-AARLHRFKNKGKDSTEMRRRR-amide 40 gM 400 nM 0.0% (SEQ ID NO: 72) PN283 Maleimide-GLGSLLKKAGKKLKQPKSKRKV-amide 40 RM 400 nM 36.3% (SEQ ID NO: 73) PN284 Maleimide-Dmt-r-FK-amide (EQ 4D-NO~) 100 pM 400 nM 0.0% PN285 Maleimide-Dmt-r-FKQqQqQqQgQq-amide (SEQ ID NO: 74) 8 pM 800 nM 90.7% PN286 Maleimide-WRFK-amide (SEQ ID NO: 75) 80 pM 400 nM 0.0% PN289 Maleimide-WRFKQqQ+qQgQqQg-amide (SEQ ID NO: 76) 8 pJiM 400 nM 91.7% PN267 Maleimido-YRFK-amide (SEQ ID NO: 77) 80 pM 400 nM 0.3% PN282 Maleimide-YRFKYRFKYRFK-amide (SEQ ID NO: 78) 40 pM 800 nM 22.8% PN286 Maleimide-WRFK-amide (SEQ ID NO: 75) 80 pM 400 nM 0.0% PN290 Maleimide-WRFKKSKRKV-amide (SEQ ID NO: 79) 80 pM 400 nM 5.3% PN291 Maleimide-WRFKAAVALLPAVLLALLAP-amide 4 pM 800 nM 12.5% (SEQ ID NO: 80) PN243 NH2-DiMeYrFKamide (SEQ ID NO: 81) 40 pM 400 nM 0.0% PN244 NH2-YrFKamide (SEQ ID NO: 82) 80 pM 400 nM 0.0% PN245 NH2-DiMeYRFKamide (SEQ ID NO: 83) 80 pM 400 nM 0.0% PN246 NH2-WrFKamide (SEQ ID NO: 84) 80 pAM 400 nM 0.0% PN247 NH2-DiMeYrWKamide (SEQ ID NO: 85) 80 pM 400 nM 0.0% PN248 NH2-KFrDiMeY-amide (SEQ ID NO: 86) 80 pM 400 nM 0.0% PN287 Maleimide-WRFKWRFK-amide (SEQ ID NO: 87) 10 pM 400 nM 8.8% PN288 Maleimide-WRFKWRFKWRFK-amide (SEQ ID NO: 88) 4 pM 400 nM 9.0% 5 EXAMPLE 4 siRNA/Delivery is Enhanced by Polynucleotide Delivery-Enhancing Polypeptides In Vitro The present example illustrates the enhancement of siRNA uptake by polynucleotide delivery-enhancing polypeptides of the invention in LacZ cells, murine primary fibroblasts and 0 human monocytes. The materials and methods used for the experiments performed in 9L/LacZ cells and mouse fibroblast cells are generally the same as described above, except that for the murine experiments, 9L/LacZ cells were replaced with mouse tail fibroblasts (MTF). The materials and methods used for the experiments performed in human monocytes are described later. The results for transfections performed with MTF cells are summarized in Table 5. 15 Included in Table 5, is the amino acid sequence of the peptide used and the concentration of the peptide and Cy5 label conjugated to the eGFP siRNA. The results for transfections performed 52 WO 2007/030619 PCT/US2006/034859 5 with both MTF and 9L/LacZ cells are summarized in Table 6. The data presented in Table 6 offers a comparison of transfection efficiencies for some peptide/siRNA complexes in different cell types. Table 5: Efficiency of siRNA Uptake Mediated by Rationally-Designed Polynucleotide 0 Delivery-Enhancing Polypeptides in Murine Tail Fibroblast (MTF) Cells Pepdite Amino Acid Sequence Status % ID# Uptake 0.5am PN250 NH2-RRRQRRKRGGDIMGEWGNEIFGAIAGFLG-amide 0.5 85.9% PN250 (EIDN:3)siRNA/ 40 85.9% (SEQ ID NO: 35) mM peptide mM peptide 0.5rmM PN73 NH2-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKV 0.siRNA/ 5 94.5%M LKQ-amide (SEQ ID NO: 59) mM peptide 0.5M peptide PEG- Peg-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKV 0.siRNA/25 91%M PN509 LKQ-amide (SEQ ID NO: 90) mM peptideA/25 91% 0.5mM peptide NH2-RGSRRAVTRAQRRDGRRRRRSRRESYSVYVYRV 0.5 M PN404 siRNA/ 25 50.4% LRQ-amide (SEQ ID NO: 91) mM peptide 0.5 mM PN361 NH2-KKDGKKRKRSRKESYSVYVYKVLKQ-amide siRNA/50 65% (SEQ ID NO: 58) mM peptide 0.5rmM PN27 AAVALLPAVLLALLAPRKKRRQRRRPPQC 0.siRNA/ 5 60.7%M PN27 (SEQ ID NO: 38) mM peptide mM peptide 1 mM siRNA/ PN58 NH2-RQIKIWFQNRRMKWKK-amide (SEQ ID NO: 53) 20 mM peptide 3.7% 0.5 mM PN158 NH2-RVIRWFQNKRCKDKK amide (SEQ ID NO: 67) siRNA/ 50 nM 86.2% peptide 0.5ram PN316 Maleimido-RVIRWFQNKRSKDKK-amide siRNA/10 0 84.8%mM PN316 (SEQ ID NO: 92) siRNA 100 84.8% mM peptide 0.5 mM PN289 Maleimide-WRFKQqQqQqQqQq-amnide 0.5siRNA 10 7%i PN29 SE II N: 6)si]RNA/ 10 7% (SEQ ID NO: 76) mM peptide PN28 NH2-RKKRRQRRRPPQCAAVALLPAVLLALLAP-amide 1 mM siRNA/ 80.5% (SEQ ID NO: 39) 8 mM peptide 0.5 mM PN173 GRKKRRQRRRPPQC (SEQ ID NO: 36) siRNA/ 130 94.8% nM peptide 0.5 mM PN159 KLALKLALKCALIKAALKLA-amide (SEQ ID NO: 13) siRNA/ 5 0% mM peptide 0.5am NH2-GWTLNSAGYLLGKINLKALAALAKKIL-amide 0.5 M PN161 siRNA/ 10 nM 0% (SEQ ID NO: 93) peptide 53peptide 53 WO 2007/030619 PCT/US2006/034859 5 Table 6: Efficiency of siRNA Uptake Mediated by Rationally-Designed Polynucleotide Delivery-Enhancing Polypeptides in LacZ Cells and Murine Tail Fibroblast Cells Peptide Percent Uptake ID#Amino Acid Sequence LacZ Primary Cells MTF Cells NH2-AAVALLPAVLLALLAPRKKRRQRRRPPQ-amide PN27 (SEQ ID NO: 94) 86% 61% NH2-RKKRRQRRRPPQAAVALLPAVLLALLAP-anmide PN28 (SEQ ID NO: 89) 79% 81% NH2-AAVALLPAVLLALLAPSGASGLDKRDYV-amide (SEQ ID NO: PN29 47) 87% not tested PN58 NH2-RQIKIWFQNRRMKWKK-amide (SEQ ID NO: 53) 76% 6% NH2-SGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGC-amide PN61 (SEQ ID NO: 56) 87% not tested NH2-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-amide PN73 (SEQ ID NO: 59) 91% 95% PN158 NH2-RVIRWFQNKRCKDKK-amide (SEQ ID NO: 67) 94% 86% PN173 NH2-GRKKRRQRRRPPQC-amide (SEQ ID NO: 36) 85% 95% PN182 NH2-KETWWETWWTEWSQPKKKRKV-amide (SEQ ID NO: 95) 85% not tested NH2-LLETLLKPFQCRICMRNFSTRQARRNHRRRHRR-amide PN202 (SEQ ID NO: 50) 71% not tested PN204 NH2-C(YGRKKRRQRRRG)2-amide (SEQ ID NO: 42) 83% not tested NH2-RRRQRRKRGGDIMGEWGNEIFGAIAGFLG-amide PN250 (SEQ ID NO: 35) 99% 86% PN361 NH2-KKDGKKRKRSRKESYSVYVYKVLKQ-amide (SEQ ID NO: 58) 42% 65% PN365 NH2-AAVALLPAVLLALLAPRRRRRR-amide (SEQ ID NO: 45) 81% not tested NH2-RGSRRAVTRAQRRDGRRRRRSRRESYSVYVYRVLRQ-amide not PN404 (SEQ ID NO: 91) tested 50% NH2-GALFLGFLGAAGSTMGAWSQPKSKRKVC-amide not PN453 (SEQ ID NO: 96) tested 79% Peg-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-amide not PN509 (SEQ ID NO: 90) tested 91% To further characterize the ability of polynucleotide delivery-enhancing polypeptides to .0 transfect cells in culture, human monocytes were incubated with 200 nM of FITC labeled siRNA complexed with various concentrations of PN73, PN250, PN182, PN58 and PN158. Human monocytes were used in addition to LacZ and mouse fibroblast cells because they are the targeted cell type in the treatment of rheumatoid arthritis. Fresh human blood samples from healthy donors were purchased from Golden West 5 Biologicals. For isolation of monocytes, blood samples were diluted with PBS at a 1:1 ratio immediately after receiving. Peripheral blood mononuclear cells (PBMC) were first isolated by Ficoll (Amersham) gradient from whole blood. Monocytes were further purified from PBMCs using the Miltenyi CD14 positive selection kit and supplied protocol (MILTENYI BIOTEC). To asses the purity of the monocyte preparation, cells were incubated with an anti-CD14 antibody 54 WO 2007/030619 PCT/US2006/034859 5 (BD Biosciences) and then sorted by flow cytometry. The purity of the monocyte preparation was greater than 95%. The follow description is a brief outline of the transfection protocol used in this example. The cells were plated at 70 ~ 90% confluence for adherent cell lines and 100,000 cells per well for suspension cells. For siRNA/transfection reagent complexes, Cy5- or FAM-conjugated 10 siRNA and peptides were diluted separately in Opti-MEM® media at 2-fold the final concentration. Equal volumes of siRNA and transfection reagent were mixed and allowed to complex 5-10 minutes at room temperature. For siRNA-peptide conjugates, the conjugates were diluted in Opti-MEM® media directly. The transfection mixtures were added to cells previously washed with PBS. Cells were transfected for 3 hours at 37 'C, 5% CO 2 . For siRNA uptake 15 analysis, cells were washed with PBS, treated with trypsin (adherent cells only), and then analyzed by flow cytometry. siRNA uptake was measured by the intensity of intracellular Cy5 or FAM fluorescence. Cell viability was determined using propidium iodide (uptake) or AnnexinV-PE (staining). The forgoing experiment shows that the exemplary polynucleotide delivery-enhancing 20 polypeptide, PN73 is an ideal candidate for the treatment of rheumatoid arthritis. Figure 3 illustrates the ability of several different polynucleotide delivery-enhancing polypeptides to enhance siRNA uptake in human monocytes in culture. Transfection by lipofectamine was used as a comparator. Cell viability was also assessed for each peptide (Figure 4). The data show the surprising and unexpected discovery that the PN73 peptide 25 transfects human monocytes with high efficiency and low toxicity indicating that it is an ideal candidate for the treatment of rheumatoid arthritis in vivo. EXAMPLE 5 siRNA/Delivery is Enhanced by Conjugation of the siRNA to Polynucleotide Delivery-Enhancing Polypeptides 30 The present example provides results from screens to evaluate activity of siRNA/polylnucleotide delivery-enhancing polypeptide conjugates for inducing or enhancing siRNA uptake in 9L/LacZ culture cell lines and primary fibroblast from mouse tail. The materials and methods employed for these studies are generally the same as described above, except that no siRNA/peptide mixing is required as needed to produce siRNA/peptide 35 complexes. The percent uptake for transfections performed with 9L/LacZ cells are summarized in Table 7. Included in Table 7, is the peptide used and the concentration of the peptide/siRNA conjugate. A FAM-j3-gal label conjugated to the siRNA molecule was used. The results for transfections performed with MTF are summarized in Table 8. Included in Table 8, is the 55 WO 2007/030619 PCT/US2006/034859 5 concentration of the peptide/siRNA conjugate used and the Cy5 label conjugated to the eGFP siRNA molecule. Table 7: Efficiency of siRNA Uptake Mediated by Rationally-Designed Polynucleotide Delivery-Enhancing Polypeptides Conjugated to siRNAs in LacZ Cells Peptide/siRNA Conjugate Name Peptide ID# Conjugate Uptake % Concentration CoP267nfR137-1 PN267 tested up to 2.0 pM 0% CoP286nfR138-1 PN286 0.8 pM 0% CoP287nfR138-1 PN287 0.8 pgM 0% CoP284nfR164-1 PN284 tested up to 1.0 pM 0% CoP282nfR165-1 PN282 tested up to 1.0 pM 0% CoP290nfR165-1 PN290 tested up to 1.0 pM 0% CoP277nfRl167-1 PN73 1.0 ipM 42.9% CoP277nfR167-2 PN73 2.0 p[M 55.4% 0 Table 8: Efficiency of siRNA Uptake Mediated by Rationally-Designed Polynucleotide Delivery-Enhancing Polypeptides Conjugated to siRNAs in Murine Tail Fibroblast Cells Peptide / siRNA % Conjugate Name Amino Acid Sequence siRConjugate Uptake Conjugate Uptake Concentration Cy5-dsCoP278nfR270 Maleimide-RRRQRRKRGGDIMGEWGNEIFGAIAGFLG-amide 0.5pM 96.3% (SEQ ID NO: 102) Maleimide dsCoP277nfR317 KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-amide 4tM 83.5% (SEQ ID NO: 103) dsCoP275nfR321 Maleimide- AAVALLPAVLLALLAPRKKRRQRRRPPQ-amide 4tM 52.1% (SEQ ID NO: 37) dsCoP285nfR322-1 Maleimide-Dmt-r-FKQgqQqqQgQq-amide (SEQ ID NO: 74) 4uM 41.3% dsCoP236nfR332 Maleimide-RQIKIWFQNRRMKWKK-amide (SEQ ID NO: 52) 4[tM 36.3% dsCoP37nR320 Maleimido-KETWWETWWTEWSQPKKKICRKV-amide (SEQ ID 2tM 29.6% dsCoP317nfR320 2NM:29.6% NO: 104) dsCoP316nfR347 Maleimido-RVIRWFQNKRSKDKK-amide (SEQ ID NO: 92) 21xM 17.1% dsCoP289nfR268 Maleimide-WRFKQgQgQqQgQgQq-amide (SEQ ID NO: 76) 4tM 3.2% dsCoP276nfR319 Maleimide- RKKRRQRRRPPQCAAVALLPAVLLALLAP-amide 2gM 3.6% (SEQ ID NO: 105) dsCoP298cfR248 NH2-WRFKC-amide (SEQ ID NO: 106) 4gM 4.1% dsCoP280nfR362-1 Maleimide-GRKIRRQRRRPPQ-amide (SEQ ID NO: 43) 4 1 iM 1.8% dsCoP458nfR363-1 Maleimido-KLALKLALKALKAALKLA-amide (SEQ ID NO: 107) 4gM 10.8% dsCoP459nfR364-1 Maleimido-GWTLNSAGYLLGKINLKALAALAIKKL-amide 4RM 54.5% dso__9_ _64- ~ (SEQ ID NO: 108) 5 The foregoing data evince that a diverse assemblage of siRNA/peptide conjugates of the invention mediate delivery of siRNAs into different cell types at high efficiency. 56 WO 2007/030619 PCT/US2006/034859 5 EXAMPLE 6 siRNA Gene Expression Knock Down is Enhanced by Polynucleotide Delivery-Enhancing Polypeptides Complexed to siRNA The instant example demonstrates effective knockdown of target gene expression by siRNA/polynucleotide delivery-enhancing polypeptide complexes of the invention. In the 0 current studies, the ability of peptide/siRNA complexes to modulate expression of a human tumor necrosis factor-a (hTNF-a) gene, implicated as mediating the occurrence or progression of RA when overexpressed in human and other mammalian subjects, was tested. Healthy human blood was purchased from Golden West Biologicals (CA), the peripheral blood mononuclear cells (PBMC) were purified from the blood using Ficoll-Pague plus 5 (Amersham) gradient. Human monocytes were then purified from the PBMCs fraction using magnetic microbeads from Miltenyi Biotech. Isolated human monocytes were resuspended in IMDM supplemented with 4mM glutamine, 10% FBS, lx non-essential amino acid and lx pen-strep, and stored at 4 0 C until use. In a 96 well flat bottom plate, human monocytes were seeded at 100,000 per well per 0 100 ptl in OptiMEM medium (Invitrogen). Transfection reagent was mixed with siRNA at desired concentration in OptiMEM medium at room temperature for 20 minutes (for Lipofectamine 2000; Invitrogen), or 5 minutes (for peptide). At the end of incubation, FBS was added to the mixture (final 3%), and 50 p1 of the mixture was added to the cells. The cells were incubated at 37 0 C for 3 hours. After transfection, cells were transferred to V-bottom plate, and :5 the cells were pelleted at 1500 rpm for 5 minutes. The cells were resuspended in growth medium (IMDM with glutamine, non-essential amino acid, and pen-strep). After overnight incubation, the cells were stimulated with LPS (Sigma) at 1 ng/ml for 3 hours. After induction, cells were collected as above for mRNA quantification, and supernatant was saved for protein quantification. 30 For mRNA measurement, branch DNA technology from Genospectra (CA) was used according to manufacturer's specification. To quantitate mRNA level in the cells, both house keeping gene (cypB) and target gene (TNF-a) mRNA were measured, and the reading for TNF-a was normalized with cypB to obtain relative luminescence unit. To quantify protein level, the TNF-a ELISA from BD Bioscience was used according to manufacturer's specification. 35 The siRNAs directed to target different regions of the TNF-oa mRNA as illustrated in Table 9 below. Not shown for each oligo listed in Table 9 is 3' overhangs (e.g. dNdN where N represents any nucleotide). 57 WO 2007/030619 PCT/US2006/034859 5 Table 9: Nomenclature, Location of Target Sequence in the TNF-a Gene and Oligo Sequence for siRNA Targeting of TNF-a H# IRNA Name Location of Oligo Sequence SEQ ID NO: # siRA Nam ITarget sequence N125 TNF-oa-1 516-534 GCGUGGAGCUGAGAGAUAA 109 N115 TNF-a-2 430-448 GCCUGUAGCCCAUGUUGUA 110 N132 TNF-a-3 738-756 GGUAUGAGCCCAUCUAUCU 111 N108 TNF-x-4 360-378 CCAGGGACCUCUCUCUAAU 112 N138 TNF-a-5 811-829 GCCCGACUAUCUCGACUUU 113 N1 13 TNF-ax-6 424-442 UGACAAGCCUGUAGCCCAU 114 N143 TNF-a-7 844-862 GGUCUACUUUGGGAUCAUU 115 N107 TNF-a-8 359-377 CCCAGGGACCUCUCUCUAA 116 N137 LC1 806-828 AAUCGGCCCGACUAUCUCGACUU 117 N122 LC2 514-532 AAUGGCGUGGAGCUGAGAGAU 118 N130 LC3 673-691 AACCUCCUCUCUGCCAUCAAG 119 N101 LC4 177-195 AACUGAAAGCAUGAUCCGGGA 120 N140 LC5 820-838 AAUCUCGACUUUGCCGAGUCU 121 N135 LC6 781-799 AAGGGUGACCGACUCAGCGCU 122 N128 LC7 636-654 AAUCAGCCGCAUCGCCGUCUC 123 N127 LC8 612-630 AACCCAUGUGCUCCUCACCCA 124 N118 LC9 472-490 AAGCUCCAGUGGCUGAACCGC 125 N111i LC10 398-416 AAGUCAGAUCAUCUUCUCGAA 126 N110 LC11 363-381 AAGGGACCUCUCUCUAAUCAG 127 N105 LC12 265-287 CCUCAGCCUCUUCUCCUUCCUGA 128 N104 LC13 264-282 AAUCCUCAGCCUCUUCUCCUU 129 N120 LC14 495-513 AACCAAUGCCCUCCUGGCCAA 130 N153 LC16 1535-1555 CUGAUUAAGUUGUCUAAACAA 131 N136 LC17 787-807 CCGACUCAGCGCUGAGAUCAA 132 N152 LC18 1327-1347 CUUGUGAUUAUUUAIUAUUUA 133 N114 LC19 428-448 AAGCCUGUAGCCCAUGUUGUA 134 N145 LC20 982-1002 UAGGGUCGGAACCCAAGCUUA 135 N101 YC-1 177-195 CUGAAAGCAUGAUCCGGGA 136 N103 YC-2 251-269 AGGCGGUGCUUGUUCCUCA 137 N106 YC-3 300-318 CCACCACGCUCUUCUGCCU 138 N109 YC-4 362-380 AGGGACCUCUCUCUAAUCA 139 N1 13 YC-5 424-442 UGACAAGCCUGUAGCCCAU 140 N115 YC-6 430-448 GCCUGUAGCCCAUGUUGUA 141 N117 YC-7 435-453 UAGCCCAUGUUGUAGCAAA 142 N120 YC-8 495-513 CCAAUGCCCUCCUGGCCAA 143 N121 YC-9 510-528 CCAAUGGCGUGGAGCUGAG 144 N123 YC-10 515-533 GGCGUGGAGCUGAGAGAUA 145 N125 YC-11 516-534 GCGUGGAGCUGAGAGAUAA 146 N126 YC-12 558-576 GCCUGUACCUCAUCUACUC 147 N130 YC-13 673-691 CCUCCUCUCUGCCAUCAAG 148 N132 YC-14 738-756 GGUAUGAGCCCAUCUAUCU 149 N133 YC-15 772-790 GCUGGAGAAGGGUGACCGA 150 N134 YC-16 776-794 GAGAAGGGUGACCGACUCA 151 N136 YC-17 787-807 GCCCGACUAUCUCGACUU 152 N141 YC-18 841-859 GCAGGUCUACUUUGGGAUC 153 N143 YC-19 844-862 GGUCUACUUUIGGGAUCAUU 154 N144 YC-20 853-871 UGGGAUCAUUGCCCUGUGA 155 58 WO 2007/030619 PCT/US2006/034859 ID# siRNA Name Location of Oligo Sequence SEQ ID NO: _Target sequence N146 YC-21 985-1003 GGUCGGAACCCAAGCUUAG 156 N147 YC-22 1179-1197 CCAGAAUGCUGCAGGACUU 157 N148 YC-23 1198-1216 GAGAAGACCUCACCUAGAA 158 N149 YC-24 1200-1218 GAAGACCUCACCUAGAAAU 159 N150 YC-25 1250-1268 CCAGAUGUUUCCAGACUUC 160 N151 YC-26 1312-1330 CUAUUUAUGUUUTGCACUUG 161 N154 YC-27 1547-1565 UCUAAACAAUGCUGAUUUG 162 N155 YC-28 1568-1585 GACCAACUGUCACUCAUU 163 5 Tables 10, 11 and 12 illustrate the effectiveness of specific oligos complexed to a polynucleotide delivery-enhancing polypeptides of the invention to target and knock down TNF-(x gene expression levels in human monocytes. Table 10: 0 Percent TNF-cc Knockdown Mediated by a PN73/siRNA Complex Peptide/siRNA Complex siRNA KD (%) (4 nM) LC1 20.08% LC2 19.06% Peptide LC3 23.17% PN73 LC4 26.67% (1.6 pM) LC5 46.78% LC6 44.10% LC7 42.76% LC8 41.24% LC9 40.32% LC10 13.52% LC11 7.89% LC12 40.61% LC13 48.29% LC14 50.76% LC16 55.91% LC17 50.78% LC18 63.44% LC19 61.83% LC20 42.68% YC12 43.60% 59 WO 2007/030619 PCT/US2006/034859 5 Table 11: Percent TNF-oa Knockdown Mediated by a PN509/siRNA Complex Peptide/siRNA Complex . siRNA KD (%) (4 nIM) LC1 31.13% LC2 37.04% LC3 30.14% LC4 22.71% LC5 34.93% LC6 50.19% Target LC7 56.11% Target Gene Peptide LC8 47.35% TNF-a PN509 LC9 58.20% (1.6 p.I) LC10 25.62% LC11 25.65% LC12 17.03% LC13 25.04% LC14 42.78% LC16 40.06% LC17 48.94% LC18 58.13% LC19 56.38% LC20 71.12% YC12 64.37% 60 WO 2007/030619 PCT/US2006/034859 5 Table 12: Percent TNF-oc Knockdown Mediated by a PN250/siRNA Complex Complex Peptide PN250 siRNA KD (%) Conc. 20nM YC11 13.70% YC12 17.06% YC17 17.30% 0.5 pm YC18 20.72% LC13 20.65% LC20 -3.80% TNF-4 0.90% YC11 21.09% Target Gene YC12 21.66% TNF-a YC17 29.82% 0.75 YC18 17.82% LC13 18.04% LC20 10.72% TNF-4 14.39% YC11 33.10% YC12 15.91% YC17 24.68% 1 KM YC18 24.66% LC13 31.35% LC20 26.53% TNF-4 26.47% The foregoing results (Tables 10, 11 and 12) evince that effective levels of TNF-a gene expression knock down can be achieved in mammalian cells using the novel 0 siRNA/polynucleotide delivery-enhancing polypeptide compositions of the invention. 61 WO 2007/030619 PCT/US2006/034859 5 Screening and Characterization Human monocytes (CD14+) treated with LPS induce TNF-a-specific mRNA within approximately 2 hours, followed by peak levels of TNF-a protein 2 hours later. siRNAs were screened for knockdown activity by transfecting monocytes with siRNA candidate sequences using Lipofectamine 2000, treating infected cells with LPS, and measuring TNF-ct mRNA levels 0 approximately 16 hrs later. Fifty six siRNA sequences were designed and screened for their ability to knockdown TNF-a mRNA and protein levels in activated human primary monocytes. Activities for a representative set of 27 siRNA sequences ranged from 80% mRNA knockdown activity to no detectable activity. In general, TNF-a protein levels were reduced more than mRNA levels, e.g., a 50% knockdown in TNF-a mRNA (TNF-a-1) resulted in a 75% reduction 5 in TNF-a protein level. Dose response curves for selected siRNAs that exhibited knockdown levels from 30% to 60 % were obtained. Calculated IC50values were in the 10 pMolar to 200 pMolar range. While the siRNA sequences evaluated were distributed throughout the TNF-a transcript, the most potent siRNAs identified were located in two areas: the middle of the coding region and the 3'-UTR. 0 EXAMPLE 7 siRNA Gene Expression Knock Down is Enhanced by Polynucleotide Delivery-Enhancing Polypeptides Conjugated with siRNA The present example demonstrates knockdown of target gene expression by peptide siRNA conjugates of the invention. The materials and methods for these studies are the same as 15 those described above, with the exception that no mixing of the siRNA and peptide is required. In the present series of studies, the knockdown experiments included comparison of peptide/siRNA-mediated knockdown with and without lipofectamine. The results of this example are illustrated in Table 13 below. 62 WO 2007/030619 PCT/US2006/034859 5 Table 13: Peptide/siRNA-Mediated Knockdown of TNF-a Gene Expression With and Without Lipofectamine Cell Type With Lipofectamine Without Lipofectamine Used in Complex Peptide + Assay Name siRNA Conc. (pMl) KD (%) Conc. (pM) KD (%) 0.4 pM no KD 0.4 pM no KD COP456 cIBR + LC20 1.3 M n 1.3 no1.3 M no KD 4 noKD 4M no KD 0.4 MMI no KD3 0.4 pM~ no KD CD14 CoP457 Peptide T + 0.4 no D 0.4 no KD LC20 1.3 pM no KD 1.3 M no KD 4 p no KD 4 M no KD CoP278 TAT/HA + 0.4 pM no KD 0.4 pM no KD COP278 YC12 1.3 pM no KD 1.3 PM no KD 4 PM noKD 4 pM no KD 0.19 pM 31.95% 0.19 pM 61.61% 0.38 pM 32.83% 0.38 M 76.31% MTF CoP277 PN73 + LC13 0.75 pM 39.29% 0.75 pM 73.94% 1.50 pM 41.42% 1.50 PM 73.14% 3.00 pM 39.88% 3.00 pM 58.14% 6.00 pM 20.23% 6.00 pM 50.71% 0.000 4M 93.06% 0.002 4M 83.63% CD14 CoP277 PN73 + LC13 0.011 pM 72.58% 0.053 pM 73.52% 0.266 pM 85.01% 0.000 PM 75.15% 0.002 pM 60.72% CD14 CoP277 PN73 + LC20 0.011 M 57.09% 0.011 PM 57.09% 0.053 pM 58.70% 0.266 pM 62.79% The foregoing data (Table 13) evince that a diverse assemblage of polynucleotide .0 delivery-enhancing polypeptides of the invention conjugated with siRNAs function to enhance siRNA-mediated knockdown of TNF-oa gene expression in mammalian subjects. EXAMPLE 8 Time Course of siRNA Gene Expression Knock Down The instant example presents studies relating to the time course of siRNA-mediated gene 15 expression knockdown. To test the duration of the siRNA effect, the siRNA transfection procedures as noted above were employed, except that fibroblasts derived from eGFP expressing mice were used. The transfection reagent used here was lipofectamine. The cells were replated 63 WO 2007/030619 PCT/US2006/034859 5 on the 18th day due to overgrowth. The second transfection was performed on the 19th day post first transfection. On the 19th day the eGFP levels were measured after the transfection. Scramble or nonsense siRNA (Qiagen) was used as a control, along with a GFPI siRNA (GFPI) and a hairpin siRNA (D#21). The knockdown activities were calibrated with scramble siRNA (Qiagen control). A higher value indicates greater knockdown activity. 0 Table 14: Time Course of TNF-ac Gene Expression Knock Down by Lipofectamine Mediated Transfection of siRNA siRNA Days Post First Transfection siRNA 1 3 5 7 9 11 13 15 17 Scramble 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 siRNA GFPI 27.61 60.87 64.75 58.40 56.72 40.46 35.56 16.59 15.50 D#21 28.22 61.11 66.91 62.86 57.36 54.71 42.96 24.66 9.88 siRNA Days Post First Transfection siRNA 19 20 21 25 27 Scramble 0.00 0.00 0.00 0.00 0.00 siRNA GFPI 59.60 37.10 57.38 66.94 59.63 D#21 46.36 35.89 65.25 74.15 58.39 15 The foregoing studies (Table 14) demonstrate that siRNA knockdown activity became apparent around day 3, and was sustained through day 9, whereafter target gene expression returned to baseline levels around day 17. After the second transfection on day 18, another reduction of eGFP expression occurred indicating that the reagent can be repeatedly administered to cells to yield repeated or enduring gene expression knockdown. 20 EXAMPLE 9 Dosage Dependence of TNF-oc Gene Expression Knock Down Mediated by siRNA Complexed With Polynucleotide Delivery-Enhancing Polypeptide The present example demonstrates that knockdown activity mediated by siRNA complexed with an exemplary polynucleotide delivery-enhancing polypeptide, PN73, in 25 activated human monocytes is dependent on dosage concentration of peptide-siRNA complex. The PN73/siRNA complex was provided in a constant ratio between PN73 and siRNA of about PN73:siRNA=82:1 (Table 15). Four hundred nanomolar siRNA was complexed with 33p~M PN73 for 5 minutes in OptiMEM medium. After complexation, the complex were serial diluted (1:2 ratio) with OptiMEM. The complex was added to human monocytes for 64 WO 2007/030619 PCT/US2006/034859 5 transfection. The following induction and mRNA quantification was performed according to the description above. Table 15: Peptide Dosage Dependence of TNF-a Gene Expression Knock Down PN73 siRNA Gene expression (%) Conc. Conc. (p) (nM) Control TNF-x2 TNF-a4 LC8 0 M 0 _nM 100% 100% 100% 100% 1.2 ipM 14.81 nM 99.99% 80.28% 70.22% 73.44% 3.6 IM 44.44 nM 100.11% 69.33% 62.97% 63.04% 11 pM 133.33 nM 99.99% 57.82% 62.71% 59.57% 33 pM 400.00 nM 99.99% 64.51% 78.48% 51.30% 10 In a related series of experiments, siRNA was serially diluted and combined with a fixed amount of PN73 (1.67 pM). Alternatively stated, the PN73 polynucleotide delivery-enhancing polypeptide was complexed with titration amounts of siRNA. PN73 (1.67 pM) was complexed with each titration amount of LC20 siRNA for 5 minutes at room temperature in OptiMEM 15 medium. After complexation, the complex was added to human monocytes for transfection. The induction and mRNA quantification data provided in Table 16, below, were obtained by methods described above. Table 16: siRNA Dosage Dependence of TNF-a Gene Expression Knock Down TNF-a Gene expression siRNA conc. (nM) Control (%) (%) 0.8 nM 100.0% 84.7% 4 nM 100.0% 59.4% 20 nM 100.0% 65.2% 100 nM 100.0% 54.7% 20 EXAMPLE 10 Multiple Dosing Protocol to Extend siRNA Knockdown Effect in Mammalian Cells The instant example demonstrates that multiple dosing schedules will effectively extend gene expression knockdown effects in mammalian cells mediated by siRNA/polynucleotide 25 delivery-enhancing polypeptide compositions of the invention. The materials and methods employed for these studies are the same as described above, with the exception that repeated transfections were conducted at the times indicated. The scramble siRNA (Qiagen) was utilized 65 WO 2007/030619 PCT/US2006/034859 5 for side by side controls. Table 17 summarizes the data for multiple transfections with a peptide/siRNA complex. The percent knockdown activity of the TNF-a gene represents the percent of total gene expression. Table 17: TNF-a Gene Expression Knock Down Activity 10 After Multiple Transfections With a Peptide/siRNA Complex Dosing Days post 1st Transfection Regime 4 5 6 7 8 9 10 11 12 Single 74.7% 61.9% 62.6% 55.5% 41.4% 39.4% 27.2% 2 nd on 5th 66.7% 69.8% 68.3% 64.2% 63.9% 64.4% 56.5% 2 nd on 6E 64.2% 65.8% 67.7% 64.1% 58.6% 54.0% 2 nd on 7 63.1% 62.5% 69.9% 62.6% 58.1% The foregoing results (Table 17) demonstrate that when multiple transfections are performed timely (in this case between about the 5th-7th day post first transfection), TNF-a gene expression knockdown effects in mammalian cells can be maintained or re-induced. 15 EXAMPLE 11 In Vivo siRNA/Peptide-Mediated TNF-a Gene Expression Knock Down Activity The present example provides in vivo data demonstrating the efficacy of siRNA/polynucleotide delivery-enhancing polypeptide compositions of the invention to mediate systemic delivery and therapeutic gene knockdown by siRNA, effective to modulate target gene 0 expression and modify phenotype of cells in a therapeutic manner. Human TNF-(c expressing mice were purchase from the Hellenic Pasture Institute, Greece) at 5weeks old. Mice were administered through intra venous (IV) with 300 p l saline twice a week (4 mice), with the RA drug Ramicade (5 mg/kg) once a week (2 mice), or with LC20 siRNA (2 mg/kg) mixed with PN73 at 1:5 molar ratio twice a week (2 mice). During the 5 injection periods, plasma samples were collected for ELISA testing (R&D Systems), and paw scores were taken twice a week as an accepted index of RA disease progression and therapeutic efficacy. TNF-a protein blood plasma levels from treated mice are shown below in Table 18. Table 18: Quantity of TNF-a Protein in Blood Plasma as Assayed by ELISA Treatment Age(week) 7 8 9 Ramicade 102.24 39.27 25.80 LC20/PN73 25.96 21.89 14.21 Saline 33.78 34.29 24.48 66 WO 2007/030619 PCT/US2006/034859 5 *These data represent the average of the mice in the experiment inpg/ml. The foregoing results demonstrate effective reduction of TNF-a protein levels in peptide/siRNA-treated mice in the circulating blood as compared to levels in Ramicade or saline (control) treated mice. 0 Additional evidence of in vivo efficacy of the siRNA/polynucleotide delivery-enhancing polypeptide compositions and methods of the invention were obtained from the above murine subjects using paw scores, an accepted phenotypic index for RA disease status and treatment efficacy. Due to the difference in the starting point (some animals present with scores at earlier points), the scores have been adjusted to 0 for all animals in the experiments. Each paw is given 5 a score between 0 and 3, with the highest score of 12, according to the following scoring index. 0: Normal 1: edema or distortion of paw-or ankle joints 2: distortion of paw and ankle joints 3: ankylosis of wrist or ankle joints. 0 The results of these paw score evaluations are presented graphically in Figure 5. The data demonstrate that the polynucleotide delivery-enhancing polypeptide PN73 can deliver therapeutic amounts of siRNAs (e.g., LC20, TNF-a2, and TNF-a9 (UAGCCCAUGUUGUAGCAAA (SEQ ID NO. 187))) when injected into animals as shown by a delayed RA progression at week 8. The PN73/siRNA treated mice faired better on the paw ,5 scoring index at week 8 compared to the Ramicade-treated mice. When paw score evaluations were carried out to 11 weeks post-treatment, PN73/LC20 complex achieved comparable paw score evaluations to the Ramicade-treated mice. At a ratio of 1:5 for the PN73 peptide/LC20 siRNA, 2 mg/kg LC20 achieved the greatest relative observed delay in RA progression compared to the lower doses of LC20 tested. The Table 19 below summarizes the relative 0 effectiveness of several siRNAs for 5 different groups evaluated after treatment with PN73 and siRNAs. 67 WO 2007/030619 PCT/US2006/034859 5 Table 19: Group Summaries Group Label Treatment* Relative Effect of siRNA TNF #1 LC20, Ramicade, PBS LC20 is as effective as Ramicade TNF #4 LC20 and LC13 Overall low paw score TNF #5 LC20 conjugated to PN73 Overall low paw score; Conjugates have lower activity than Complexes TNF #6 LC20, YC12 and LC17 Overall low paw score. YC12 and LC17 not as effective as LC20 TNF #7 (Figure 5) LC20, TNF-a2 and TNF-a9 LC20 and TNF-a9 are more effective than Ramicade by week 8; LC20 is equally effective as Ramicade by week 11 *siRNAs were tested in the presence ofabsence ofPN73,; Ramicade is a positive treatment control; PBS is a negative treatment control. 0 The foregoing results demonstrate that siRNA and polynucleotide delivery-enhancing polypeptide compositions of the invention provide promising new therapeutic tools for regulating gene expression and treating and managing disease. siRNAs of the invention, for example siRNAs targeting human TNF-a-specific mRNAs for degradation, offer higher specificity, lower immunogenicity and greater disease modification than current small molecule, 5 soluble receptor, or antibody therapies for RA. More than 50 candidate siRNA sequences were screened that targeted hTNF-a and yielded single administration knockdowns of 30 to 85%. Over 20 in silico designed peptide complex and/or covalent molecules were compared for fluorescent RNA uptake by monocytes and a number were found to have significantly better uptake than Lipofectamine or cholesterol-conjugated siRNA and with < 10 pM ICs 50 values. The 3 peptide-siRNA formulations efficiently knockdown TNF-a mRNA and protein levels in activated human monocytes in vitro. One exemplary candidate delivery peptide/siRNA formulation was evaluated in two transgenic mouse models of rheumatoid arthritis (RA) constitutively expressing human TNF-a. Animals treated with 2 mg/kg siRNA by IV injection or infliximab twice weekly beginning at 5 age 6 weeks showed RA score stabilization (paw and joint inflammation) beginning at age 7 weeks, compared to controls where these disease conditions persisted through week 10. At age 9 weeks, siRNA treated animals showed comparable reductions in RA scores, but significantly lower plasma TNF-a protein levels than infliximab treated animals. Based on the disclosure herein, the use of siRNA to inhibit the expression of target genes, ) for example cytokines such as TNF-a, that play important roles in pathological states, such as 68 WO 2007/030619 PCT/US2006/034859 5 inflammation, provides effective treatments to alleviate or prevent symptoms of disease, as exemplified by RA, in mammalian subjects. Exemplary peptide/siRNA compositions employed within the methods and compositions of the invention provide advantages relating to their ability to reduce or eliminate target gene expression, e.g., TNF-a expression, rather than by complexing with the product of the target gene, e.g., TNF-a, as in the case of antibodies or soluble receptors. 0 Improving systemic delivery of nucleic acids according to the teachings of the invention provides yet additional advantages for development of siRNAs as drugs. Specific challenges in this context include delivery through tissue barriers to a target cell or tissue, maintaining the stability of the siRNA, and intracellular delivery getting siRNAs across cell membranes into cells in sufficient quantities to be effective. The present disclosure demonstrates for the first time an 5 effective in vivo delivery system comprising novel peptide/siRNA compositions targeting specific gene expression, such as expression of human TNF-a, which attenuate disease activity in transgenic animal models predictive of target diseases, as exemplified by studies using murine models of RA. In related studies, the compositions and methods of the invention effectively inhibit TNF-a expression in activated monocytes derived from patients with RA. These results 0 indicate that the RNAi pathway effectively mediates alteration of cellular phenotype and disease progression through intracellular effects on TNF-pathways, and avoids toxicity effects due to circulating antibody/TNF-a complexes with residual immunoreactivity that characterize current antibody therapies for RA. Notably, all of the tests herein were implemented with associated toxicity effects minimized, such that the dosages of siNAs and polynucleotide 5 delivery-enhancing polypeptides shown in these examples always correlated with cell viability levels of at least 80-90% or greater. EXAMPLE 12 Optimizing Rational Design of Polynucleotide Delivery-Enhancing Polypeptides The instant example provides an exemplary design and data for optimizing 0 polynucleotide delivery-enhancing polypeptides of the invention. The subject rational design manipulations were conducted for a histone H2B-derived polynucleotide delivery-enhancing polypeptide. 69 WO 2007/030619 PCT/US2006/034859 5 Table 20: Deletion and Modification of PN73 PN73 PN360 PN361 PN404 PN509 Table 20 provides a diagram of the primary structure of PN73 and its derivatives generated for optimizing rational design of PN73-based polynucleotide delivery-enhancing 10 polypeptides. The gray colored C-terminus of each peptide represents the hydrophobic domain of the peptide and the black N-terminus of each peptide represents the hydrophilic domain. The parent peptide PN73 was demonstrated above to be an example of a polynucleotide delivery-enhancing polypeptides for inducing or enhancing siRNA delivery to cells. In order to better understand the function-structural activity relationships of this and other 1 .5, polynucleotide delivery-enhancing polypeptides, primary structural studies were performed by characterizing C- and N-terminal function, and activity of conjugates between PN73 and other chemical moieties. The amino acid sequence for the human histone 2B (H2B) protein is shown below. PN73, PN360 and PN361 are peptide fragments of H2B and the portion of the H2B 0 protein that they represent are identified below in parentheses following the peptide name. The amino acids sequence for PN360 and PN361 listed below are aligned with the corresponding amino acid sequence found in PN73. The PN73 peptide fragment is underlined in the H2B amino acid sequence and represents H2B amino acids 13 through 48. It may also be represented by H2B amino acids 12 through 48. PN360 shares the N-terminus with PN73 but lacks PN73's ,5 C-termnninus while PN361 shares the C-tenrminus with PN73 but lacks PN73's N-terminus. The PN73 conjugate is PN73 covalently linked to a single siRNA strand (e.g., sense strand). PN404 70 WO 2007/030619 PCT/US2006/034859 5 is a version of PN73 in which all of lysines are replaced with arginines and PN509 is a pegylated PN73 (PEG molecular weight 1k Dalton) derivative that is pegylated at the N-terminus. HI2B (histone 2B) amino acid sequence MPEPAKSAPAPKKGSKKAVTKAQKKDSKKRKRSRKESYSVYVYKVLKV IPDTGISSKAMGIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRL 0 LLPGELAKHAVSEGTKAVTKYTSSK (SEQ ID NO: 164) PN73 (13-48) NH2-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-amide (SEQ ID NO: 59) 5 PN360 (13-35; N-terminus of PN73) NH2-KGSKKAVTKAQKKDGKKRKRSRK-amide (SEQ ID NO: 57) PN361 (24-48; C-terminus of PN73) 0 NH2-KKDGKKRKRSRKESYSVYVYKVLKQ-amide (SEQ ID NO: 58) PN73 (13-48)-siRNA (sense strand) conjugates siRNA-KGSKKAVTKAQKKDGKKIRKRSRKESYSVYVYKVLKQ-amide (SEQ ID NO 59) 5 PN404 (PN73 where all lysines are replaced with arginines) NH2-RGSRRAVTRAQRRDGRRRRRSRRESYSVYVYRVLRQ-amide (SEQ ID NO: 91) 0 PN509 (pegylated PN73) PEG- RGSRRAVTRAQRRDGRRRRRSRRESYSVYVYRVLRQ-amnide (SEQ ID NO: 90). Figure 6 provides the results of uptake efficacy and viability studies in mouse tail fibroblast cells for the foregoing PN73 rationally-designed derivative polynucleotide delivery 5 enhancing polypeptides. The activity changes of modified PN73 in mouse tail fibroblast cells are illustrated. Unlike PN404, PN509 increases uptake without increasing toxicity. While deleting part of the N-terminus of PN73 reduces activity, removal of C-terminal residues 71 WO 2007/030619 PCT/US2006/034859 5 abolishes the activity. Both PN73 and PN509 show higher activity in primary cells than Lipofectamine (Invitrogen, CA). EXAMPLE 13 Acetv1ated Polynucleotide Delivery-Enhancing Polypeptide Has Increased Stability in Plasma S The purpose of the instant example was to determine if modification of the exemplary 0 polynucleotide delivery-enhancing polypeptide PN73 would provide increased stability to the peptide and consequently enhance its transfection activity. The stability of unmodified, N-terminus pegylated and N-terminus acetylated forms of PN73 in plasma was compared. The C-terminus of the PN73 is amidated. Size exclusion chromatography coupled with an ultraviolet detector were used to characterize the stability of the unmodified and modified forms of PN73 5 before and after incubation in plasma. In the absence of plasma, the unmodified, pegylated and acetylated forms of PN73 showed distin4 yet overlapping UV traces at approximately 9 minutes. However, after 4 hours of exposure to plasma, UV traces specific to unmodified PN73 and pegylated PN73 were no longer present indicating significant degradation. In contrast, the distinct UV trace for acetylated 0 PN73 remained indicating that this modification significantly increased stability of the PN73 in plasmid compared to the unmodified and pegylated PN73 forms. These data show the surprisingly and unexpected discovery that PN73 stability in plasma can be enhanced by N-terminus acetylation of the PN73 peptide. The primary structure of the acetylated PN73 peptide is as follows: 5 Ac-KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-amide (SEQ ID NO: 59) EXAMPLE 14 Polynucleotide Delivery-Enhancing Polypeptide Does Not Elicit an Interferon Response The purpose of the instant example was to compare the interferon response of cells 0 transfected with either liposomal reagent plus siRNA or the exemplary polynucleotide delivery-enhancing polypeptide, PN73 peptide plus siRNA. Interferon responsiveness was assayed by ELISA (protein) and bDNA (mRNA levels). Traditionally, siRNA molecules are delivered into cells by a liposomal mediated transfection. However, this typically results in a poor efficiency of delivery, an inflammatory 5 response in vivo and an upregulation of interferon gene expression which results in an inhibition of cell growth. Consequently, there is a limited reduction in targeted gene expression levels thus making siRNA an ineffective method of treatment and tool for studying gene expression. Delivery of siRNA by PN73 overcomes this problem. 72 WO 2007/030619 PCT/US2006/034859 5 Figure 7 provides the results of the bDNA assay of lipofectamine versus PN73 peptide transfection of several different siRNAs. siRNAs were complexed with either lipofectamine or PN73 at concentrations of 1 nM, 10 nM, 100 nM or 200 nM. Interleukin 1 3 (IL-1 3) served as a molecular marker to determine interferon responsiveness and Qneg was used as a negative control. As shown in Figure 7, lipofectamine complexed with the 100 nM or 200 nM 0 TNF-a9 siRNA caused a significant increase in IL-1 3 mRNA levels. Furthermore, all other siRNAs tested caused a mild increase in IL-1 3 mRNA levels. In contrast, the same siRNAs complexed with the PN73 peptide did not cause an increase in IL-13 mRNA levels. To further characterize the difference in interferon responsiveness observed between cells transfected with either lipofectamine and PN73 transfection, an ELISA assay was performed to 5 determine the protein expression levels of the following molecular markers: Interleukin 1 3 (IL 103), Interferon-c (INF-a), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-12 (1L-12), MIP-1 a, Interferon-y (IFN-y), and Tumor Necrosis Factor-a (TNF-a). Table 21 summarizes the relative protein expression levels of cells transfected with Lipofectamine complexed with siRNA or PN73 complexed with siRNA. D Table 21: Relative Protein Expression Levels of Molecular Markers of Interferon Responsiveness Lipofectamine Transfection PN73 Transfection Interferon For All siRNAs Response IFN-1 LC17 LC20 TNF-a9 R ke siRNA siRNA siRNA siRNA (IFN-1; LC17; LC20; MarkerTNF-(x9) IL-1 ++ - -+ INF-ca Background Background Background Background Background IL-6 ++ - + IL-8 IL-12 Background Background Background Background Background MIP-l a +++ - ++ IFN-yt Background Background Background Background Background TNF-a + As presented in Table 21, both siRNA LC20 and LC17 had no interferon response regardless of what transfection reagent was used. However, transfection of IFN-1 or TNF-a9 5 with lipofectamine caused an increase in IL-13, EIL-6, and MIP-la, protein expression levels. In contrast, transfection of all tested siRNAs with PN73 caused no observable induction in protein expression in any of the interferon response markers tested. These data from the ELISA assay show the surprisingly and unexpected discovery that PN73 mediated transfection of siRNAs does not elicit an interferon response. 73 WO 2007/030619 PCT/US2006/034859 5 EXAMPLE 15 siRNA Conjugated with a Polynucleotide Delivery-Enhancing Polypeptide Provides Greater Knockdown Activity than siRNA Complexed with Polynucleotide Delivery-Enhancing Polypeptide The purpose of the instant example was to compare the knockdown activities in human 0 monocytes of the siRNAs LC13 and LC20 either conjugated or complexed with the exemplary polynucleotide delivery-enhancing polypeptide PN73. Isolation and transfection of human monocytes as well as the methods used to measure knockdown activity were discussed earlier. Qneg represents a random siRNA sequence and functions as the negative control in these experiments. The observed Qneg knockdown activity is normalized to 100% (100% gene 5 expression levels) and the activity of LC20 and LC13 is presented as a relative percentage of the negative control. LC20 and LC13 are siRNAs targeted against the human TNF-ac gene. Figure 8 shows the knockdown activity for the siRNAs LC20 and LC13 without PN73 (Figure 8-C), complexed with PN73 (Figure 8-B) or conjugated with PN73 (Figure 8-A). LC20 and L13 were tested over a concentration range of 0 nM to 2.5 nM. PN73 was kept at a 1:1 ratio in both the 3 complex and conjugate experiments. As expected, in the absence of PN73, LC13 and L20 showed little knockdown activity (Figure 8-C). Both LC13 and LC20 caused an approximate 15% and 30% decrease in TNF-a gene expression relative to the Qneg control when complexed with PN73 (Figure 8-B). However, knockdown activity for TNF-ca was reduced to below 60% when the siRNA was 5 conjugated to PN73 (Figure 8-A). This is significant increase the siRNA knockdown activity compared to the PN73/siRNA complex. Thus, these data show the surprisingly and unexpected discovery that siRNA knockdown activity is significantly enhanced when the siRNA is conjugated to the exemplary polynucleotide delivery-enhancing-polypeptide PN73. EXAMPLE 16 ) Serum Inhibition of Cholesterol-Enhanced siRNA Uptake is Rescued by a Polynucleotide Delivery-Enhancing Polypeptide The present example demonstrates that the addition of permeabilizing peptide to a delivery formulation comprising a siRNA conjugated to a cholesterol moiety reduces the inhibitory effects of serum on cholesterol-siRNA uptake in a dose dependent manner. For siRNA uptake analysis, cells were washed with PBS, treated with trypsin (attached cells only), and then analyzed by flow cytometry. Uptake of the siRNA designated BA, described above, was also measured by intensity of Cy5 or FAM fluorescence in the cells and cellular viability assessed by addition of propidium iodide or AnnexinV-PE. In order to differentiate the cellular 74 WO 2007/030619 PCT/US2006/034859 5 uptake from the membrane insertion of fluorescence labeled siRNA, trypan blue was used to quench the fluorescence on the cell membrane surface. Table 22: PN73 Mediated Transfection Rescues Serum Induced Inhibition of Cholesterol Conjugated siRNA Cell Uptake as Assayed by Mean Fluorescent Intensity (MFI) Percent Serum Cholesterol siRNA alone Unconjugated siRNA with 20 ItM PN73 (MI) (MF) 0 24.8 32.9 5% 1.55 11.5 10% 1.34 6.39 20% 1.19 5.85 ) The data in Table 22 shows that the presence of serum significantly reduces cellular uptake of the siRNA conjugated to a cholesterol moiety according to the invention. However, unconjugated siRNA cellular uptake is rescued in the presence of an exemplary delivery enhancing peptide, PN73. 5 A comparison of cellular uptake of a cholesterol-conjugated siRNA according to the invention in complex with a penneabilizing peptide delivery enhancing agent, PN73 (cholesterol siRNA+PN73), and on an unconjugated siRNA in complex with PN73 (siRNA+PN73) was performed. As shown in Figure 9, equivalent cell uptake activity can be achieved at high concentrations of PN73 with either unconjugated siRNA or a cholesterol-conjugated siRNA. For ) these and related uptake assays, cholesterol-conjugated siRNA and siRNA/PN73 complex were transfected into mouse tail fibroblast cells (MTF) in Opti-MEM® media (Invitrogen) as described above, with serum added in fixed or varied concentration(s). The final concentration of siRNA for both cholesterol and complex were 0.2 [tM. The uptake efficiency and Mean fluorescence intensity were assessed by flow cytometry. 5 The ability of the PN73 and additionally PN250 to rescue serum inhibition of cell uptake of cholesterol conjugated siRNA was further characterized in mouse tail fibroblast (MTF) cells. Figure 10 illustrates the effect of increasing concentration of fetal bovine serum (FBS) on siRNA cell uptake. In the absence of either PN73 or PN250, the cell uptake of cholesterol conjugated siRNA is drastically compromised at just 5% FBS. However, in the presence of either 40 pM ) PN73 or 80 pM PN250, siRNA uptake is rescued. The foregoing data (Table 22 and Figure 10) demonstrate that cholesterol-conjugation of siRNAs can significantly enhance their cellular uptake. However, uptake of cholesterol 75 WO 2007/030619 PCT/US2006/034859 5 conjugated siRNAs can be substantially diminished or even eliminated by the presence of serum. This is likely due to binding of the cholesterol moiety with serum proteins-inhibiting the ability of the cholesterol-bound siRNAs to enter target cells. However, in the presence of a delivery enhancing agent, exemplified by the permeabilizing peptides PN73 and PN250, serum inhibition of cellular uptake can be rescued. More specifically, the addition of a permeabilizing peptide to 0 a delivery fonnulation comprising a siRNA conjugated to a cholesterol moiety reduces the inhibitory effects of serum on cholesterol-siRNA uptake in a dose dependent manner. EXAMPLE 17 Deletion Analysis of the Exemplary Polynucleotide Delivery-Enhancing Polypeptide The present example illustrates the experimental design employed to optimize the siRNA 5 cell-uptake and siRNA mediated target gene knockdown activities of the exemplary polynucleotide delivery-enhancing polypeptide PN73. Table 23 below shows the exemplary polynucleotide delivery-enhancing polypeptide PN73 and truncated derivatives thereof. The amino acids sequence for PN360 and PN361 listed below are aligned with the corresponding amino acid sequence of PN73. PN360 shares its .0 N-terminus with PN73 but lacks PN73's C-terminus while PN361 shares its C-terminus with PN73 but lacks PN73's N-terminus. PN766 represents the 15 C-terminal amino acids of PN73. PN73, PN360, PN361 and PN766 are not tagged with a C-terminal FITC (fluorescein-5 isothiocyanate) (i.e., -GK[EPSILON]G-amide). Table 23 further shows the 11 truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide PN73 that were created by 15 sequentially deleting 3 residues at a time, except PN768, from the N-terminus of the peptide. All these peptides were tagged with a C-terminus FITC (fluorescein-5-isothiocyanate) label (i.e., -GK[EPSILON]G-amide) so that cells containing the peptide could be detected by fluorescent microscopy and/or sorted by flow cytometry. Of note, PN766 and PN708 have the same amino acid sequence but differ in that PN708 has the C-terminus FITC tag. Below is an 30 explanation of the primary structure of PN73 and the truncated forms that will be examined for transfection activity. 76 WO 2007/030619 PCT/US2006/034859 5 Table 23: PN73 Deletion Series SEQ C-Term. Peptide ID Amino Acid Sequence Label ID# NO: PN73 59 KGSKKAVTKAQKIKDGKKRKRSRKESYSVYVYKVLKQ-amide None PN360 57 KGSKKAVTKAQKKDGKKRKRSRK-amide PN361 58 KKDGKKRKRSRKESYSVYVYKVLKQ-amnide PN766 (PN708)97 RKESYSVYVYKVLKQ-amide (PN708) PN690 KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-GK[EPSLON-5CFG ' 98 S (PN73) amide PN661 99 KKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ-GK[EPSlLON-5CFG-amide 2 - PN685 100 VTKAQKKDGKKRKRSRKESYSVYVYKIVLKQ-GK[EPSILON-5CFG amide , PN660 101 AQKKDGKKRKRSRKESYSVYVYKVLKQ-GK[EPSLON-SCFG-amide PN735 165 KDGKKRKRSRKESYSVYVYKVLKQ-GK[EPSILON-5CFG-amide 0 PN655 166 KKRKRSRKESYSVYVYKVLKQ-GKEPSLON-CFG-amide S PN655 166 KKRKRSRKESYSVYVYKVLKQ-GK[EPSILON-5CFG-amide PN654 167 KRSRKESYSVYVYKVLKQ-GK[EPSLON-5CFG-amide S PN708 168 RKESYSVYVYKVLKQ-GK[EPSLON-5CFG-amide PN653 169 SYSVYVYKVLKQ-GK[EPSILON-5CFG-amide PN652 170 VYVYKVLKQ-GK[EPSlLON-SCFG-amide PN652 170 VYVYKVLKQ-GK[EPSLON-5CFG-amide PN651 171 YKVLKQ-GK[EPSILON-5CFG-amide PN768 172 KVLKQ-GK[EPSILON-5CFG-amide EXAMPLE 18 0 Deletion Analysis of the Exemplary Polynucleotide Delivery-Enhancing Polypeptide The functional domains of the exemplary polynucleotide delivery-enhancing polypeptide PN73 are critical to the polynucleotide delivery-enhancing polypeptide's ability to efficiently deliver siNAs into cells. These functional domains include membrane attachment, fusogenic and nucleotide binding regions. Briefly, membrane attachment describes the ability of the exemplary 5 polynucleotide delivery-enhancing polypeptide to bind the cell membrane. The fusogenic character reflects an ability to detach from the cell membrane and enter the cytoplasm. The membrane attachment and fusogenic domains of the peptide are closely linked mechanistically (i.e., peptide's ability to enter the cell) and therefore may be difficult to differentiate 77 WO 2007/030619 PCT/US2006/034859 5 experimentally. Therefore, these two properties (domains of the peptide) will be combined into a single analysis. Lastly, the nucleotide binding describes the peptide's ability to bind nucleotides. The approaches taken to define each of the above described domains of the polynucleotide delivery-enhancing polypeptide is discussed in greater detail below. Table 24 summarizes the data for defining the membrane attachment/fusogenic and nucleotide binding domains of the 3 exemplary polynucleotide delivery-enhancing polypeptide PN73 (the data for all concentrations tested is not shown). Table 24: Summary of Functional Domain Analysis of the PN73 Peptide Deletion Series C-Term. Peptide % Peptide Cell- Peptide FITC % siRNA Cell- siRNA Cy5 Knockdown Label ID# Uptake MFI Uptake MFI Activity PN73 N/A N/A 98% (10 pM) 13 (10 pM) + None PN360 N/A N/A 0% NT NT PN361 N/A N/A 55% (20 gM) NT NT PN690 (PN73) 100% (10lM) 125 (10 pM) 58% (2.5pM) 50 (10 pM) + PN661 100% (10 gM) 128 (10 M) 49% (2.5 jiM) 59 (10 M) NT 100% IPN685 . 151 (10 gM) 24% (2.5 pM) 61 (10 pM) NT 31 a (2.5 RM) Cd 9 S PN660 100% (10 pM) 121 (10 [M) 41% (2.5 pM) 68 (10 pM) + c PN735 100% (10 RM) 82 (10 gM) 13% (2.5 gM) 38 (10 gM) S PN655 100% (10 gM) 63 (10 [M) 14% (10 M) 44 (10 gM) NT S PN654 95% (10 gM) 10 (10 pM) 27% (10 gM) 14 (10 gM) ' PN708 97% (10 gM) 10 (10 pM) 42% (10 tM) 34 (10 pM) + U PN653 95% (10 gM) 8 (10 pM) 1.7% (10 pM) 4 (10 gM) PN652 86% (10 gM) 5 (10 gM) 1.8% (10 pjM) 5 (10 M) NT PN651 90% (10 pM) 5 (10 gM) 0% 3 (0.65 gM) NT PN768 91% (50 gM) 9 (50 pM) NT NT NT NT = not tested; peptide concentrations ( in parenthesis) given are those that achieved the given uptake, in percent, or MFI in relative values. 78 WO 2007/030619 PCT/US2006/034859 Membrane Attachment and Fusogenic Domain of the Exemplary Polynucleotide Delivery-Enhancing Polypeptide: The efficacy of the full-length and truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide PN73 to enter cells was tested in vitro by a cell-uptake assay with primary mouse tail fibroblast (MTF) cells. The number of cells in culture that receive the FITC-labeled peptide was measured by flow cytometry. The percentage peptide cell-uptake was expressed relative to the total number of cells present in the culture. In addition, the Mean Fluorescence Intensity (MFI) was used to evaluate the quantity of FITC-labeled peptide found within cells. MFI directly correlates with the amount of FITC-labeled peptide within the cell: higher relative MFI value correlates with a greater amount of intracellular FITC-labeled Speptides. Peptides in Table 23 were evaluated at 0.63 gM, 2.5 gM and 10 pM concentrations; PN768 was tested at 2 gM, 10 pM and 50 gM. Full-length and truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide PN73, were exposed to cells the day before transfection. FITC-tagged peptides were diluted in Opti-MEM® media (Invitrogen) for about 5 minutes at room temperature and ) then added to cells. Cells were transfected for 3 hours at and washed with PBS, treated with trypsin, and then analyzed by flow cytometry. Cell viability was determined as above. Cellular uptake was distinguished from the membrane insertion using trypan blue to quench any fluorescence on the cell membrane surface. For the cell-uptake assay, the full-length FITC-labeled PN73 peptide (PN690) achieved 5 nearly 100% cell uptake at all tested concentrations (10 pM results shown in Table 24 column entitled "% Peptide Cell-Uptake"). The remaining truncated forms of PN73, at 10 pM concentration except for PN768 which required 50 pM, achieved a percent cell uptake (values in parentheses) comparable to that of PN690 indicating that the N-terminal residues of PN73 are not required for the peptide's ability to enter cells. The five C-terminal residues of the exemplary 0 polynucleotide delivery-enhancing polypeptide PN73, identified as PN768, are sufficient for peptide cell-uptake. However, of note and not shown in Table 24, the truncated forms of PN73 at 0.63 pM showed a decrease in cell uptake activity proportionate to the length of the peptide. In other words, the general observation of the peptides tested at a 0.63 gM concentration is that, as the PN73 peptide's length decreased, its cell uptake activity decreased thus indicating peptide 5 cell-uptake activity is dose dependent. These results showed that all the truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide retain ability to enter a high percentage of cells in culture. 79 WO 2007/030619 PCT/US2006/034859 5 While the cell-uptake assay showed that the truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide PN73 had comparable cell-uptake activities, the MFI measurements indicated that the truncated forms of the P73 peptide were distinguishable based on the mean quantity of FITC-labeled peptide that entered the cells. As shown in column entitled "Peptide FITC MIF" of Table 24, the full-length FITC-labeled PN73 peptide (PN690) 0 showed a dose-dependent increase in MFI with 10 pM achieving the highest MFI at approximately 125 units. PN661, PN685 and PN660 had MFI levels comparable to that of the full-length PN73 (PN690). However, PN735 and PN655 had reduced MFI levels of approximately 80 MFl units and 60 MFI units, respectively. And, a significant decrease in MFI detectability was observed with PN654, PN708, PN653, PN652, PN651 and PN768 indicating 5 that efficient uptake of the peptide by cells is ablated upon deletion of the 18 N-terminal residues of PN73. These results showed that all truncated formnns of PN73 are capable of entering a high percentage of cells in culture and, specifically, that the first 18 N-terminal residues of the exemplary polynucleotide delivery-enhancing polypeptide PN73 are essential for the efficient 3 uptake of the peptide by cells in culture. These results showed that truncated derivative of the of the exemplary polynucleotide deliver-enhancing polypeptide PN73 (PN661; PN685; PN660; PN735; and PN655) can efficiently enter cells in culture. In summary, the peptide cell-uptake data show that the C-terminal five residues of the exemplary polynucleotide delivery-enhancing polypeptide PN73 is sufficient for cell entry 5 indicating that the membrane attachment/fusogenic domain of the peptide is located in the C-terminus. However, the peptide FITC MFI data show that removal of the N-terminal eighteen residues of the exemplary polynucleotide delivery-enhancing polypeptide PN73 limits the efficiency at which the peptide enters cells indicating that the N-terminus of the peptide is necessary for efficient uptake characteristic of the membrane attachment/fusogenic domain. ) Nucleotide Binding Domain of the Exemplary Polynucleotide Delivery-Enhancing Polypeptide: The ability of each peptide in the deletion series to complex and deliver siRNA into primary MTF cells was measured by a cell-uptake assay and by MFI. The nucleotide binding domain(s) of the exemplary polynucleotide delivery-enhancing polypeptide PN73 was 5 characterized by comparing the relative amount of siRNA cell-uptake of the different peptides in the deletion series. Peptides either showed high percentage of siRNA cell-uptake (40% or above), which correlated with the presence of a nucleotide binding region. A low percentage of siRNA cell-uptake (below 30%) reflected the absence of the nucleotide binding domain(s). 80 WO 2007/030619 PCT/US2006/034859 5 To test the full-length and truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide PN73, MTF cells were treated with Cy5- or FAM-conjugated siRNA and peptides as described above. After washing, cells were treated with trypsin, and then analyzed by flow cytometry. Intracellular uptake of siRNA was measured by the intensity of intracellular Cy5 fluorescence; trypan blue was used to quench any fluorescence on the cell 0 membrane surface. Uptake was expressed relative to the total number of cells. Table 24 shows the results percent siRNA cell-uptake of peptide with 0.5 PM Cy5-conjugated siRNA. The non-FITC labeled PN73 (PN643) peptide achieved nearly a 100% uptake of siRNA at 10 RM concentration (data not shown). However, when the PN73 peptide was labeled with the FITC tag (PN690), its maximum cell-uptake activity, which was observed 5 with 2.5 gM, was reduced to approximately 60% indicating that the addition of the FITC label interferes with the peptide's cell-uptake function. Thus, the observed cell-uptake activity for each peptide in this assay may not reflect the peptide's true siRNA cell-uptake activity. Nonetheless, a slight decrease in siRNA cell-uptake activity was observed upon removal of the three most N-terminal residues of the PN73 (PN690) peptide as represented by PN661. 0 Similarly, both PN660 and PN708 had moderate decreases in siRNA cell-uptake activity compared to the full-length PN73 (PN690). These data show that the polynucleotide delivery-enhancing polypeptides of the invention, including PN661, PN660 and PN708, bind nucleic acids. In contrast, a reduction in siRNA uptake activity was observed with PN685, PN735, PN655 and PN654. No significant 5 siRNA uptake activity was observed with PN653, PN652 or PN651 which suggests that the C-terminal 12 amino acids of the exemplary polynucleotide delivery-enhancing polypeptide (residues 37-48 of the H2B protein) do not contain a nucleotide binding domain. Additionally, since peptides PN661, PN660 and PN708 do not include three residue deletions of the full-length peptide (PN690) yet retain the inferred siRNA binding activity. These data suggest that the 0 capacity of the nucleotide binding domain present within the N-tenninus of the exemplary polynucleotide delivery-enhancing polypeptide to bind nucleic acids is sensitive to the presence of specific residues within the N-terminus. In general, these data show that the siRNA cell-uptake activity of the PN73 deletion series indicates that PN708 (residues 34-48) represents the minimum C-terminal fragment of the 5 PN73 peptide that is required for siRNA cell-uptake activity. This is consistent with the nucleotide binding domain of the exemplary polynucleotide delivery-enhancing polypeptide PN73 is located in the first 24 N-terminal residues. 81 WO 2007/030619 PCT/US2006/034859 5 The PN73 peptide deletion series were further characterized for their ability to transfect siRNAs into cells by MIFI, which determined the relative mean quantity of Cy5-conjugated siRNA that entered the cells. Delivery of the Cy5-conjugated siRNA by the full-length FITC-labeled PN73 peptide (PN690) achieved a MFI of approximately 50 relative units. Peptides PN735, PN655, PN654 and PN708 of the PN73 deletion series showed a reduced MFI, 0 ranging from approximately 34 units to 44 units. PN661, PN685 and PN660 of the PN73 deletion series had MFI levels that were slightly above that of the full-length PN73 (PN690) peptide. In contrast, PN654, PN653, PN652 and PN651 had relatively little to no MFI (3-14 units) indicating little to no Cy5-conjugated siRNA entered the cells after transfection with theses peptides. The low MFI values observed with PN653, PN652 and PN651 correlated with 5 the siRNA cell-uptake data that showed that PN654, PN653, PN652 and PN651 do not complex with or facilitate entry of siRNA into cells. Fluorescence microscopic imaging was used to compare the cellular localization of Cy5 labeled siRNAs complexed with the polynucleotide delivery-enhancing polypeptide PN73 to that of siRNAs transfected with lipofectamine (Invitrogen). Localization of siRNA delivered with 0 lipofectamine is characterized by a more punctate staining, indicative of possible endosomal localization, while PN73 exhibits more uniform peri-nuclear staining. siRNA localized in endosomes is not accessible to the RISC complex in the cytoplasm, unable to silence expression of the targeted gene. In comparison, the uniform cytoplasmic distribution of siRNA observed with PN73 mediated delivery is prerequisite for access to the RISC complex, and for reducing 5 expression of the targeted gene. The results show that the polynucleotide deliver-enhancing polypeptides of the invention substantially improve siRNA delivery over cationic lipids, and substantially improve targeted gene silencing (knock down). These data show that the ability of the exemplary polynucleotide deliver-enhancing polypeptide PN73 to enhance the delivery of siRNA with high efficiency into cells depends on 0 the 24 most N-terminal residues of the peptide. These data show that shorter derivatives of the exemplary polynucleotide deliver-enhancing polypeptide PN73 (PN661; PN685 PN660; PN735; PN655; and PN708) can efficiently complex with and deliver siRNA into cells. Analysis of the Truncated Forms of Polynucleotide Delivery-Enhancing Polypeptides PN360 and PN361: 5 The function-structural activity relationships of the C-terminal and N-terminal regions of PN73 were shown by characterizing PN360 (C-terminal) and PN361 (N-terminal) in a siRNA cell-uptake assay performed as described above. 82 WO 2007/030619 PCT/US2006/034859 5 Table 24 shows that deleting part of the N-terminus of PN73 (see PN361) reduced siRNA cell-uptake activity by 50%; removal of C-terminal residues (see PN360) abolishes all siRNA cell-uptake activity. These data show that the C-terminal domain of the exemplary polynucleotide deliver-enhancing polypeptide PN73 is required for nucleotide cell-uptake activity of the peptide. 0 Peptide-siRNA conjugates Enhanced the Delivery of Covalently Linked Cargo into Cells: The peptide cell-uptake activity and MFI measurements of the truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide indicate that these peptides may function as delivery vehicles for a variety of molecular cargo. This includes covalently linking the desired effector molecule, including nucleic acids and peptides to the full-length PN73 or 5 derivates thereof. Restricted delivery of the effector molecule to a particular cell type and/or organelle within cells may be achieved by modifying the delivery peptide with a specific moiety (lipid, peptide and/or sugar group). The deletion analysis of the exemplary polynucleotide delivery-enhancing polypeptide suggests that the N-terminus is critical to the peptide's ability to bind and deliver nucleotides 0 (e.g., siNAs) into cells. However, even in the absence of the N-terminal residues, these non nucleotide binding and severely compromised nucleotide binding peptides retain their membrane attachment and fusogenic domains (e.g., PN361; PN735; PN655; PN654; PN653; PN652 and PN651 and derivates thereof). In light of the peptides inability to bind nucleotides, these peptides can still be used for purposes of siNA delivery into cells by covalently linking the siNA 5 to the peptide's membrane attachment and/or fusogenic domains. As a consequence, the siNA covalent linkage remedies the peptide's inability to bind nucleotides and allows for the efficient peptide mediated delivery of siNA into cells. Furthermore, siNA/peptide conjugates need not be limited to the select truncated forms of the exemplary polynucleotide delivery-enhancing polypeptide but may also include the full-length PN73 and derivates thereof. 0 The following is a non-limiting example of the methods used to generate a siNA/peptide covalent linkage. Both the peptide and siRNA molecules must be functionalized with specific moieties to allow for covalent attachment to each other. For the peptide, the N-terminus is functionalized, for example, with 3-maleimidopropionic acid. However, it is recognized that other functional groups such as bromo or iodoacetyl moieties will work as well. For the RNA 5 molecule the 5' end of the sense strand or 3' end of the antisense strand is functionalized with, for example, a 1-O-dimethoxytrityl-hexyl-disulfide linker according to the following synthetic method. 83 WO 2007/030619 PCT/US2006/034859 5 The 5' modified siNA will be reduced to the free thiol group with 0.393 mg (3 eq) of tris(2-carboxyethyl)phosphine (TCEP) in 0.3 ml of 0.1 M triethylamine acetate (TEAA) buffer (pH 7.0) at room temperature for 3 h. The reduced oligonucleotide will be purified by RP HPLC on XTerraMS C 1 s 4.6x50mm column using a linear gradient from 0 to 30% of CH 3 CN in 0.1 M TEAA buffer pH 7 within 20 min. (tr=5.931 rmin). 0 Such conjugates as described above were prepared. Purified reduced siNA (1.361 rmg, 0.19085 tmol) was dissolved in 0.2 ml of 0.1 M TEAA buffer pH=7 and then the peptide with the maleimido moiety was attached to the peptide N-tenrminus (0.79 rmg, 1.5 eq) and added to the siNA solution. After addition of peptide a precipitate was dissolved by addition of 150 pl of 75% CH 3 CN/0.1M TEAA. After stirring overnight at room temperature, the resulting conjugate 5 was purified by RP HPLC on XTerra@MS C 1 8 4.6x5Omrn column using a linear gradient from 0 to 30% of CH 3 CN in 0.1 M TEAA buffer pH 7 within 20 minutes and 100% C within next 5 min (tr=21.007 rmin). The amount of the conjugate was determined by spectrophotometry based on the calculated molar absorption coefficient at X=260 nm. MALDI mass spectrometric analysis showing a peak observed for the conjugate (10 585.3 amu) matching the calculated 3 mass. The peptide conjugate sense strand and complimentary antisense strand was annealed in 50 mM potassium acetate, 1 mM magnesium acetate and 15 mM HEPES pH 7.4 by heating at 90 0 C for 2 minutes followed by incubation at 37 0 C for 1 hour. The formation of the double stranded RNA conjugate was confirmed by non-denaturing (15%) polyacrylamide gel 5 electrophoresis followed by ethidium bromide staining. The results of cell uptake activity are shown in the following Table 25. 84 WO 2007/030619 PCT/US2006/034859 5 Table 25: Percent of Cells that Uptake siRNA by Peptide-siRNA Conjugates Transfection Reagent Peptide/siRNA Conjugate % siRNA Uptake Concentration No Treatment N/A 0.5% Lipofectamine 5 ng/pil 91.9% PN73 5 pM 92.3% 5 gM 25.4% 10 JM 60.3% 20 gM 83.7% PN654 40 pM 87.5% (8merH2B) 80 pM 94.3% 0.31 gM 6.1% 0.63 pM 10.8% 1.25 pM 16.5% 2.5 JM 35.7% 5 pM 49.8% PN654 + Lipofectamrnine (5 5 RM 96.2% ng/gl) 0.31 gM 3.4% PN651 0.63 pM 11.3% (6mer H2B) 1.25 iM 14.4% 2.5 pM 29.6% 5 gM 45.6% PN651 + Lipofectamnine (5 5 93.4% 5 RM 93.4% ng/pgl) The results in Table 25 show that the PN651-siRNA conjugate enhances uptake of siRNA into cells. Next, MFI was measured. The results are presented in Table 26. 85 WO 2007/030619 PCT/US2006/034859 5 Table 26: Relative Quantity (MFI) of Cy5-siRNA Delivered by Peptide-siRNA Conjugates Transfection Reagent Peptide/siRNA Conjugate siRNA Cy5 MFI Transfection Reagent siRNAnCy5tMFI Concentration No Treatment N/A 0.62 Lipofectamine 5 ng/pil 56.50 PN73 5 )M 47.70 5 RM 3.38 10M 12.20 20 M 28.00 PN654 40 gM 35.50 PN654 80 gM68.00 (18mer H2B) 80 m 68.00 0.31 pM 1.36 0.63 pM 1.83 1.25 pM 2.45 2.5 gM 4.64 5 jM 6.87 PN654 + Lipofectamine (5 ng/pl) 5 M 49.80 0.31 M 1.02 PN651 0.63 M 1.90 (6mer H2B) 1.25 RM 0.62 2.5 gM 56.50 5 gM 47.70 PN651 + Lipofectamine (5 5 ng/p l) 5 M 3.38 The MFI results shown in Table 26 are consistent with the percent siRNA uptake data shown in Table 25. These data show that the PN651-siRNA conjugate enhanced siRNA uptake 0 into cells. Gene Target Knockdown Activity of Select Truncated Forms of the Exemplary Polynucleotide Delivery-Enhancing Polypeptide: The effective knockdown of target gene expression by siRNA/polynucleotide delivery enhancing polypeptide complexes of the invention was demonstrated. Specifically, the ability of 5 siRNA/ polynucleotide delivery-enhancing complexes to modulate expression of the human tumor necrosis factor-a (hTNF-a) gene was assessed. The significance of targeting the hTNF-x gene is that it is implicated in mediating the occurrence or progression of rheumatoid arthritis (RA) when over-expressed in human and other mammalian subjects. Human monocytes were used as a model system to determine the effect of siRNA/ 0 polynucleotide delivery-enhancing complexes on hTNF-oa gene expression. Qneg represents a random siRNA sequence and functioned as the negative control. The observed Qneg knockdown 86 WO 2007/030619 PCT/US2006/034859 5 activity is normalized to 100% (100% gene expression levels) and the knockdown activity of each of the following siRNAs Al 9S21, 21/21 and LC20 was presented as a relative percentage of the negative control. A19S21, 21/21 and LC20 are siRNAs that target hTNF-a mRNA. The exemplary polynucleotide delivery-enhancing polypeptides PN643 (full-length PN73 minus a C-terminal label), PN690 (full-length PN73 with a C-terminal FITC-label) and the truncated 10 forms of PN73 from the deletion series, PN660, PN735, PN654 and PN708 were complexed with the Al 9S21, 21/21 and LC20 siRNAs to determine their effect on each siRNA's ability to reduce hTNF-a. gene expression levels in human monocytes. The experiment was performed as follows: In a 96 well flat bottom plate, human monocytes were seeded at 100K/well/100gl in OptiMEM medium (Invitrogen). Exemplary 15 polynucleotide delivery-enhancing polypeptides were mixed with 20 nM siRNA at a molar ratio of 1 to 5 in OptiMEM medium at room temperature for 5 minutes. At the end of incubation, FBS was added to the mixture (final 3%), and 50gl of the mixture was added to the cells. The cells were incubated at 37 0 C for 3 hours. After incubation, the cells were transferred to V-bottom plate and pelleted at 1500 rpm for 5 min. The cells were resuspended in growth Z0 medium (IMDM with glutamine, non-essential amino acid, and pen-strep). After an overnight incubation, the monocytes were stimulated by application of LPS (Sigma) at 1 ng/ml for 3 hours to increase expression of TNF-oa expression levels. After induction by LPS, cells were collected as above for mRNA quantification, and supernatant was saved for protein quantification if desired. 5 For mRNA measurement, branch DNA technology from Genospectra was used according to manufacturer's specification. To quantitate mRNA level in the cells, both house keeping gene (cypB) and target gene (TNF-a) mRNA were measured, and the reading for TNF-a was normalized with cypB to obtain relative luminescence unit. The knockdown activity for the full length and truncated forms of the exemplary 0 polynucleotide delivery-enhancing polypeptide PN73 are summarized above in Table 24. A "+" in the "Knockdown Activity" column indicates that the peptide/siRNA complex had knockdown activity of 80% of the Qneg negative control siRNA (20% reduction in mRNA levels compared to the Qneg negative control). A "+/-" indicates that the peptide/siRNA complex had a knockdown activity of approximately 90% of the Qneg negative control siRNA (10% reduction 5 in mRNA levels compared to the Qneg negative control). Finally, a "-" indicates that the peptide/siRNA complex had no significant knockdown activity compared to the Qneg negative control. 87 WO 2007/030619 PCT/US2006/034859 5 In general, PN643 (full-length non-FITC-labeled PN73) and PN690 (full-length FITC-labeled PN73) had equivalent siRNA knockdown activities for all siRNAs tested as indicated by "+" in the "Knockdown Activity" column (results shown in Table 24). Additionally, PN660 had siRNA knockdown activities for all siRNAs tested that were comparable to PN643 and PN690 indicating that the removal of the 9 most N-terminal residues 0 of the PN73 peptide did not affect siRNAs mediated knockdown activity of the targeted TNF-ocx mRNA. PN654 showed moderate knockdown activity for both the A19S21 and 21/21 siRNAs but not for the LC20 siRNA (knockdown activity is shown by "-" in knockdown activity column). However, the siRNAs complexed with either PN708 or PN735 resulted in no observable knockdown activity for any of the siRNAs. 5 These results showed that truncated forms of the exemplary polynucleotide delivery enhancing polypeptide PN73, specifically PN660 and PN654, do not interfere with siRNAs' ability to decrease mRNA levels of a target gene and are offer a new approach for improving the delivery of therapeutic siRNAs for the treatment of human diseases such as RA. EXAMPLE 19 3 Characterization of the Polynucleotide Delivery-Enhancing Polypeptide PN708 The present example further explores the siRNA cell-uptake activity, MFI measurements and knockdown activity of siRNAs complexed with the PN708 peptide. Of the available peptides listed in the PN73 deletion series (refer to Table 23 ini Example 17). As described above, the cell-uptake assay determines the number of cells that receive 5 Cy5-conjugated siRNA when complexed with a peptide. siRNA cell-uptake was assessed by flow cytometry. Uptake was expressed as a percentage calculated by dividing the number of cells containing Cy5-conjugated siRNA by the total number of transfected and untransfected cells in culture. Mean Fluorescence Intensity (MFI) was measured by flow cytometry and determined the amount of Cy5-conjugated siRNA found within cells. The MFI value directly S correlates with the amount of Cy5-conjugated siRNA within the cell, thus, a higher MFI value indicates a greater number of Cy5-conjugated siRNA within the cells. In the present example, a greater range of peptide concentrations compared to the previous example were used to detenmnine the efficacy of siRNA cell-uptake activity and MIF measurements. Furthermore, cell viability was assessed. In the instant example, the exemplary 5 polynucleotide delivery-enhancing polypeptides PN643 (full-length PN73 minus a C-terminal label), PN690 (full-length PN73 with a C-terminal FITC-label) and PN708 (15-mer derived by deletion of the 21 N-terminal residues of PN73) were tested at 5 pM, 10 pM, 20 pM and 40 pM. 88 WO 2007/030619 PCT/US2006/034859 5 PN643 and PN690 were also tested at 2.5 M and PN690 was additionally tested at 1.25 JIM. PN643 and PN708 were also both tested at 80 M. As shown in Table 27 below, the non-FITC labeled PN73 (PN643) peptide achieved nearly a 100% uptake of siRNA at 10 pM concentration. However, when the PN73 peptide was labeled with the FITC tag (PN690), its maximum cell-uptake activity was reduced to 0 approximately 70%. PN708 showed a dose dependent increase in siRNA cell-uptake activity. PN708 achieved a maximum siRNA cell-uptake activity of 95% at 80 pM. For the full-length PN73 peptides, cell viability decreased as the concentration of peptide increased. In contrast, cells incubated with the PN708 peptide maintained over 90% cell viability in the presence of all tested concentrations. The Cy5-MFI measurements further showed that the truncated peptide 5 PN708 practically doubled the amount of Cy5-siRNA it delivered into cells compared to the full-length PN73 (PN690) peptide. Table 27: Summary of siRNA Delivery-Enhancing Characteristics of PN708 Concentration % siRNA Cell- siRNA % Cell Treatment Peptide Concentration Uptake Cy5-MFI Viability Negative Control (no 0 0 0 98% treatment) 2.5 pM 61% 8 95% 5 pM 96% 13 95% Cy5-LC20 siRNA + 10 pM 97% 17 94% PN643 20 pM 84% 10 93% 40 pM 44% 7 7,8% 80 gpM 12% 14 26% 1.25 pM 30% 7 95% 2.5 pM 47% 17 97% Cy5-LC20 siRNA+ 5 pM 71% 56 94% PN690 10 pM 64% 67 92% 20 pM 55% 90 91% 40 pM 45% 218 71% 5 pM 35% 9 96% 10 pM 55% 23 96% Cy5-LC20 siRNA + 10M 55% 23 96% PN708 20 pM 83% 85 97% PN708 20 pM 93% 212 94% 80 pM 96% 378 91% 0 These results showed that the truncated exemplary polynucleotide delivery-enhancing polypeptide PN768 (H2B residues 34-38) has the ability to enhance the delivery of siRNA with high efficiency into cells without adversely affecting cell viability. 89 WO 2007/030619 PCT/US2006/034859 5 The truncated exemplary polynucleotide delivery-enhancing polypeptide PN708 was further characterized by determining its affect on siRNA mediated target gene expression reduction. In this section of the example, the C-terminal FITC-label of the PN708 peptide was removed prior to assessing its ability to enhance targeted gene expression reduction when complexed with a siRNA. In the absence of the FITC-label, the truncated exemplary 0 polynucleotide delivery-enhancing polypeptide was named PN766 (refer to Table 23 in Example 17). The ability of siRNA/peptide complexes to modulate expression of the human tumor necrosis factor-oa (hTNF-ax) gene was assessed. In the instant example, the random siRNA sequence, Qneg, served as a negative control and the siRNAs LC20 and LC17 were used to target the hTNF-( mRNA in human monocytes. The molar ratios of siRNA to peptide tested 5 were 1:5; 1:10; 1:25; 1:50; 1:75 and 1:100. Both LC20 and LC17 were used at 20 nM concentration. The knockdown results show that both the LC20/PN766 and LC1 7/PN766 siRNA/peptide complexes at 1:5; 1:10; and 1:25 reduced hTNF-oa mRNA levels to approximately 70%-80% of the Qneg siRNA negative control (i.e., 20% -30% reduction in 0 mRNA levels compared to the Qneg negative control). The siRNA/peptide ratios of 1:50; 1:75 and 1:100 had no significant affect on hTNF-a mRNA levels compared to the Qneg control. No cytotoxicity effects were observed with human monocytes in the presence of the PN766 peptide. These data showed that the truncated exemplary polynucleotide delivery-enhancing polypeptide PN766 when complexed with siRNA significantly reduces mRNA levels of the 5 targeted gene indicating that PN766 is an ideal siRNA delivery peptide for therapeutic siRNAs in the treatment of RA in mammalian subjects. EXAMPLE 20 Amino Acid Substitutions and Deletions within the Exemplary Polynucleotide Delivery Enhancing Polypeptide Do Not Affect Peptide Mediated siRNA Cell-Uptake Activity 0 The present example demonstrates that the mutant exemplary polynucleotide delivery enhancing polypeptides listed in Table 28 below generated by residue substitution and/or deletion did not affect siRNA cell-uptake activity or the MFI measurements compared to the unmodified exemplary polynucleotide delivery-enhancing polypeptide PN73. Table 28 below represents the residue substitutions made within the exemplary polynucleotide delivery 5 enhancing polypeptide PN73. The amino acids in gray highlight represent unmodified, substituted and/or deleted residues. The gray highlight allows for easy identification and comparison of the unmodified residues within the PN73 peptide with the substituted and/or deleted residues within the mutant exemplary polynucleotide delivery-enhancing polypeptides 90 WO 2007/030619 PCT/US2006/034859 5 PN644, PN645, PN646, PN647 and PN729. Substituted residues within the mutant exemplary polynucleotide delivery-enhancing polypeptides are bolded and underlined. Furthermore, the bold and underlined symbol "^" represents a deleted residue within PN729. The purpose of generating mutant exemplary polynucleotide delivery-enhancing polypeptides by residue substitution or deletion was to assess the effect of these modifications on 0 siRNA cell-uptake activity and the efficiency at which siRNAs enter the cells. Table 28: PN73 Residue Substitution and Deletion Series Peptide ID# SEQ ID NO: Amino Acid Sequence PN73 59 KGS KAVTKAQKK.GKKRKRS KS VYVYKVLKQ PN644 173 KGSXKAVTKAQKK GKKRKRS S VYVKVLKQ PN645 174 KGSgKAVTKAQKKGKKRKRSKI S VYVYKVLKQ PN646 175 KGSXKAVTKAQKK GKKRKRSKS:SVYVYKVLKQ PN647 176 KGSOKAVTKAQKK GKKRKRS KIS _VYVYKVLKQ PN729 177 KGSkKAVTKAQKK GKKRKRSKStSVYVYKVLKQ X = represents a substituted amino acid; _A = deleted amino acid; 5 Specific residue substitutions and/or deletions within the exemplary polynucleotide delivery-enhancing polypeptide PN73 include changing or increasing the number of aromatic amino acids and/or decreasing the number of negatively charged amino acids. Amino acids with aromatic functional groups (e.g., phenylalanine, tyrosine, tryptophan and derivatives thereof) are typically found in the membrane spanning domains of proteins due to their relatively non-polar ) (hydrophobic) character and ability to facilitate protein cell membrane penetration. Negatively charged amino acids repulse the negatively charged phosphodiester backbone of nucleic acids and thus impair the ability of a protein to bind nucleic acids. Thus, the rational for aromatic amino acid substitutions within the PN73 peptide include enhancing the peptide's cell penetration function and/or the removal of negatively charged amino acids to enhance the peptide's nucleic 5 acid binding. The peptide's nucleic binding abilities may also be promoted by simply deleting negatively charged amino acids or substituting the negatively charged amino acid with a positively charged or neutral amino acid. 91 WO 2007/030619 PCT/US2006/034859 5 The siRNA cell-uptake assay and MFI measurements were performed as described previously. The data is summarized in Table 29 below. Each peptide was tested at 0.63 IM, 1.25 gM, 2.5 pM and 5 pM concentrations. The results show that despite residue substitutions and/or deletions within the exemplary polynucleotide delivery-enhancing polypeptide PN73, siRNA cell-uptake activity and MFI measurements of the mutant peptides remained equivalent to 0 that of the unmodified PN73. These data indicate that the residue substitutions and/or deletions did not affect the peptide's ability to bind nucleic acids and penetrate the cell membrane. Furthermore, cell viability was unaffected by the presence of substituted and/or deleted residues within the exemplary polynucleotide delivery-enhancing polypeptide PN73. Table 29: 5 Summary of PN73 Mutant Mediated siRNA Delivery Characteristics % siRNA Cell Peptide ID# Concentration Uptake siRNA Cy5 MFI % Cell Viability Uptake No Treatment N/A 0% 2 92% 0.63 gM 52% 2 87% PN73 1.25 gM 62% 4 82% 2.5 pM 74% 14 88% 5 pM 91% 22 93% 0.63 pM 67% 4 88% PN644 1.25 pM 71% 8 90% 2.5 pM 70% 24 86% 5 pM 83% 37 87% 0.63 pM 68% 5 84% PN645 1.25 gM 70% 11 89% PN645 2.5 pM 78% 21 90% 5 pM 88% 28 90% 0.63 pM 67% 4 81% PN646 1.25 pM 70% 10 85% PN646 2.5 pM 73% 24 87% 5 pM 88% 24 92% PN647 0.63 pM 71% 13 85% 1.25 gM 74% 34 83% 2.5 pM 83% 39 88% 92 WO 2007/030619 PCT/US2006/034859 5 gM 85% 41 87% 0.63 gM 61% 4 82% 1.25 gM 69% 10 91% PN729 2.5 pM 79% 16 92% 5 gM 86% 30 90% 5 These results showed that modifications of the exemplary polynucleotide delivery-enhancing polypeptide generated for example via amino acid substitutions or deletions or combinations thereof deliver siRNA to a high percentage of cells with great efficiency. EXAMPLE 21 0 Polynucleotide Delivery-Enhancing Polypeptide Mediated siRNA Cell-Uptake Activity The present example illustrates the efficacy of siRNA cell-uptake activity for the polynucleotide delivery-enhancing polypeptides listed in Table 30 complexed with siRNA. Table 31 summarizes the siRNA cell-uptake data, mean fluorescence intensity (MFI) measurements and cell viability data for each of the polypeptides. Polypeptides that achieved a .5 percent siRNA cell-uptake of 75% or greater are highlighted in gray in the "Treatment" column. The specific percent siRNA cell-uptake for each these highlighted siRNA/peptide complexes is also highlighted in gray in the "% siRNA Cell-Uptake" column. Table 30: Delivery-Enhancing Polypeptides Screened for siRNA Cell-Uptake Activity Peptide SEQ ID Amino Acid Sequence Name ID# NO: PN680 178 RSVCRQIKICRRRGGCYYKCTNRPY-amide Androctonin PN665 179 GFFALIPKIISSPLFKTLLSAVGSALSSSGDQE-amide Paradaxin m-Calpain + PN734 180 GTAMRILGGVIPRIKRRQRRRPPQ-amide m-Calpain + TAT PN681 181 KKKKKRFSFKKSFKLSGFSFKKNKIK-amide MARCKS PN694 182 RQIKIWFQNRRMKWKK-amide Penetratin PN714 183 RQIRIWFQNRRMRWRR-amide PenArg TAT + PN760 184 RKKRRQRRRPPVAYISRGGVSTYYSDTVKGRFTRQKYNKRA-amide Peptide P3a Bindin + PN759 185 LGLLLRHLRHHSNLLANIPRKKRRQRRRPP-amide TAT PN682 186 KETWWETWWTEWSQPIKKKRKV-amide Pep-1 20 The siRNA cell-uptake assay in the present example determines the number of cells that received Cy5-conjugated LC20 siRNA in the presence of peptide. LC20 is an oligo used for the 93 WO 2007/030619 PCT/US2006/034859 5 siRNA targeting of the human tumor necrosis factor-alpha (hTNF-cx) mRNA. siRNA uptake by cells was assessed by flow cytometry. Uptake was expressed as a percentage calculated by dividing the number of cells containing Cy5-conjugated siRNA by the total number of transfected and untransfected cells in culture. Mean Fluorescence Intensity (MFI) was measured by flow cytometry and determined the amount of Cy5-conjugated siRNA found within cells. 0 The MFI value directly correlates with the amount of Cy5-conjugated siRNA within the cell, thus, a higher MFI value indicates a greater number of Cy5-conjugated siRNA within the cells. The following protocol was used to test the polynucleotide delivery-enhancing polypeptides listed in Table 30. Approximately 80,000 mouse tail fibroblast (MTF) cells were plated per well in 24-well plates the day before transfection in complete media. Each delivery 5 peptide, except the positive control, was tested at 0.63 pM, 2.5 pM, 10 pM and 40 pM concentrations in the presence of 0.5 pM Cy5-conjugated siRNA. For siRNA/peptide complexes, the Cy5-conjugated siRNA and peptide were diluted separately in Opti-MEM ® media (Invitrogen) at two-fold the final concentration. Equal volumes of siRNA and peptide were mixed and allowed to complex five minutes at room temperature. The siRNA/peptide 0 complexes were added to cells previously washed with phosphate buffered saline (PBS). Cells were transfected for three hours at 37 0 C, 5% CO 2 . Cells were washed with PBS, treated with trypsin, and then analyzed by flow cytometry. siRNA cell-uptake was measured by the intensity of intracellular Cy5 fluorescence. Cell viability was determined using propidium iodide uptake or AnnexinV-PE (BD Biosciences) staining. In order to differentiate the cellular uptake from the 5 membrane insertion of labeled siRNA (or fluorescein-labeled peptide), trypan blue was used to quench any fluorescence on the cell membrane surface. Trypan blue (Sigma) was added to cells to a final concentration of 0.04% and re-run on the flow cytometer to assess whether there was any change in fluorescence intensity which would indicate fluorescence localized to the cell membrane. 94 WO 2007/030619 PCT/US2006/034859 5 Table 31: Data of Polypeptide Mediated siRNA Delivery Screen (NT = not tested) Treatment Peptide % siRNA Cell- % Cell (siRNA/Polypeptide Complex) Concentration Uptake Cy5-siRNA MFI Viability No treatment N/A 0.0% 0.0 97.6% Cy5-LC20 + PN643 (positive 5 95.4% 7.2 98.8% control) 5 lV 95.4% 7.2 98.8% 0.63 lM 0.2% N/T 98.2% Cy5-LC20 + PN680 2.5 pMlVI 1.8% 1.4 98.3% 10 pMlV 82.6% 4.5 99.2% 40 plVM 79.1% 5.2 95.7% 0.63 pMlVI 0.0% N/T 97.7% Cy5-LC20 + PN665 2.5 plVI 0.6% N/T 95.1% 10 plVM N/T N/T N/T 40 pM N/T N/T N/T 0.63 pM 0.1% N/T 98.2% Cy5-LC20 + PN734 2.5 pMVI 0.2% N/T 98.7% 10 pMlVI 1.2% 1.3 98.4% 40 pM 4.5% 1.6 97.0% 0.63 pM 0.2% 1.8 97.1% Cy5-LC20 + PN681 2.5 pM 69.9% 4.6 98.9% 10 pM 97.3% 15.3 98.2% 40 pMVI 91.2% 13.7 92.6% 0.63 pM 0.2% 1.4 97.1% Cy5-LC20 + PN694 2.5 lM 0.2% 1.8 97.9% 10 pMlV 48.0% 4.2 97.8% 40 pM 54.0% 3.9 83.6% 0.63 pM 0.4% 1.2 95.1% Cy5-LC20 + PN714 2.5 plV 0.5% 2.3 96.4% 10 pM 19.1% 2.5 97.6% 40 pMlV 43.0% 4.9 94.7% 0.63 pM 0.1% 1.0 94.0% Cy5-LC20 + PN709 2.5 pMlVI 0.2% 1.0 96.6% 10 pMlV 18.6% 1.9 97.1% 40 pMlV 76.6% 5.8 97.1% 0.63 pMlV 60% 2.9 84.7% Cy5-LC20 + PN760 2.5 PlM 85.5% 78.5 90.8% 10 pMlVI 90.6% 96.9 91.9% 40 pMlVI 82.8% 77.4 83.2% 0.63 pMlVI 43% 2.1 81.7% Cy5-LC20 + PN759 2.5 PMlV 72.9% 7.3 85.2% 10 pM 83.6% 40.9 86.7% 40 pVM 25% 10.5 26.6% 0.63 pM 52.1% 2.4 86.2% Cy5-LC20 + PN682 2.5 pM 50.6% 2.2 91.3% 10 plVM 56.9% 2.3 90.6% 40 pi 92% 9.0 97.1% 95 WO 2007/030619 PCT/US2006/034859 5 As shown in the column entitled "% siRNA Cell-Uptake" of Table 31, the "no treatment" negative control showed no siRNA cell-uptake while the positive control peptide achieved a percent siRNA cell-uptake activity of 95%. The Cy5 conjugated LC20 siRNA complexed with the polynucleotide delivery-enhancing polypeptides PN680; PN681; PN709; PN760; PN759 or PN682 achieved a percent siRNA cell-uptake activity that exceeded 75% or greater. The 0 polynucleotide delivery-enhancing polypeptides PN694 and PN714 exhibited a moderate siRNA cell-uptake activity of 54% and 43%, respectively. In contrast, the polynucleotide delivery-enhancing polypeptides PN665 and PN734 demonstrated no significant siRNA cell-uptake activity (less than 5%). The polynucleotide delivery-enhancing polypeptides were further characterized for their 5 ability to transfect siRNAs into cells by analyzing Mean Fluorescence Intensity (MFI). While the cell-uptake assay determined the percentage of cells that contain the Cy5-conjugated siRNA, the MFI measurement determined the relative mean quantity of Cy5-conjugated siRNA that entered the cells. As shown in the column entitled "siRNA Cy5 MFI" of Table 31, delivery of the Cy5-conjugated siRNA by the positive control peptide PN643 achieved a MFI of 0 approximately seven units. As expected, the "no treatment" negative control has no measurable MFI. The polynucleotide delivery-enhancing polypeptide PN665 was not tested by MFI. PN743, PN694 and PN714 had MFI measurements significantly lower than that of the positive control. The polynucleotide delivery-enhancing polypeptides PN680, PN709 and PN682 exhibited MFI measurements comparable to that of the PN643 positive control while PN681 had 5 an MFI double that of the positive control. Surprisingly, the polynucleotide delivery-enhancing polypeptides PN760 and PN759 had MFI measurements that were approximately 13-fold and 6 fold greater, respectively, than that of the positive control. These data show that the polynucleotide deliver-enhancing polypeptides PN680; PN681; PN709; PN760; PN759 and PN682 when complexed with siRNA efficiently deliver siRNA into ) cells. EXAMPLE 22 Gene Expression Knockdown Activity of siRNAs Transfected Into Cells with Polynucleotide Delivery-Enhancing Polypeptides The present example demonstrates that siRNA complexed with polynucleotide delivery 5 enhancing polypeptides effectively knockdown mRNA expression of the siRNA targeted gene. Specifically, the ability of siRNA/peptide complexes to modulate expression of the human tumor necrosis factor-ca (hTNF-a) gene was assessed. The significance of targeting the hTNF-o gene 96 WO 2007/030619 PCT/US2006/034859 5 is that it is implicated in mediating the occurrence or progression of rheumatoid arthritis (RA) when over-expressed in human and other mammalian subjects. Human monocytes were used as a model system to determine the effect of siRNA/peptide complexes on hTNF-a gene expression. Qneg represents a random siRNA sequence and functioned as the negative control. The observed Qneg knockdown activity is normalized to 0 100% (100% gene expression levels) and the knockdown activity for each of the following siRNAs A19S21 MD8, 21/21 MD8 and LC20 was presented as a relative percentage of the negative control. A19S21 MD8, 21/21 MD8 and LC20 are siRNAs that target hTNF-oa mRNA. The polynucleotide delivery-enhancing polypeptide PN602 represented an acetylated form of the positive control used in prior Examples and is used herein as a positive control for 5 both the effective delivery of siRNA into human monocytes and the permissive knockdown activity of hTNF-ac mRNA levels mediated by siRNA. The polynucleotide delivery-enhancing polypeptides PN680 and PN681 were complexed with the above listed siRNAs to determine their effect on each siRNA's ability to reduce hTNF-oa gene expression levels in human monocytes. The knockdown activity of all three polynucleotide delivery-enhancing polypeptides 0 is summarized below in Table 32. A "+" in the "Knockdown Activity" column indicates that the peptide/siRNA complex had knockdown activity of 80% of the Qneg negative control siRNA (20% reduction in mRNA levels compared to the Qneg negative control). A "+/-" indicates that the peptide/siRNA complex had a knockdown activity of approximately 90% of the Qneg negative control siRNA (10% reduction in mRNA levels compared to the Qneg negative 5 control). Finally, a "-" indicates that the peptide/siRNA complex had no significant knockdown activity compared to the Qneg negative control. Transfections in human monocytes for the instant example was performed according to protocols previously described. For mRNA measurement, branch DNA technology from Genospectra (CA) was used 0 according to manufacturer's specification. To quantitate mRNA level in the cells, both house keeping gene (cypB) and target gene (TNF-a) mRNA were measured, and the reading for TNF a was normalized with cypB to obtain relative luminescence unit. 97 WO 2007/030619 PCT/US2006/034859 5 Table 32: siRNA Knockdown Activity for siRNAs Complexed with Polynucleotide Delivery-Enhancing Polypeptides Peptide ID # siRNA:Peptide siRNA Peptide ID # Ratio A19S21 MD8 21/21 MD8 LC20 PN602 1:5 +/- +/- +/_ (Positive control) 1:10 +/- +/- +/ 1:5 + + + PN680 1:10 +/- +/- + 1:5
+/
PN681 1:10 +/ The results shown in Table 32 indicate that all three siRNAs complexed with the positive ) control PN602 polynucleotide delivery-enhancing polypeptide at ratios of 1:5 and 1:10 moderately reduced hTNF-a gene expression levels compared to the Qneg negative control complexed with the same polypeptide. However, the same siRNAs complexed with the polynucleotide delivery-enhancing polypeptide PN681 at 1:5 and 1:10 showed little to no knockdown activity relative to the Qneg negative control siRNA/PN681 complex. In contrast, Sthe polynucleotide delivery-enhancing polypeptide PN680 complexed with any of the hTNF-a specific siRNAs at a 1:5 ratio exhibited significant knockdown activity of the hTNF-a. mRNA relative to the Qneg/PN680 control complex. Furthermore, the LC20/PN680 complex at a 1:10 ratio also demonstrated significant knockdown activity compared to the Qneg/PN680 control complex. These data show that the polynucleotide delivery-enhancing polypeptide PN680 delivers siRNAs into cells and permits effective siRNA mediated gene silencing. 98 WO 2007/030619 PCT/US2006/034859 Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications may be practiced within the scope of the appended claims which are presented by way of illustration not limitation. In this context, various publications and other references have been cited within the foregoing disclosure for economy of description. Each of these references is incorporated herein by reference in its entirety for all purposes. It is noted, however, that the various publications discussed herein are incorporated solely for their disclosure prior to the filing date of the present application, and the inventors reserve the right to antedate such disclosure by virtue of prior invention. 99
Claims (37)
1. A composition comprising a polynucleotide delivery-enhancing polypeptide and a double stranded ribonucleic acid (dsRNA), wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties.
2. The composition of Claim 1, wherein the polynucleotide delivery-enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a sequence selected from the group consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, Mellitin, Histone H1, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186.
3. The composition of Claim 1, wherein the composition causes uptake of the dsRNA into an animal cell.
4. The composition of the Claim 3, wherein the animal cell is a mammnualian cell.
5. The composition of Claim 1, wherein the composition is administered to an animal.
6. The composition of the Claim 5, wherein the animal is a mammal.
7. The composition of Claim 1, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated.
8. The composition of Claim 1, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is pegylated.
9. The composition of Claim 1, wherein the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tumor Necrosis Factor-alpha (TNF-a) gene.
10. The composition of Claim 1, wherein the dsRNA is a siRNA consisting of about 10 to about 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187. 100 WO 2007/030619 PCT/US2006/034859
11. The composition of Claim 1, wherein the polynucleotide delivery-enhancing polypeptide is admixed, complexed or conjugated to the dsRNA.
12. The composition of Claim 1, wherein the polynucleotide delivery-enhancing polypeptide binds to the dsRNA.
13. The composition of Claim 1, further comprising a cationic lipid.
14. The composition of Claim 13, wherein the cationic lipid is selected from the group consisting of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, 1,2 bis(oleoyloxy)-3-3-(trimethylammonium)propane, 1,2-dimyristyloxypropyl-3 dimethylhydroxyethylammonium bromide, dimethyldioctadecylanunonium bromide, 2,3 dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminiu m trifluoracetate, 1,3-dioleoyloxy-2-(6-carboxyspennrmyl)-propylamid, 5-carboxyspermylglycine dioctadecylamide, tetramethyltetrapalmitoyl spermine, tetramethyltetraoleyl spermine, tetramethyltetralauryl spermine, tetramethyltetramyristyl spennrmine and tetramethyldioleyl spermine, DOTMA (N-[1 (2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAP (1,2-bis(oleoyloxy) 3,3-(trimethylammonium)propane), DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide), DDAB (dimethyl dioctadecyl ammonium bromide), polyvalent cationic lipids, lipospermines, DOSPA (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl 1-propanamini um trifluoro-acetate), DOSPER (1,3-dioleoyloxy-2-(6carboxy spermyl)-propyl amid, di- and tetra-alkyl-tetra-methyl spermines, TMTPS (tetramethyltetrapalmitoyl spennrmine), TMTOS (tetramethyltetraoleyl spermine), TMTLS (tetramethlytetralauryl spermine), TMTMS (tetramethyltetramyristyl spermine), TMDOS (tetramethyldioleyl spermine) DOGS (dioctadecyl amidoglycylspermine (TRANSFECTAM@), cationic lipids combined with non-cationic lipids, DOPE (dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine) or cholesterol, a cationic lipid composition composed of a 3:1 (w/w) mixture of DOSPA and DOPE, and a 1:1 (w/w) mixture of DOTMA and DOPE.
15. A method for causing uptake of a double stranded ribonucleic acid (dsRNA) into an animal cell, which comprises incubating the animal cells with a mixture comprising a polynucleotide delivery-enhancing polypeptide and the dsRNA, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties.
16. A method for modifying expression of a target gene in an animal cell, which comprises incubating the animal cell with a mixture comprising a polynucleotide delivery 101 WO 2007/030619 PCT/US2006/034859 enhancing polypeptide, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA), wherein the dsRNA is complementary to a region of the target gene.
17. The method of Claim 15 or 16, wherein the animal cell is a mammalian cell.
18. A method for changing a phenotype of an animal subject, which comprises administering to the animal subject a mixture of a polynucleotide delivery-enhancing polypeptide, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA), wherein the dsRNA is complementary to a region of a target gene in the subject.
19. The method of Claim 18, wherein the animal is a mammal.
20. The method of Claim 15, 16 or 18, wherein the polynucleotide delivery enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a sequence selected from the group consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, Mellitin, Histone Hi, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186.
21. The method of Claim 15, 16 or 18, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated.
22. The method of Claim 15, 16 or 18, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is pegylated.
23. The method of Claim 15, 16 or 18, wherein the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tumor Necrosis Factor-alpha (TNF-c) gene.
24. The method of Claim 15, 16 or 18, wherein the dsRNA is a siRNA consisting of about 10 to about 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187.
25. The method of Claim 15, 16 or 18, wherein the polynucleotide delivery enhancing polypeptide is admixed, complexed or conjugated to the dsRNA. 102 WO 2007/030619 PCT/US2006/034859
26. The method of Claim 15, 16 or 18, wherein the polynucleotide delivery enhancing polypeptide binds to the dsRNA.
27. The method of Claim 15, 16 or 18, further comprising a cationic lipid.
28. The method of Claim 27, wherein the cationic lipid is selected from the group consisting of N-[ 1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, 1,2 bis(oleoyloxy)-3-3-(trimethylammonium)propane, 1,2-dimyristyloxypropyl-3 dimethylhydroxyethylanmonium bromide, dimethyldioctadecylammonium bromide, 2,3 dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl- I -propanaminiu m trifluoracetate, 1,3-dioleoyloxy-2-(6-carboxyspernyl)-propylamid, 5-carboxyspermylglycine dioctadecylamide, tetramethyltetrapalmitoyl spermine, tetramethyltetraoleyl spermine, tetramethyltetralauryl spennine, tetramethyltetramyristyl spermine and tetramethyldioleyl spermine, DOTMA (N-[1 (2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAP (1,2-bis(oleoyloxy) 3,3-(trimethylanmmonium)propane), DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide), DDAB (dimethyl dioctadecyl ammonium bromide), polyvalent cationic lipids, lipospermnnines, DOSPA (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl 1-propanamini um trifluoro-acetate), DOSPER (1,3-dioleoyloxy-2-(6carboxy spermyl)-propyl amid, di- and tetra-alkyl-tetra-methyl spermines, TMTPS (tetramethyltetrapalmitoyl spermine), TMTOS (tetramethyltetraoleyl spermine), TMTLS (tetramethlytetralauryl spermine), TMTMS (tetramethyltetramyristyl spermine), TMDOS (tetramethyldioleyl spermine) DOGS (dioctadecyl amidoglycylspermine (TRANSFECTAM@), cationic lipids combined with non-cationic lipids, DOPE (dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine) or cholesterol, a cationic lipid composition composed of a 3:1 (w/w) mixture of DOSPA and DOPE, and a 1:1 (w/w) mixture of DOTMA and DOPE.
29. A use of a mixture comprising a polynucleotide delivery-enhancing polypeptide, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties, and a double stranded ribonucleic acid (dsRNA) for the production of a medicament for the treatment of a Tumor Necrosis Factor-alpha (TNF-c) associated inflammatory condition(s) in an animal subject, wherein the medicament is capable of reducing TNF-a RNA levels thereby preventing or reducing the occurrence or severity of one or more symptom(s) of the TNF-oa associated inflammatory condition(s). 103 WO 2007/030619 PCT/US2006/034859
30. The use of a mixture of Claim 29, wherein the polynucleotide delivery-enhancing polypeptide comprises about 5 to about 40 amino acids, and has all or part of a sequence selected from the group consisting of Poly (Lys, Tryp) 4:1 MW 20,000-50,000, Poly (Orn, Trp) 4:1 20,000-50,000, Mellitin, Histone H1, Histone H3 and Histone H4, SEQ ID NOS 27 to 31, 35 to 42, 45, 47, 50 to 59, 62, 63, 67, 68, 73, 74, 76, 78 to 87, 89 to 92, 94 to 108, 164 to 178 and 180 to 186.
31. The use of a mixture of Claim 29, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is acetylated.
32. The use of a mixture of Claim 29, wherein the N-terminus of the polynucleotide delivery-enhancing polypeptide is pegylated.
33. The use of a mixture of Claim 29, wherein the dsRNA is a small interfering ribonucleic acid (siRNA) consisting of about 10 to about 40 base pair sequence that is complementary to a portion of a Tumor Necrosis Factor-alpha (TNF-oc) gene.
34. The use of a mixture of Claim 29, wherein the dsRNA is a siRNA consisting of about 10 to about 40 base pair sequence selected from the group consisting of SEQ ID NOS 109 to 163 and 187.
35. The use of a mixture of Claim 29, wherein the polynucleotide delivery-enhancing polypeptide is admixed, complexed or conjugated to the dsRNA.
36. The use of a mixture of Claim 29, wherein the polynucleotide delivery-enhancing polypeptide binds to the dsRNA.
37. The use of a mixture of Claim 29, wherein the animal subject is a mammal. 104
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/223,699 | 2005-09-08 | ||
US11/223,699 US20060035815A1 (en) | 2004-05-04 | 2005-09-08 | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
US72721605P | 2005-10-14 | 2005-10-14 | |
US60/727,216 | 2005-10-14 | ||
US73366405P | 2005-11-04 | 2005-11-04 | |
US60/733,664 | 2005-11-04 | ||
PCT/US2006/034859 WO2007030619A2 (en) | 2005-09-08 | 2006-09-08 | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006287481A1 true AU2006287481A1 (en) | 2007-03-15 |
Family
ID=37836462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006287481A Abandoned AU2006287481A1 (en) | 2005-09-08 | 2006-09-08 | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1934359A2 (en) |
JP (1) | JP2009507852A (en) |
AU (1) | AU2006287481A1 (en) |
CA (1) | CA2621694A1 (en) |
WO (1) | WO2007030619A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1583562T3 (en) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, Related Compounds and Uses thereof |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
ES2383901T5 (en) | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Aprotinin polypeptides to transport a compound through the blood-brain barrier |
ES2424242T3 (en) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
DK2056845T3 (en) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | STRUCTURE AND USE OF 5'-PHOSPHATE OLIGONUCLEOTIDES |
CA2661093A1 (en) * | 2006-08-18 | 2008-02-21 | Nastech Pharmaceutical Company Inc. | Dicer substrate rna peptide conjugates and methods for rna therapeutics |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
CN101946001A (en) * | 2007-12-20 | 2011-01-12 | 安吉奥开米公司 | Polypeptide-nucleic acid conjugates and uses thereof |
RU2501859C2 (en) | 2008-03-31 | 2013-12-20 | Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи | Two-stranded rna modified with lipids and having powerful effect of rna interference |
JP5689413B2 (en) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 5 'triphosphate oligonucleotide having blunt ends and uses thereof |
BRPI0920209A2 (en) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugates of glp-1 agonists and their uses |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
ES2729261T3 (en) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Ovarian cancer treatment using an anticancer agent conjugated to an Angiopep-2 analog |
IN2012DN00248A (en) | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
US20140134178A1 (en) | 2012-01-06 | 2014-05-15 | H. Lee Moffit Cancer Center And Research Institute | Phosphorylation of histones and uses thereof |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
ES2826827T3 (en) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Methods for the treatment of leptomeningeal carcinomatosis |
CN114259460B (en) * | 2020-09-16 | 2024-03-15 | 苏州大学 | Hydrogel composition based on immunoadjuvant and application thereof |
CN114632161B (en) * | 2020-12-16 | 2024-02-06 | 中国人民解放军军事科学院军事医学研究院 | Application of tumor necrosis factor-alpha as nucleic acid gene medicine in-vivo delivery carrier |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679559A (en) * | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
US6589503B1 (en) * | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
AU2001256319A1 (en) * | 2000-04-24 | 2001-11-07 | Novartis Ag | Histone h2a-derived peptides useful in gene delivery |
JP2005517433A (en) * | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | RNA interference-mediated inhibition of TNF and TNF receptor superfamily gene expression using short interfering nucleic acids (siNA) |
AU2003219576A1 (en) * | 2003-04-03 | 2004-10-25 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
ES2411962T3 (en) * | 2003-10-24 | 2013-07-09 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
JP2007536253A (en) * | 2004-05-04 | 2007-12-13 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | Compositions and methods for enhancing delivery of nucleic acids into cells and modifying expression of target genes in cells |
-
2006
- 2006-09-08 AU AU2006287481A patent/AU2006287481A1/en not_active Abandoned
- 2006-09-08 WO PCT/US2006/034859 patent/WO2007030619A2/en active Application Filing
- 2006-09-08 CA CA002621694A patent/CA2621694A1/en not_active Abandoned
- 2006-09-08 JP JP2008530199A patent/JP2009507852A/en active Pending
- 2006-09-08 EP EP06803119A patent/EP1934359A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2621694A1 (en) | 2007-03-15 |
WO2007030619A3 (en) | 2007-10-04 |
JP2009507852A (en) | 2009-02-26 |
WO2007030619A2 (en) | 2007-03-15 |
EP1934359A2 (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8299236B2 (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
US20060035815A1 (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
AU2006287481A1 (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
WO2005117991A2 (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
CA2628113A1 (en) | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna | |
CA2526831C (en) | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) | |
KR101692063B1 (en) | MODULATION OF hsp47 EXPRESSION | |
US20080076701A1 (en) | Dicer substrate rna peptide conjugates and methods for rna therapeutics | |
US20070275923A1 (en) | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY | |
US20070281900A1 (en) | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY | |
US20050032733A1 (en) | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) | |
JP2007525192A (en) | RNA interference-mediated suppression of gene expression using chemically modified small interfering nucleic acids (siNA) | |
US20070213257A1 (en) | Compositions and methods for complexes of nucleic acids and peptides | |
US20070269892A1 (en) | FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA | |
KR20080044909A (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
CN101355970A (en) | Peptide-DICER substrate RNA conjugates as delivery vehicles for SIRNA | |
US20070276134A1 (en) | Compositions and methods for complexes of nucleic acids and organic cations | |
US20070293657A1 (en) | Complexes and methods of forming complexes of ribonucleic acids and peptides | |
MX2008003380A (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
CN101208438A (en) | Method of treating an inflammatory disease by double stranded ribonucleic acid | |
MX2007003667A (en) | Method of treating an inflammatory disease by double stranded ribonucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |